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Site Background and Program Establishment
Decades of historical mining activities in Butte-Silver Bow, Montana, have led to elevated levels of lead,
arsenic, and, to a lesser extent, mercury in the community, especially within the boundaries of the Butte
Priority Soils Operable Unit (BPSOU). Elevated metals content, particularly related to lead, has been
found in residential yards and attics within the BPSOU. The Residential Metals Abatement Program
(RMAP) was established to address the elevated metals levels and mitigate the impact to human health,
particularly among children. The RMAP is a public health program, with the Butte-Silver Bow County
Health Department (Health Department) and RMAP collaborating to determine blood-lead levels in the
community and mitigate lead exposure to children and adults whenever possible.

Management
Staff
The medical monitoring program for young children and pregnant women is operated by the Women,
Infants, and Children (WIC) Program in the Community Health Division of the Health Department. The
Community Health Division is directed by the Health Officer who works for the Chief Executive and the
Board of Health. The department organization chart is included as Attachment A.
The Community Health Division Manager and WIC Program Manager provide patient intake, capillary
blood testing, and coordinate venous confirmation sampling. This same staff is responsible for
documenting results of capillary screening in the Medical Monitoring Database and the input of venous
confirmation sampling. The staff is also responsible for coordinating environmental sampling with the
RMAP in cases where confirmed blood leads are identified and for providing analyses of urine arsenic
and mercury.

Problem Definition
Exposure to lead, arsenic, or mercury is possible in residential locations in Butte. Butte-Silver Bow
provides a medical monitoring program free of charge to Butte residents to determine if exposure has
occurred and offers an environmental sampling program to eliminate the possibility of exposure in the
home. The first element is a well-developed program to screen children for blood lead. The second is an
environmental sampling program to determine if contamination is present at the residence.
To ensure public and environmental health of the residents of Butte, the RMAP provides medical
monitoring (biomonitoring) services to identify resident exposure to lead, arsenic, or mercury. The WIC
Program seeks to obtain blood lead samples from all young children who participate in the WIC program
regardless of whether their residence has been tested. Biomonitoring services are also available to other
Butte residents, particularly if an environmental investigation reveals lead, arsenic, or mercury
contamination above action levels. Affected populations, as determined through biomonitoring, have
elevated levels of lead in blood samples or elevated arsenic or mercury in urine samples.
If an elevated blood lead is found, an environmental investigation of the residence where the participant
resides will be scheduled to potentially determine the source of contamination. The prioritization for
environmental assessment is described in Section 4 of the Revised Final Multi-Pathway Residential
Metals Abatement Program Plan (RMAP Program Plan) (BSB/Atlantic Richfield Company, 2021).
Affected populations shall be prioritized for an environmental assessment and remediation if
contamination is identified during the environmental investigation.

1

The RMAP performs routine environmental sampling efforts in residences throughout the BPSOU and
the RMAP Expanded Area. This program is detailed in the RMAP Program Plan and focuses on
eliminating the potential for exposure to contamination by identifying whether contamination is present
and performing remediation if it is.

Biomonitoring Thresholds

Biomonitoring data for the U.S. provides a source of population reference values that can be used to
identify elevated levels of blood lead, and urine arsenic and mercury. Values considered elevated are
listed in Table 1 and an explanation is provided in the following text. Biomonitoring of sensitive
populations within Butte-Silver Bow is also described in Section 3 of the RMAP Program Plan.
Table 1. Indicators of Potential Exposure to Environmental Lead, Mercury, and Arsenic
Analysis
Blood lead
Urine mercury
Inorganic arsenic-related species in urine

Value Considered Elevated
≥ 5 μg/dL, confirmed
≥ 1 μg/g creatinine
≥ 24 μg/g creatinine for children < 6 years old ≥
16 μg/g creatinine for older children and adults

≥: greater than or equal to. µg/dL: microgram per deciliter. µg/g: microgram per gram

Lead
Consistent with Montana Department of Public Health and Human Services (MDPHHS) guidance
(https://dphhs.mt.gov/publichealth/cdepi/diseases/lead), confirmed blood lead levels greater than or equal
to 5 micrograms per deciliter (μg/dL) will be considered elevated for children less than 6 years of age.
This value was based on the 97.5th percentile of blood lead levels in young children in the U.S. during the
mid-2000s. Blood lead is analyzed by performing a capillary draw and venous confirmation sampling for
participants, which is evaluated against the Medical Monitoring Program biomonitoring thresholds.
Detailed methods are described below.

Mercury

Mercury in urine is used as a biomarker for inorganic mercury exposure. Blood mercury is used as a
biomarker of methylmercury exposure, which is primarily from fish and other foods. Since elemental or
inorganic mercury is the concern in Butte, urine mercury will be used as the biomarker for mercury
exposure. Urine mercury can be reported either as a urine concentration in micrograms mercury per liter
(μg/L) or as micrograms mercury per gram of creatinine (µg/g creatinine), which uses the amount of the
metabolite, creatinine, excreted in the urine to adjust for variations in hydration state (i.e., how
concentrated or dilute the urine is) 1. MDPHHS identifies urine levels that indicate mercury poisoning
(greater than or equal to 200 µg/L total mercury or greater than or equal to 20 µg elemental mercury/g
creatinine); however, these levels are far higher than population reference levels. Population reference
values for total mercury in urine were selected based on U.S. biomonitoring data from 2011 through 2016
reported in the 2019 updated tables in the National Report on Human Exposure to Environmental
Chemicals, https://www.cdc.gov/exposurereport/index.html, see Attachment B – Extracts from the tables.
Urinary mercury levels greater than or equal to 1 µg/g creatinine will be considered as elevated mercury
levels for all participants. The selected value is the 95th percentile of the U.S. population values for
children and for adults. The analytical method may vary based on the analytical laboratory conducting the
Creatinine is a waste product excreted by the kidneys that is produced by muscles from the breakdown of a
compound called creatine.

1

2

analyses. Note that potential for exposure from dental amalgams will be assessed by the physician prior to
assuming environmental exposure.

Arsenic
Analysis of total arsenic in urine is used to assess exposure to arsenic in food, as well as other sources.
Much of the arsenic in food is organic forms that are relatively non-toxic. Consequently, total arsenic in
urine may reflect recent meals that included fish, shellfish, rice, or other foods high in arsenic, and is not
considered a reliable indicator of inorganic arsenic exposure. Instead, analytical methods that test for
inorganic arsenic and its metabolites (termed speciated arsenic or inorganic arsenic-related species) are
considered more reliable. Some foods such as rice and shellfish may still cause false positives in results
for inorganic arsenic so retesting may be required after a period of at least 72 hours without consuming
these foods to provide reliable information on potential environmental exposure to inorganic arsenic.
Similar to mercury, urine arsenic can be reported either as a urine concentration in μg/L or as µg/g
creatinine, which adjusts for variations in hydration state (i.e., how concentrated or diluted the urine is).
Population reference values for inorganic arsenic-related species in urine (as µg/g creatinine) were
selected based on U.S. biomonitoring data from 2011-2016 reported in the 2019 updated tables in the
National Report on Human Exposure to Environmental Chemicals,
https://www.cdc.gov/exposurereport/index.html, see Attachment B – Extracts from the tables. For the
inorganic arsenic-related species, a value greater than or equal to 24 μg/g creatinine was selected for
children less than 6 years old, and a value of greater than or equal to 16 µg/g creatinine was selected for
older children and adults. The selected values are the 95th percentile of the U.S. population values for
young children and for adults. The analytical method may vary based on the analytical laboratory
conducting the analyses. One laboratory that may be selected performs arsenic speciation by ion
chromatography inductively coupled plasma collision reaction cell mass spectrometry (IC-ICP-CRCMS). Arsenic species are first chromatographically separated on an ion exchange column and then
quantified using ICP-CRC-MS. Results are provided for arsenite, arsenate, monomethylarsonic acid
(MMA), and dimethylarsinic acid (DMA).

Program Protocols

The biomonitoring services of the RMAP program are provided by the Health Department through the
WIC program. Since the WIC program serves a particularly at-risk population it was selected to be the
site at which medical monitoring is carried out, focusing on low-income children.
Biomonitoring participants or their guardian will be required to complete a consent form for participation
and an individual questionnaire for urinary collection (Attachment C1). Blood lead screening will be
conducted by the WIC program and subsequent venous sample analysis will be conducted by an
accredited laboratory. 2 Urinary arsenic and mercury samples will be collected by participants using
sample collection cups provided by the Health Department (see instruction flyer in Attachment C2). The
Health Department will then ship the samples to the contracted laboratory.
Participation in the blood lead program will be encouraged through a variety of means, such as the
existing WIC program and referrals from local physicians. Residents will also be encouraged to
participate when they are contacted for residential sampling access. Participation is voluntary and

During much of 2020 and into 2021, the WIC program has not been able to conduct any blood lead screening due
to pandemic restrictions on in-person visits.
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available to all residents. Primary emphasis is placed on children and pregnant or nursing mothers, but all
other residents are eligible with a recommendation from program staff.
WIC staff manages the programmatic responsibilities of the medical monitoring process. Their
responsibilities include participant communication and outreach, sample collection, documentation,
shipping, and result documentation, quality control elements including chain of custody, shipping, and
result receipt. Finally, they provide result information to the participant.
When individuals are found to have a confirmed elevated blood lead, urinary mercury, or urinary arsenic,
the home where the affected person or persons live will be scheduled for immediate sampling and
evaluation. Elevated blood lead values will be confirmed by multiple tests. Influencing factors such as
food consumption for arsenic, (i.e., seafood) and dental amalgams for mercury will be taken into
consideration.
The details of the program process are further defined and described in subsequent sections of this
document.

Collection
Participant Intake
WIC uses a proprietary database system to capture pertinent information for the client. This includes
medical monitoring data, consent for services, and releases of information. The local WIC office will, to
the extent legally permissible, begin to collect information pertaining to individual characteristics such as
race, maternal education, and household income level to improve result interpretation and evaluate
community trends.
Blood Lead Sampling Procedures
Screening
The WIC program uses the LeadCare® II system to perform lead screening services. The protocols are
attached to this document as Attachment D1, which describe the kit contents and required materials. The
procedure is as follows:
1. Perform capillary draw.
a. Thoroughly wash hands and don powder-free gloves, face shield, and mask.
b. Clean patient skin surface.
c. Prick patient finger and draw blood.
2. Perform calibration procedure, if necessary.
3. Perform quality control to monitor accuracy and precision, if necessary.
4. Prepare the sample.
a. Label the tube with Patient ID.
b. Holding the capillary tube almost horizontally with the green band on top, fill the
capillary to the 50 microliter (µL) black line.
c. Inspect the capillary tube for proper filling.
d. Place the capillary tube into the treatment reagent tube. Insert a plunger into the top of the
capillary tube and push down, ensuring the entire volume of sample is dispensed into the
treatment reagent.
e. Replace the tube cap. Invert 8 to 10 times to mix the sample completely.
f. The sample is ready when the mixture turns brown. Samples may be stored up to one
week if refrigerated.
5. Analyze the sample.
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a. Remove a sensor from the sensor container.
b. Insert the sensor under the sensor guides on the sensor deck. Insert completely into the
analyzer until it beeps.
c. Make sure the sensor lot number matches the display.
d. Make sure the sample is thoroughly mixed. Allow samples that were stored refrigerated
to reach room temperature before use.
e. Remove the cap from the treatment reagent tube. Squeeze the walls of the dropper and
insert into the sample. Release the pressure to draw some sample into the dropper.
f. Touch the dropper tip to the x on the sensor and squeeze the walls to dispense the sample.
The analyzer will “beep” and begin the 3-minute countdown.
g. Wait 3 minutes until the test is done.
h. Record the test results on the LeadCare® II worksheet.
i. Remove the sensor immediately after recording the test result.
j. Discard materials in appropriate containers.
6. Interpret patient test results.
a. The result is in micrograms of lead per deciliter of whole blood. No calculation is needed.
Results are displayed to one decimal place. The reportable range of the test is 3.3 to 65
µg/dL.
b. “Low” in the display window indicates a blood lead test result less than 3.3 µg/dL. When
this occurs, report the blood lead results as less than 3.3 µg/dL.
c. “High” in the display window indicates a blood lead test result greater than 65 µg/dL.
When this occurs, report the blood lead result as greater than 65 µg/dL. “High” results on
LeadCare® II should be followed up immediately as an emergency laboratory test.
Venous Confirmation
When results from the blood lead analyzer LeadCare® II capillary test are greater than or equal to 5
µg/dL, confirmatory testing will occur. The contents of the Venipuncture Collection Kit are attached as
Attachment D2.
1. Venipuncture collection:
a. Thoroughly wash hands and don powder-free gloves.
i. Expose the selected antecubital fossa and apply tourniquet to mid-biceps. Scrub
the puncture site briskly with the alcohol pad to remove any environmental
contamination and to increase blood flow.
ii. Allow the site to air dry or use the sterile gauze to dry the area.
b. Collection of the sample:
i. Prepare needle assembly, either needle and vacutainer holder or needle and
syringe.
ii. Perform venipuncture per standard operating procedures. Make sure the
vacutainer tube is completely filled before stopping collection. If using a needle
and syringe, obtain a minimum of 2 milliliters (mL) of whole blood.
iii. Remove tourniquet first, then remove the needle from the arm.
iv. Apply pressure to the puncture site with a gauze pad to stop the patient’s
bleeding. Parent/guardian or child may continue holding direct pressure on the
puncture site.
v. If drawn directly into vacutainer tube, immediately mix the specimen manually
by inverting a minimum of 10 times.
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vi. If drawn with a needle into the syringe, immediately inject the blood from the
syringe into the vacutainer tube, gently mixing while filling. Continue to mix the
specimen by inverting 10 times.
vii. Dispose of used needle and syringe equipment into puncture proof sharps
container.
viii. Identify each skin puncture specimen with the patient’s name, at a minimum, and
collection date.

Shipping
1. Standing Orders: Venipuncture Specimens for Transport
a. Specimens should be clearly labeled with two patient identifiers (name and date of birth)
and collection date.
b. Complete a Montana Public Health Laboratory Request Form to include the patient’s
name, date of birth, gender, collection date, and submitter information (see Attachment E
for the Montana Public Health Laboratory Request form).
c. Place the well-mixed, unclotted blood specimen in an individual biohazard zip lock bag
containing absorbent material and seal bag tightly. Fold the requisition form and place it
in the sleeve of the bag
d. Store specimen(s) in the refrigerator until transported to the St. James Healthcare
Laboratory the same day, to coincide with the courier schedule to the Montana Public
Health Laboratory in Helena, Mont. Specimens are stable for 7 days at refrigeration
temperatures.

Analysis
Refer to Attachment F, Montana Public Health Laboratory Services Manual. Please find Montana Public
Health Laboratory CLIA certificate attached as Attachment G.

Quality Control
Refer to Attachment F, Montana Public Health Laboratory Services Manual.

Sample Documentation
•
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If screening via LeadCare® II identifies a blood lead greater than 5 µg/dL, a confirmatory venous
draw is coordinated. Currently, venous draws are completed by local doctors’ offices, but given
the difficulties with participant follow-up and data collection, the program will utilize the
following process:
o A patient entry is created in the Medical Monitoring Database incorporating name,
address, telephone number, physician, and demographic information such as family status
and income.
o The results of the screening sample collected through capillary draw and analyzed via the
LeadCare® II system will be entered in the system.
o If a result is greater than 5 µg/dL, then the on-site Medical Monitoring
Nurse/environmental health full time employee (FTE) will be contacted and same day
venous confirmation sampling will take place.
o The venous draw sample will be shipped according to the previously described procedure
to the local St. James Laboratory.
o The results will be provided to the Medical Monitoring Nurse/environmental health FTE
and the lab results will be entered in the Medical Monitoring Database.

o

If an elevated blood lead is identified, the Medical Monitoring Nurse/environmental
health FTE will then coordinate participant follow-up, which includes environmental
assessment through the RMAP Program.

Result Documentation
The Montana Public Health Laboratory emails the ordering provider when lab results are entered into
state systems – these orders are issued under standing orders from the Health Department’s medical
director (see the Montana Public Health Laboratory Services Manual in Attachment F).

Database

These data are currently entered into an Excel spreadsheet by the WIC program manager. The current
Excel spreadsheet, containing anonymous information, is available to medical monitoring team members,
including the Health Department, RMAP, and associated research personnel.

Data review
Sample information and laboratory results will be reviewed and entered in the Medical Monitoring
Database by the Medical Monitoring Nurse/environmental health FTE, per concurrence from Atlantic
Richfield Company (Atlantic Richfield). Data validation procedures will be provided by the
Environmental Protection Agency (EPA).

Participant Communication and Outreach
Participant Intake
WIC standards prevent medical monitoring data entry into the WIC system. Because of this, medical
monitoring data, such as consent forms (which contain areas for information about blood-lead data) and
releases of information are scanned into the WIC client’s file. Separately, anonymous blood-lead data are
entered onto an Excel spreadsheet which serves as the Medical Monitoring Database. These data are
eventually provided to medical monitoring officials for the five-year health studies.
Communication of Results
Per Health Department standing orders, after test results are received by the department from the state lab,
the patient (or parent/legal guardian) is contacted to discuss the results and any next steps if applicable.
EPA will provide example result letters and any fact sheets that will be provided to the public to aid in
result interpretation.
Environmental Assessment Coordination
If WIC program staff identifies a participant with elevated blood lead, confirmed by venous sample, then
WIC staff coordinates with the Reclamation Department Human Health Program Manager to schedule an
environmental assessment.
RMAP staff will reach out via telephone to schedule a time for an environmental assessment. Samples
will be collected in accordance with the protocols described in Section 6 and Section 7 of the RMAP
Program Plan.

Periodic Evaluation of Medical Monitoring Data and Approaches (Health Studies)
Collecting and analyzing medical monitoring data is part of a continuous biomonitoring process within
the RMAP. In addition to blood lead screening, confirmation sampling, and communication of laboratory
results to participants, data is summarized and interpreted in a comprehensive report every five years.
Butte-Silver Bow evaluates biomonitoring approaches and data compiled under the RMAP every 5 years
and will continue this evaluation schedule for a period of 30 years. The first and second of these studies
7

(Phase 1 and Phase 2 studies) were completed and approved by EPA in 2014 and 2020, respectively. Four
additional periodic evaluations will be conducted over the next 20 years (2025, 2030, 2035, and 2040).
These evaluations will be overseen by a Medical Monitoring Working Group that includes representatives
of the relevant regulatory agencies, responsible parties, and community, (i.e., the stakeholders). The
Medical Monitoring Group is composed of representatives who bring knowledge of the daily operations
of the RMAP program, its biomonitoring aspect, the stipulated responsibilities of the biomonitoring
program, and advocacy for sensitive populations. The Medical Monitoring Working Group’s
responsibilities are singularly focused on the preparation of the 5-year evaluations and interpretation of
data associated with that period not the day-to-day operations of the program itself unless specifically
charged with that responsibility as part of a job duty or board term of service.
The Medical Monitoring Working Group may expand to other reviews and potential studies that may be
conducted beyond medical monitoring data associated with the medical monitoring program. This will
occur through collaborative discussions with the stakeholder group over the next 20 years, and as funding
is available, with the Health Department as the lead agency in coordinating these reviews and studies. The
Agency for Toxic Substances and Disease Control and the MDPHHS will be substantially involved in this
effort, along with EPA and the Montana Department of Environmental Quality (DEQ). As the expanded
RMAP is developed, EPA and DEQ will work with community members and Butte Silver Bow County to
continually address public health concerns associated with historical mining waste and current public
health issues to the extent practical and as funding is available.
Reports documenting these periodic evaluations will be available to the public, the EPA, Montana DEQ,
and potentially responsible parties for the BPSOU. All stakeholder parties will continue to facilitate,
participate, and contribute to the Medical Monitoring Working Group and other public health reviews and
studies. However, the data associated with this analysis and interpretation will respect the privacy of the
participants. Specifically, the biomonitoring data associated with specific names or addresses will be
scrubbed to ensure no identifying characteristics associated with personal health information is shared
with the working group or the public.
While the RMAP has focused on arsenic, lead, and mercury, lead has proven to be the primary metal
triggering abatements and is the only metal routinely included in biomonitoring. Thus, periodic
evaluations will focus on lead. While not a focus, any applicable data for arsenic and mercury will also be
reviewed. Similarly, periodic evaluations will focus on affected and sensitive populations as defined by
the RMAP. Data gathered through the RMAP’s routine activities, as well as the results of prior periodic
evaluations, will be considered in each periodic evaluation.
The purpose of conducting periodic evaluation of biomonitoring data compiled in conjunction with the
RMAP is two-fold. First, because the state of the science related to collection and interpretation of
biomonitoring data continues to evolve, it is necessary to periodically evaluate the medical monitoring
approaches used to ensure that the biomonitoring data can continue to be used to support the RMAP’s
mitigation of potentially harmful exposures of BPSOU residents to sources of lead, arsenic, and mercury
contamination. Second, examination of the complete biomonitoring database every five years can provide
valuable information regarding exposure trends over time. Information and analysis supporting both
purposes can inform potential improvements to routine activities as needed to ensure the RMAP’s
continued effectiveness.
In addition to evaluation of the biomonitoring data, the Phase 2 study included evaluations of topics
identified by Butte citizens at public meetings and from community stakeholders. The primary Phase 2
study elements included:
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•

•

•

•

•

•

Butte Superfund History and Community Characteristics – A summary of the history of
Superfund remediation in Butte with a focus on BPSOU and residential areas. Other community
characteristics and information about health status that are important determinants of public
health were described, followed by a description of a survey of perceptions of environmental
health issues in Butte.
Review of Risk Assessments and Cleanup Levels – Prior human health risk assessments
(HHRAs) conducted within and near the BPSOU were summarized as well as the derivation of
cleanup levels and the periodic review of cleanup levels during the reviews conducted every 5
years of the Record of Decision (ROD), Butte Priority Soils Operable Unit (EPA, 2006)
Review of Past Exposure/Biomonitoring Studies – Current biomonitoring sampling procedures,
analytical methods, and concentration benchmarks, and assessment of the need for any potential
updates/improvements. Prior BPSOU exposure studies (including the Phase 1 study) were
summarized.
Review of Disease Prevalence and Rate Studies – Prior studies of disease prevalence in Butte
were summarized, including results of an updated MDPHHS analysis of morbidity and mortality
statistics for the Butte population compared with state and national data. Additional relevant
published literature was also described.
Phase 2 Blood Lead Data Analysis – Blood lead data from 2012 through 2017 and summary
statistics were compiled. Exposure trends over time, by Butte neighborhood, and (to the extent
supported by available data) in comparison to a defined reference population were evaluated.
Key Findings and Recommendations – A final section presented key findings related to
epidemiological and exposure studies, as well as recommendations of any areas where changes to
activities conducted via the RMAP might be useful. Recommendations for public outreach were
also provided.

It is anticipated that much of the information provided in the Phase 2 study report will provide a baseline
of information that can be updated in subsequent studies. For each remaining evaluation period, the
following activities are anticipated:
•
•
•

•

•

•
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The Medical Monitoring Working Group will meet periodically during and between studies to
ensure that data needed for each subsequent study is being collected.
Community outreach will solicit input at the beginning of each subsequent phase, starting with a
reminder of the prior study findings.
Summary statistics for available arsenic, lead, and mercury biomonitoring data will be updated
with biomonitoring data for BPSOU populations of interest that have been compiled since the
prior evaluation period. Quality assurance review of the database will seek to identify and address
incomplete or missing records from the compilation.
The most recent biomonitoring database will be used to describe exposure trends over time. To
the extent supported by the available data the approaches and methodologies of the 2014 or 2020
evaluations will be used to compare blood lead data across Butte neighborhoods. If feasible, the
data will also be compared to a defined reference population.
As available, recent peer-reviewed epidemiology studies examining the relationship between
environmental exposures to arsenic, lead, and/or mercury and diseases with increased incidence
in Butte will be reviewed and summarized.
As available, the results of recent morbidity and mortality statistics for the Butte population
reported by the Montana state public health entities will be reviewed and summarized.

•

•
•

Recommendations of any improvements or additions to activities conducted via the RMAP will
be developed. Specifically, the current state of the science regarding collection and interpretation
of biomonitoring data will be reviewed to determine whether any updates are needed to the
sampling, analysis, and interpretation of biomonitoring data collected in conjunction with the
RMAP. This will include review of the benchmarks currently being used to assess elevated
biomonitoring results for the RMAP.
Recommendations for other reviews and potential health studies will be considered.
After EPA approval, a report will be issued with the results of each study and study results will be
shared with the community.

References
BSB/Atlantic Richfield Company, 2021. Revised Final Multi-Pathway Residential Metals Abatement
Program Plan. City and County of Butte Silver Bow and Atlantic Richfield Company, November
2021.
EPA, 2006. Record of Decision, Butte Priority Soils Operable Unit, Silver Bow Creek/Butte Area NPL
Site. U.S. Environmental Protection Agency, September 2006.

10

Attachment A: RMAP Organizational Chart

Attachment A: BPSOU Reclaimed Areas Program Organization and Communication Structure
Atlantic Richfield
Remediation Management Services
Company

Butte-Silver Bow
Chief Executive

Agency Oversight
(EPA/MDEQ)

John Gallagher

EPA Remedial
Project Manager
Nikia Greene

Montana Portfolio
Manager

DEQ Project Officer
Daryl Reed

Chris Grecco

Department of
Reclamation &
Environmental
Services

Health and Medical
Monitoring Department
Program Director

Quality
Assurance Manager (QAM)
David Gratson

Liability Manager (LM)
Mike McAnulty

Program Director

Karen Sullivan;
Medical Monitoring
Director

Eric Hassler;
Program Manager

Contractors

Pioneer Technical Services

Assistant Director
Julia Crain;
Quality Assurance
Manager

Health and Safety
Field Sampling Teams
Remediation Contractors

Data Manager
Abigail Peltomaa;
Quality Assurance
Officer

Human Health/
RMAP Manager
Chad Anderson;
Manager

Woodward and Curran
Health and Safety
Field Sampling Teams
Remediation Contractors

Assessment and Sampling
Teams
Remediation and Abatement
Field Teams
M

Specialty Contractors

Contract
Laboratories

Reporting
Communication

Attachment B: National Report on Human Exposure to Environmental
Chemicals Table Extracts

Fourth National Report on Human Exposure to Environmental Chemicals
Updated Tables, January 2019, Volume One

U.S. Department of Health and Human Services
2019

Urinary Total Arsenic (2011 – 2016)
CAS Number 7440-38-2
Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population from the National Health and Nutrition Examination Survey.
Categories

Geometric Mean (95%

50th Percentile

75th Percentile

90th Percentile

95th Percentile

(Survey Years)

conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

Sample
Size

Total population (2011 - 2012)
Total population (2013 - 2014)

6.85 (5.85-8.02)
6.29 (5.58-7.08)

6.09 (5.22-7.12)
5.82 (5.10-6.69)

13.0 (10.9-16.6)
11.7 (10.5-13.2)

32.0 (25.9-39.0)
26.6 (23.7-30.1)

52.5 (41.9-66.2)
46.0 (37.5-56.1)

2504
2662

Total population (2015 - 2016)

5.96 (5.53-6.43)

5.41 (4.92-5.84)

11.1 (9.91-12.2)

25.0 (20.8-30.0)

44.6 (35.7-53.8)

3061

Age 3-5 years (2015 - 2016)

4.05 (3.58-4.58)

3.72 (3.27-4.23)

6.67 (5.66-8.35)

12.8 (9.93-19.9)

22.4 (13.4-54.8)

486

Age 6-11 years (2011 - 2012)
Age 6-11 years (2013 - 2014)

6.02 (5.03-7.19)
5.21 (4.57-5.95)

5.50 (4.58-6.56)
4.78 (4.27-5.57)

10.5 (7.93-14.1)
8.79 (7.52-10.3)

30.1 (16.7-46.5)
17.1 (12.4-25.3)

53.0 (37.5-70.3)
29.0 (17.9-47.7)

399
402

Age 6-11 years (2015 - 2016)

4.89 (4.29-5.56)

4.51 (4.21-4.96)

7.59 (6.66-8.71)

15.7 (11.1-22.7)

28.9 (17.1-56.9)

379

Age 12-19 years (2011 - 2012)
Age 12-19 years (2013 - 2014)

6.01 (4.45-8.11)
5.79 (4.96-6.75)

5.26 (3.95-7.47)
5.33 (4.83-5.91)

10.9 (7.74-16.9)
9.40 (8.44-11.8)

25.9 (16.6-44.0)
22.0 (17.4-28.1)

44.0 (25.9-153)
44.1 (27.0-90.8)

390
451

Age 12-19 years (2015 - 2016)

5.00 (4.52-5.54)

4.75 (4.07-5.23)

8.78 (7.64-10.6)

17.1 (14.6-20.1)

29.8 (19.2-35.6)

402

Limit of detection (LOD, see Data Analysis section) for Survey years 11-12, 13-14, and 15-16 are 0.05, 0.13, and 0.13, respectively.

Biomonitoring Summary: https://www.cdc.gov/biomonitoring/Mercury_BiomonitoringSummary.html
Factsheet: https://www.cdc.gov/biomonitoring/Mercury_FactSheet.html

Urinary Total Arsenic (creatinine corrected) (2011 – 2016)
CAS Number 7440-38-2
Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population from the National Health and Nutrition Examination Survey.
Categories

Geometric Mean (95%

50th Percentile

75th Percentile

90th Percentile

95th Percentile

(Survey Years)

conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

Sample
Size

Total population (2011 - 2012)

7.77 (6.85-8.81)

6.39 (5.57-7.24)

13.7 (11.5-16.5)

30.8 (24.6-38.6)

50.4 (38.2-70.1)

2502

Total population (2013 - 2014)

7.27 (6.62-7.99)

6.10 (5.39-6.88)

11.9 (10.5-13.5)

27.6 (23.8-32.8)

52.0 (43.5-60.9)

2661

Total population (2015 - 2016)

6.69 (6.32-7.08)

5.56 (5.32-5.85)

10.7 (9.74-11.5)

24.9 (20.1-30.0)

45.8 (32.0-65.3)

3058

Age 3-5 years (2015 - 2016)

9.31 (8.18-10.6)

8.27 (7.40-9.15)

12.5 (10.6-14.9)

21.1 (17.3-28.8)

40.9 (22.8-83.5)

485

Age 6-11 years (2011 - 2012)

8.63 (7.26-10.3)

6.87 (5.84-8.00)

12.3 (9.58-15.5)

27.7 (17.7-57.7)

91.2 (26.2-129)

398

Age 6-11 years (2013 - 2014)

7.78 (7.08-8.54)

6.91 (5.91-7.65)

12.5 (10.3-13.6)

17.7 (16.1-21.1)

29.9 (20.4-52.1)

402

Age 6-11 years (2015 - 2016)

6.93 (6.48-7.41)

6.09 (5.66-6.56)

9.53 (8.15-11.0)

18.2 (13.6-25.0)

28.1 (21.9-40.6)

379

Age 12-19 years (2011 - 2012)

5.75 (4.49-7.36)

4.69 (3.70-5.73)

8.73 (6.26-13.3)

22.1 (11.5-52.6)

34.9 (21.1-159)

390

Age 12-19 years (2013 - 2014)

5.24 (4.53-6.06)

4.21 (3.61-4.61)

7.92 (5.75-10.3)

17.6 (12.6-23.0)

30.5 (20.3-54.1)

451

Age 12-19 years (2015 - 2016)

4.67 (4.34-5.03)

3.94 (3.55-4.54)

7.09 (5.91-7.91)

14.7 (11.6-16.8)

22.3 (15.4-31.5)

402

Biomonitoring Summary: https://www.cdc.gov/biomonitoring/Mercury_BiomonitoringSummary.html
Factsheet: https://www.cdc.gov/biomonitoring/Mercury_FactSheet.html

Urinary Inorganic-related Arsenic Species (2011 – 2016)
CAS Number 7440-38-2
Geometric mean and selected percentiles of urine concentrations (in µg As/L) for the U.S. population from the National Health and Nutrition Examination Survey.
Categories

Geometric Mean (95%

50th Percentile

75th Percentile

90th Percentile

95th Percentile

(Survey Years)

conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

Sample
Size

Total population (2011 - 2012)

5.59 (5.24-5.96)

5.15 (4.73-5.56)

7.73 (7.09-8.57)

12.2 (11.1-13.9)

17.2 (14.6-19.9)

2517

Total population (2013 - 2014)

4.80 (4.53-5.09)

4.53 (4.18-4.94)

7.22 (6.74-7.70)

11.2 (10.3-12.0)

14.7 (13.5-16.8)

2654

Total population (2015 - 2016)

4.41 (4.17-4.67)

4.08 (3.79-4.49)

6.55 (6.16-7.06)

10.5 (9.43-11.7)

14.5 (12.8-17.3)

3094

Age 3-5 years (2015 - 2016)

4.03 (3.71-4.36)

3.75 (3.50-3.96)

5.57 (5.12-6.43)

9.54 (7.82-11.8)

13.2 (10.3-20.6)

507

Age 6-11 years (2011 - 2012)

5.48 (5.05-5.95)

5.36 (4.50-5.98)

7.58 (7.08-8.34)

11.2 (9.93-12.1)

13.4 (11.6-16.2)

401

Age 6-11 years (2013 - 2014)

4.91 (4.44-5.43)

4.59 (4.02-5.00)

7.21 (6.20-8.38)

11.3 (9.91-13.9)

14.2 (11.4-19.6)

397

Age 6-11 years (2015 - 2016)

4.32 (4.00-4.68)

4.12 (3.66-4.56)

6.15 (5.45-6.66)

9.05 (7.98-11.1)

13.1 (10.2-21.0)

380

Age 12-19 years (2011 - 2012)

5.37 (4.67-6.17)

5.09 (4.24-6.00)

7.28 (6.27-8.32)

11.1 (8.34-14.9)

15.6 (10.8-23.9)

392

Age 12-19 years (2013 - 2014)

5.09 (4.64-5.57)

5.02 (4.51-5.46)

7.29 (6.53-8.08)

11.9 (9.80-13.7)

14.5 (12.5-15.9)

450

Age 12-19 years (2015 - 2016)

4.32 (3.97-4.70)

4.01 (3.58-4.52)

6.03 (5.37-6.77)

10.1 (8.75-11.8)

14.2 (11.2-17.1)

402

**See Calculation of Inorganic-related Arsenic Species for additional information. Limit of detection (LOD, see Data Analysis section) for Survey years 11-12, 13-14, and 1516 are 4.04, 3.02, and 3.02, respectively.

Biomonitoring Summary: https://www.cdc.gov/biomonitoring/Mercury_BiomonitoringSummary.html
Factsheet: https://www.cdc.gov/biomonitoring/Mercury_FactSheet.html
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Urinary Inorganic-related Arsenic Species (creatinine corrected) (2011 – 2016)
CAS Number 7440-38-2
Geometric mean and selected percentiles of urine concentrations (in µg As/g of creatinine) for the U.S. population from the National Health and Nutrition Examination Survey.

Categories (Survey Years)

Geometric Mean (95%

50th Percentile

75th Percentile

90th Percentile

95th Percentile

conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

Sample
Size

Total population (2011 - 2012)

6.31 (6.02-6.63)

6.00 (5.64-6.37)

9.46 (8.88-10.1)

15.1 (13.4-16.5)

19.6 (18.3-20.4)

2516

Total population (2013 - 2014)

5.53 (5.24-5.83)

5.28 (4.91-5.61)

8.09 (7.61-8.62)

13.0 (11.9-14.1)

17.4 (15.6-18.8)

2653

Total population (2015 - 2016)

4.94 (4.70-5.20)

4.77 (4.60-5.05)

7.51 (7.29-7.66)

11.6 (10.7-12.5)

16.2 (14.3-17.9)

3091

Age 3-5 years (2015 - 2016)

8.95 (8.20-9.78)

8.52 (7.89-9.27)

12.9 (11.4-14.1)

19.0 (15.4-22.4)

23.7 (21.3-30.4)

506

Age 6-11 years (2011 - 2012)

7.77 (7.36-8.20)

7.33 (6.95-8.26)

10.6 (9.74-11.9)

15.9 (14.3-16.8)

20.2 (16.8-22.3)

401

Age 6-11 years (2013 - 2014)

7.38 (6.78-8.04)

6.73 (5.99-8.30)

10.4 (9.30-12.3)

15.4 (14.1-16.8)

17.8 (15.5-19.4)

397

Age 6-11 years (2015 - 2016)

6.16 (5.78-6.56)

5.92 (5.49-6.27)

8.53 (7.98-9.36)

12.6 (11.2-15.2)

17.7 (14.2-20.7)

380

Age 12-19 years (2011 - 2012)

5.13 (4.48-5.88)

4.76 (4.40-5.11)

7.40 (5.86-8.81)

11.4 (8.17-16.8)

16.8 (11.4-28.7)

392

Age 12-19 years (2013 - 2014)

4.61 (4.14-5.15)

4.38 (3.92-4.81)

6.57 (5.55-7.69)

9.38 (8.11-11.1)

11.7 (9.46-16.7)

450

Age 12-19 years (2015 - 2016)

4.04 (3.78-4.31)

3.96 (3.46-4.43)

5.59 (5.20-6.16)

8.64 (7.50-10.2)

12.9 (9.76-15.3)

402

**See Calculation of Inorganic-related Arsenic Species for additional information.

Biomonitoring Summary: https://www.cdc.gov/biomonitoring/Mercury_BiomonitoringSummary.html
Factsheet: https://www.cdc.gov/biomonitoring/Mercury_FactSheet.html

Urinary Mercury (2011 – 2016)
CAS Number 92786-62-4
Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population from the National Health and Nutrition Examination Survey.
Categories

Geometric Mean (95%

50th Percentile

75th Percentile

90th Percentile

95th Percentile

(Survey Years)

conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

Sample
Size

Total population (2011 - 2012)

.324 (.285-.368)

.320 (.280-.370)

.660 (.580-.770)

1.37 (1.15-1.59)

1.83 (1.62-2.14)

2507

Total population (2013 - 2014)

.246 (.221-.273)

.200 (.170-.240)

.470 (.400-.570)

1.07 (.900-1.22)

1.64 (1.35-1.96)

2666

.680 (.570-.780)

1.18 (.920-1.29)

3080

.280 (.190-.510)

496

Total population (2015 - 2016)

*

< LOD

Age 3-5 years (2015 - 2016)

*

< LOD

Age 6-11 years (2011 - 2012)

.241 (.206-.283)

.220 (.190-.270)

Age 6-11 years (2013 - 2014)

*

< LOD

Age 6-11 years (2015 - 2016)

*

< LOD

Age 12-19 years (2011 - 2012)

.257 (.212-.312)

.270 (.220-.340)

Age 12-19 years (2013 - 2014)

*

< LOD

Age 12-19 years (2015 - 2016)

*

< LOD

.280 (.250-.320)
< LOD

.160 (<LOD-.240)

.450 (.390-.530)

.930 (.680-1.36)

1.37 (.990-2.03)

401

.220 (.150-.310)

.560 (.340-.840)

.890 (.640-1.10)

401

.300 (.200-.380)

.520 (.360-.700)

380

.490 (.390-.600)

.840 (.650-1.24)

1.31 (.920-1.75)

390

.240 (.200-.310)

.560 (.400-.860)

1.02 (.610-1.81)

452

.350 (.200-.470)

.610 (.380-1.14)

402

< LOD

.130 (<LOD-.160)

Limit of detection (LOD, see Data Analysis section) for Survey years 11-12, 13-14, and 15-16 are 0.05, 0.13, and 0.13, respectively.
< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
* Not calculated: proportion of results below limit of detection was too high to provide a valid result.

Biomonitoring Summary: https://www.cdc.gov/biomonitoring/Mercury_BiomonitoringSummary.html
Factsheet: https://www.cdc.gov/biomonitoring/Mercury_FactSheet.html

Urinary Mercury (creatinine corrected) (2011 – 2016)
CAS Number 92786-62-4
Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population from the National Health and Nutrition Examination Survey.
Categories

Geometric Mean (95%

50th Percentile

75th Percentile

90th Percentile

95th Percentile

(Survey Years)

conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

(95% conf. interval)

Sample
Size

Total population (2011 - 2012)

.367 (.333-.405)

.353 (.306-.394)

.676 (.623-.754)

1.33 (1.13-1.50)

1.75 (1.49-2.32)

2505

Total population (2013 - 2014)

.283 (.260-.309)

.270 (.250-.290)

.571 (.511-.644)

1.20 (1.05-1.36)

1.61 (1.47-1.81)

2665

.356 (.318-.391)

.708 (.628-.817)

1.10 (.912-1.25)

3077

Total population (2015 - 2016)
Age 3-5 years (2015 - 2016)
Age 6-11 years (2011 - 2012)
Age 6-11 years (2013 - 2014)
Age 6-11 years (2015 - 2016)
Age 12-19 years (2011 - 2012)

*
*
.345 (.298-.398)
*
*
.246 (.219-.277)

< LOD
< LOD
.306 (.276-.344)
< LOD
< LOD
.221 (.190-.269)

Age 12-19 years (2013 - 2014)

*

< LOD

Age 12-19 years (2015 - 2016)

*

< LOD

.994 (.818-1.13)

495

.537 (.441-.613)

< LOD

1.08 (.884-1.43)

1.62 (1.07-2.34)

400

.429 (.310-.529)

.750 (.563-.897)

1.11 (.713-1.72)

401

< LOD

.667 (<LOD-.818)

.474 (.409-.529)

.643 (.500-1.00)

380

.405 (.368-.453)

.735 (.571-1.11)

1.21 (.742-1.49)

390

.257 (.200-.281)

.580 (.391-.735)

.846 (.580-1.07)

452

.320 (.246-.568)

.650 (.385-.967)

402

.194 (<LOD-.220)

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
* Not calculated: proportion of results below limit of detection was too high to provide a valid result.

Biomonitoring Summary: https://www.cdc.gov/biomonitoring/Mercury_BiomonitoringSummary.html
Factsheet: https://www.cdc.gov/biomonitoring/Mercury_FactSheet.html
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Attachment C1: Lead, and Arsenic and Mercury Exposure Questionnaires

Lead Investigation Questionnaire
Address:
Property Owner:
Current Resident:
Children/Children’s Habits:
1.
(a) Do any children live in the home? Yes
No
(b) If yes, how many? ____
Ages? ____ ____ ____ ____
(c) Record blood lead levels, if known. ____ ____ ____ ____
(d) Are women of child-bearing age present?
Yes
No
2. Location of the rooms/areas where each child sleeps, eats, and plays.
Child

Location of BR

Rooms where
child eats

Primary location Primary location
where child plays where child plays
indoors
outdoors.

3. Where are toys stored/kept? _______________________________________________________
4. Is there any evidence of chewed or peeling paint on woodwork, furniture, or toys? Yes No
Family Use Patterns:
5. Which entrances are used most frequently?
6. Which windows are opened most frequently?
(a) Which windows are inoperable?
7. Do you use a window air conditioner? Yes No
If yes, where?
8.
(a) Do any household members garden? Yes
No
(b) Location of garden
(c) Are there plans to do any landscaping activities that will remove
grass or ground covering?
Yes
No
9
(a) How often is household cleaned?
(b) What cleaning methods are used? ___wet mopping ___sweeping___vacuuming___dusting
10
(a) Were building renovations recently conducted?
Yes
No
(b) If yes, where?
(d) Was building debris stored in the yard? If yes, where?
11.
Are renovations planned? Y N
If yes, where?
12.
Occupation/workplace of household members:
Observations:
Housekeeping: Good____
Fair____
Poor____
Pets:
Inside____
Outside____
Personal hygiene: Good____ Fair____
Poor____
Flooring: Carpet________________________ Cleanable surfaces_____________________________

2

Lead Investigation Questionnaire
Housing Condition (List Locations):
Generally deteriorated paint:

Paint being abraded:

Paint chipping due to impact:

Roof or plumbing leaks:

Paint in exterior soil?

Yes

No

Other painted structures (garage, shed, fence)?

3

Arsenic and Mercury Exposure Investigation Questionnaire
Introduction - Hello my name is {SAY NAME}.
We are part of the RMAP team from the Health Department conducting environmental sampling in Butte. We are
following up with you because we have found arsenic or mercury above action levels at your home, or because
you have requested analyses of arsenic or mercury in urine. We will be asking you some common questions like
your name and address. We will also ask questions on your potential contact with arsenic or mercury. We are
asking these questions to better understand all the data we collect.
The questions should take about 20 minutes. Once we receive the results for your samples, you will be given a
copy and details of the testing results for you and your children (if you have them). Generally, we are able to get
results to you within 12 weeks.
1. Person Administering Questionnaire _______________________________________
2. Date Questionnaire Administered _________________________________________
3. Participant last name ___________________________________________________
4. Participants first name __________________________________________________
5. Address: _____________________________________________________________
______________________________________________________________
______________________________________________________________

6. Mailing address if different from home address: ______________________________
______________________________________________________________
______________________________________________________________

7. Laboratory ID ________________________________________________________
Now I want to ask you questions about how I can contact you. I will also be asking how long you have lived at or
visited certain places. This is needed to find out how long you may have had contact with arsenic or mercury and
how long it may have lasted. We will also ask your age, address, and about how you spend your time (e.g, child at
daycare, how often they play outside, your jobs and hobbies). This is useful to help us better understand your test
results.
8. Is the person being interviewed a minor?
Yes
No (skip to question 15)

4

Arsenic and Mercury Exposure Investigation Questionnaire
9. Name of person answering questions for minor child:
10. Relationship to child:
Mother
Father
Grandparent
Guardian
11. Does the child put their hands or toys in their mouth?
Yes
No (skip to question 13)
12. If yes, what and how often?

13. Have you noticed the child eating dirt while playing outside?
Yes
No (skip to question 15)
14. If yes, how often?

Demographic Questions. Script: The next questions are about qualities of the person who is being
tested (you or your child/ward). This information and will help us better understand your test results.

15. What is your or your child/ward’s sex?
Male
Female
16. What is your or your child/ward’s age and date of birth?
Age
Date of Birth

17. If female between 15-44 yrs, are you pregnant? If yes in what month of pregnancy?
Don't know

5

Arsenic and Mercury Exposure Investigation Questionnaire
No
Yes, 0 to 3 months
Yes, 4 to 6 months
Yes, 7 to 9 months
18. Do you or your child/ward regularly spend time at another location outside the home (e.g., work or
daycare/school)?
Yes
No (skip to question 22)
19. If yes, how long are your or your child/ward out of the house during the day?
1 to 4 hours
5 to 8 hours
Over 8 hours
Don’t know

20. If you or your child/ward are out of the house during the day, how many times per week?
1-3 days per week
4 or more days per week
Don’t know
21. How many hours per day do you or your child/ward typically spend outdoors?
Do not spend time outdoors
Less than 2 hours per day
2 to 4 hours per day
4 to 6 hours per day
Over 6 hours per day
Don’t know
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22. Does you or your child/ward wash hands before eating?
Always
Sometimes
Never
23. How long have you lived at this address?
Less than 6 months
6 months to less than 2 years
2 to 5 years
6 to 10 years
More than 10 years
24. How long have you lived in Butte, MT?
Less than 6 months
6 months to less than 2 years
2 to 5 years
6 to 10 years
More than 10 years

Attributes of the Structure or Home. The following questions are about the qualities and
characteristics of your home.
25. Do you live in a(n):
Apartment
Single Family Home
Townhouse or Condominium
Mobile Home

7
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Other
No
Don’t know

26. How often do you clean your home using a wet mop?
Daily
Several times a week
Weekly
Monthly
Other
27. How often do you clean your home using a vacuum cleaner?
Daily
Several times a week
Weekly
Monthly
Other
28. Do you have an attic in your home?
Yes
No (skip to question 32)
29. If you have an attic in your home, how often do you enter the attic?
Daily
Weekly
Monthly
Yearly
Never
30. Has your attic been cleaned by a professional?
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Yes
No
31. If yes, when was it cleaned?

Soil Information (Tracking inside home)
32. Does your home have a yard with bare dirt?
Yes
No
33. Has soil in your yard been removed and replaced with clean soil?
Yes
No (skip to question 35)
34. If yes, when was it done?

35. How often do you or your child/ward remove shoes before entering your home?
Never do this
Seldom do this
Sometimes do this
Always do this
36. Does anyone in the home work primarily outdoors in a job with frequent soil or slag contact? (slag
reprocessor, construction worker, landscaping, etc.) (if NO, skip to question 38)
Yes
No
Don’t know
37. How often do they change clothing when entering the home after work outdoors?
Never do this
Seldom do this
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Sometimes do this
Always do this

Arsenic Exposure Questions
38. Do you have a job that may bring you into contact with arsenic?
Wood preservation
Arsenate pesticide production
Sand blaster
Other

39. How many portions of fish and other seafood (including shrimp, canned tuna and clam chowder) did
you or your child/ward eat in the past week?
None
1-2
3-4
5 or more
Don’t know
40. How many portions of rice (white or brown) did you or your child/ward eat in the past week?
None
1-2
3-4
5 or more
Don’t know

Mercury Exposure Question
41. Do you or your child/ward have mercury amalgam fillings?
Yes (if yes, approximately how many?)

10
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No
42. Is there anything you want us to know about you or your child that we did not ask about?
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URINE COLLECTION INSTRUCTIONS
BUTTE-SILVER BOW EXPOSURE INVESTIGATION
Please READ CAREFULLY:
• Enclosed is a plastic cup and a plastic bag with an absorbent pad inside.
• DO NOT take the cap off the cup until you are about to collect your urine.
• We would like you to collect your first morning urine, if possible
• Make sure you fill out all the items on the plastic cup label before you put your
urine in the freezer.
Instructions for collecting your urine:
• Wash your hands with soap and water.
• Rinse and dry your hands with a clean
towel.
• Keep the cup closed until you are ready to
collect your urine.
• DO NOT TOUCH the inside of the cup or
cap.
• Open the cup and leave the cap turned up.
• Collect your urine inside the cup.
• Put the cap back on the filled container and
tighten it.
• Wash your hands with soap and water again.
• Fill out the label on the plastic cup as follows:
o Name
o Date
o Time of urine collection
o First Morning Urine? Yes or No
o Time urine put into freezer
• Put the closed cup filled with urine on the absorbent pad in the plastic bag we
gave you,
• SEAL the BAG,
• Put the sealed plastic bag with the filled urine cup in the FREEZER.
• Bring the CUP of FROZEN URINE in the sealed plastic bag to your
scheduled blood draw appointment.

Thanks!
13
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Preface
NOTE:

The LeadCare® II Blood Lead Analyzer is a CLIA-waived
device. Facilities that perform tests with the LeadCare II
system must have a CLIA Certificate of Waiver (COW) or
higher, as issued under the authority of the Public Health
Service Act (PHSA) (42 U.S.C. 263(a)). In addition to a
Certificate of Waiver, all laboratories performing this test
must comply with all applicable state and local laws.
All laboratories eligible for a CLIA Certificate of Waiver
must follow the manufacturer's instructions as specified in
the LeadCare II User's Guide (this guide), LeadCare II Quick
Reference Guide and in the LeadCare II Package Insert.

Other LeadCare II Documents
•

LeadCare II Quick Reference Guide (English)

•

LeadCare II Test Kit Package Insert

•

LeadCare II Flash Drive

Troubleshooting
Troubleshooting procedures are described in detail in Chapter 5
of this guide. Read this section carefully. If you continue to
experience problems with device operation, contact Magellan
Diagnostics Product Support at 1-800-275-0102 or
LeadCareSupport@magellandx.com.
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Chapter 1 Before Testing
Read all instructions carefully before you perform a blood
lead test.
This chapter contains important information that you need to know before you
use the LeadCare® II Blood Lead Analyzer. Please read the following sections
before using the analyzer.
•

Unpacking the LeadCare II Blood Lead Analyzer

•

Setting up the Analyzer

•

About the LeadCare II Blood Lead Analyzer

•

Intended Use

•

Operating Requirements

•

Reading the Analyzer Display

•

Important Precautions

•

How to Get Help
CAUTION: Magellan Diagnostics recommends that you
practice using the system before performing a patient test.

LeadCare® II User's Guide

1-1

Definitions and Precaution Symbols
WARNING: This symbol identifies conditions or practices that
could result in injury or loss of life.

CAUTION: This symbol indicates conditions or practices that
could cause erroneous results or damage to the analyzer.

This symbol indicates that you should read the instructions
carefully.

This symbol indicates the potential for electrostatic discharge.
Static electricity can damage or destroy the internal components
of devices. It can be generated by scuffing shoes on a carpet or
brushing some other materials such as fabrics. When running the
analyzer, discharge static electricity by touching a metal object
(such as the outside of a computer) in your work area.

This symbol indicates a biohazard.

NOTE:

LeadCare® II User's Guide

A note provides additional information to help you perform
procedures correctly, or help you understand how the system
works.
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Compliance Statements
CE Mark
IVD - 98/79/EC (27/10/1998) – Annex I and III

EMC
EMC Standard EN 61326-1 (2005) also FCC Part 15 Subpart B Class B

Safety
Complies with:
Low Voltage Directive 2006/95/EC, EN61010-1:2001 (EU) UL61010-1:2004 (USA) CSA
C22.2 No. 61010-1:2004 (Canada) and Requirements for In Vitro Diagnostic (IVD) IEC
61010-2-101:2002.

NOTE:

Protection of this equipment may be impaired if operated in a way not
described in this User’s Guide. Use only the accessories and cables
supplied or specified.
The ETL label on the bottom of the instrument indicates that Intertek Electrical
Testing Labs (ETL) has certified the LeadCare II to the applicable safety
standards.
This device complies with Part 15 of the FCC rules. Operation is subject to the
following two rules:
1. This device may not cause harmful interference.
2. This device must accept any interference received, including interference
that may cause undesired operation.
This device complies with the Waste Electrical and Electronic Equipment
(WEEE) directive of the European Union (EU). For information regarding the
proper decontamination procedure for this product please contact Magellan
Diagnostics. Instruments labeled with the associated symbol (see left) must not
be disposed of as regular waste material.

LeadCare® II User's Guide
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Symbols
The following symbols are used in the labeling of the LeadCare II Analyzer and
Blood Lead Test Kit.
Symbol

Description
This product fulfills the requirements of Directive 98/79/EC
on In Vitro Diagnostic Medical Devices.
Temperature Limitation
Use By
Manufacturer
Batch Code
Biological Risk
Caution: See Instructions for Use
Caution: Risk of Electric Shock
Consult Instructions for Use
Catalog Number
Serial Number
In Vitro Diagnostic Medical Device
Authorized Representative in the European Union

О

Off (supply)

І

On (supply)
Prescription Use Only

LeadCare® II User's Guide
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Unpacking the LeadCare II Blood Lead Analyzer
LeadCare II materials are contained in two (2) packages:
1.

LeadCare II Analyzer Kit
•
•
•
•
•

Analyzer
AC Adapter & International Power Plug Set
4 AA Alkaline Batteries
Quick Reference Guide (not pictured)
LeadCare II Flash Drive (contains User’s Guide and Instructional Videos)

Figure 1-1

LeadCare® II User's Guide
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2.

LeadCare II Test Kit
•
•
•
•
•
•
•
•
•

48 Blood Lead Sensors
48 LeadCare Treatment Reagent Tubes
50 LeadCare II Heparinized Capillary Tubes and Plungers
50 LeadCare II Droppers
Level 1 Control
Level 2 Control
Calibration Button
LeadCare II Package Insert
LeadCare Labels, Worksheets and Assayed Control Sheet

Figure 1-2

Test Kit Contents

WARNING: Be careful when handling the LeadCare II
Treatment Reagent. This reagent contains dilute Hydrochloric
acid. Refer to the LeadCare Treatment Reagent Safety Data
Sheet that appears in Appendix D of this manual for safe
handling instructions.

Register Your System
Please take a moment to complete the registration form online at:
https://www.magellandx.com/leadcare-products/leadcare-ii/support/gettingstarted/
Registering your analyzer with Magellan Diagnostics will allow you to receive
important updates about your LeadCare II Test System.

LeadCare® II User's Guide
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Setting up the Analyzer
The Work Area
Set up the LeadCare II Blood Lead Analyzer in an area that is free of drafts and
temperature extremes. The analyzer needs a stable temperature to operate. You
can use the analyzer with an AC power adapter or with batteries.
Using the Analyzer with a Power Adapter
CAUTION: Use only the AC adapter supplied with this unit.
Attempting to use a different type of manufacturer’s product
could damage the analyzer.
To use the analyzer with a power adapter:
1.

Plug the DC connector into the back of the analyzer as shown in Figure 1-3.

Figure 1-3

Plug in DC Connector/AC Adapter

2.

Plug the adapter into an AC power outlet.

3.

Move the power switch to the left to turn the analyzer on.

Installing Batteries
CAUTION: When replacing batteries, use only 1.5 V AA size
alkaline or lithium batteries (4 ea). Shut the analyzer off prior to
battery removal. Dispose according to local, state and country
regulations.
WARNING: Batteries may explode if mishandled or replaced
incorrectly. Do NOT dispose of batteries in fire. Do NOT attempt
to disassemble or recharge batteries. Keep batteries away from
children.

LeadCare® II User's Guide
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The battery holder is located at the rear of the analyzer. To install the batteries:
1.
2.
3.

Turn the analyzer to access the battery area.
Remove the DC input connector.
Remove the battery cover as shown in Figure 1-4.

Figure 1-4
4.
5.

Remove Battery Holder Cover

Press on the locking tab with one or both thumbs and slide it away from the
analyzer.
Insert four 1.5 V AA size alkaline or lithium batteries as shown in Figure 1-5.

Figure 1-5

Insert Batteries

CAUTION: Observe the polarity of each battery. Inserting one
backwards could damage the analyzer.
6.

Replace the cover by sliding it back on. Make sure it “clicks” into place.
NOTE:

When the analyzer is not in use it will automatically shut off:
Battery: 15 minutes
AC Adapter: 60 minutes
Test results are lost when the analyzer becomes idle.

LeadCare® II User's Guide
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About the LeadCare II Blood Lead Analyzer
The LeadCare II Blood Lead Analyzer is a portable device for testing the amount
of lead in capillary whole blood.

Figure 1-6

LeadCare II Blood Lead Analyzer

About Blood Lead Testing
According to the US Centers for Disease Control (CDC), there is no known safe
level of lead. Consult your local public health department and/or CDC
recommendations for information on the management of blood lead levels.
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How the LeadCare II System Works
The LeadCare II System uses an electrochemical technique called Anodic
Stripping Voltammetry (ASV) to determine the amount of lead in a blood sample.
The diagram below illustrates the methodology.

1

Blood is mixed with LeadCare Treatment Reagent and the red
blood cells (RBC) are lysed, which releases the lead that is
bound to the RBC wall.
Pb+2
Pb

+2

Reagent
Pb+2
Pb+2

2

A negative potential is applied to the sensor to accumulate lead
atoms on the test electrode. The potential is rapidly reversed
releasing the lead ions.
Pb+
Pb+
Pb

Pb Pb

Pb Pb

Pb

Pb+

Pb

Reduction step

3

Pb+

Pb+
Pb+
Pb+

Oxidation (stripping) step

The current produced is directly proportional to the amount of
lead in the sample. The area underneath the curve is used to
calculate a quantitative blood lead result.

Analysis
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Intended Use
The LeadCare II Blood Lead Analyzer and Test Kit provide a measurement of the
amount of lead in a fresh capillary whole blood sample. The LeadCare II Blood
Lead Analyzer is intended for in vitro (external) use only. It is for lead testing
only. The test kit components are designed for use only with the LeadCare II
Blood Lead Analyzer. This test system is for professional use only.

Operating Requirements
CAUTION: Do NOT place the LeadCare II Blood Lead
Analyzer in a drafty area. For example, do NOT place the
analyzer near air conditioning or heating vents. If the
temperature is out of operating range, or if the temperature is
unstable, the following messages appear on the display.
TEMP IS TOO HOT
PLEASE WAIT UNTIL
ANALYZER IS IN
TEMP RANGE
TEMP IS TOO COLD
PLEASE WAIT UNTIL
ANALYZER IS IN
TEMP RANGE

If the temperature is unstable, the WARNING message appears on the display
and flashes on for 2 seconds. Move the analyzer to a more suitable location and
try again later.
WARNING
TEMP IS UNSTABLE
TEST MAY FAIL

LeadCare® II User's Guide
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Reading the Analyzer Display
The LeadCare II Blood Lead Analyzer displays messages that guide you through
the test. Do NOT go to the next step until the message tells you to proceed.
The test takes three (3) minutes. When the test is complete, the blood lead level
appears on the display. The test result remains on the screen until you insert a
new sensor or for a minimum of 15 minutes.
Display
Screen

Figure 1-7

Message Display

The analyzer monitors the test conditions and displays error messages on the
screen if a problem is detected. Chapter 5, Troubleshooting and Maintenance,
includes a list of the messages and what to do if they appear.

Important Precautions
This section lists important things you need to know about using the LeadCare II
Blood Lead Analyzer. Understand these precautions.

Precautions When Preparing Samples
WARNING: Use universal precautions while collecting
and handling blood samples. Blood can transmit
infectious diseases. Follow the procedures set up by
your institution for meeting local, state and federal
regulations.

LeadCare® II User's Guide
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CAUTION: When preparing blood samples for testing:
•

Wear powder-free gloves to prevent lead contamination.
Because there is lead in the environment, it is easy to
contaminate blood samples, collection tubes, and test kit
items. Contamination of the work environment can cause
inaccurate blood lead test results.

•

Use only the heparinized capillary tubes provided with the
LeadCare II Test Kit. The capillary tube must be filled to the
fill line (50 µl) for accurate results. Check to make sure that
the tube is free of gaps and bubbles. After collection, wipe
off the sides of the capillary tube with a gauze pad (wipe
downward). The accuracy of the test depends on a precisely
measured sample.

•

Use only fresh, unrefrigerated, whole blood with the
LeadCare Treatment Reagent. Do NOT refrigerate the blood
prior to mixing with the reagent. Blood must be stored at
10o - 32oC (50o - 90oF).

•

Add blood sample to the treatment reagent within 24 hours
of collection. Blood older than 24 hours may produce false
negative results. Make sure the blood sample is free of blood
clots, which can cause inaccurate results.

• Visual Impairment: Any visual impairment, such as color
blindness may affect the operator's ability to detect the
sample color change. Operators with vision deficiencies
should invert the tube 8 to 10 times to ensure that the
sample is properly mixed.

Precautions for Testing a Patient Sample
CAUTION: When testing blood samples:
•

Wear powder-free gloves to prevent lead contamination.
Because there is lead in the environment, it is easy to
contaminate blood samples, collection tubes, and test kit
items. Contamination of the work environment can cause
inaccurate blood lead test results.

•

Do NOT allow the inside of the treatment reagent vial or the
vial cap to touch anything. This could cause inaccurate blood
lead test results.

• Mix the blood sample with the treatment reagent thoroughly,
but do NOT shake the tube. Gently invert the tube ten times
until the reagent turns brown. Avoid foam and air bubbles.

LeadCare® II User's Guide
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CAUTION:
• Do NOT leave the treatment reagent vial uncapped other
than to add the sample or remove the sample/reagent
solution. The tube and its contents could become
contaminated causing inaccurate test results.
•

Before placing the sample on the sensor, make sure the
display calls for sample addition.

• Keep the sensors in their container until you need them. Do
NOT touch “X” on the sensors, except when applying the
sample. This could cause contamination and an inaccurate
test result.

Precautions When Performing Quality Control Testing
CAUTION: When testing controls, make sure that the value falls
within the acceptable range for each control. Do NOT proceed
to patient samples if the control results are NOT within
acceptable limits. Refer to the Troubleshooting section of the
User's Guide, or call Product Support at 1-800-275-0102 to help
you resolve any problem.

Using the Control Materials
CAUTION: Treat control material as you would patient samples;
add the control to treatment reagent prior to testing. Store the
controls at room temperature with all other kit components.
Discard unused control material when the kit is finished. Using
control material with the wrong kit lot number could yield
inaccurate results. Refer to Quality Control chapter for more
information about the control test procedures.

LeadCare® II User's Guide
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More Information
The following references provide additional information about blood sample
collection, blood lead testing, and Magellan Diagnostics LeadCare II products.
Blood Sample Collection
Information about sample collection is available from the Clinical Laboratory
Standards Institute (CLSI) or the Centers for Disease Control (CDC).
•

CLSI (Clinical and Laboratory Standards Institute) GP44-A4:
Procedures for the Handling and Processing of Blood Specimens;
Approved Guideline – 4th ed. (ISBN 1-56238-724-3). www.clsi.org

•

CDC Guidelines for Collecting and Handling Blood Lead Samples 2004 - Video presentation describes how to collect and handle
samples that will be used for blood lead testing.
www.cdc.gov/nceh/lead/training/blood_lead_samples.htm

Blood Lead Testing
According to the US Centers for Disease Control (CDC), there is no known safe
level of lead. Consult your local public health department and/or CDC
recommendations for information on the management of blood lead levels.
LeadCare II Product Information
Visit www.leadcare2.com for additional information about our products and
resources.

How to Get Help
A Product Support Specialist is available Monday through Friday,
8:00 a.m. to 6:00 p.m. (EST).
Call LeadCare Product Support at 1-800-275-0102.
Email LeadCareSupport@magellandx.com.

LeadCare® II User's Guide
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Chapter 2 Calibrating the Analyzer
This chapter describes how to calibrate the analyzer. The analyzer must be
calibrated to the lot of sensors to ensure accurate results. This chapter contains
the following topics:
Turning the Analyzer On and Off
Analyzer Self-Tests
About Calibration
Calibrating the Analyzer

•
•
•
•

CAUTION:
• Calibration is required for each new lot of test kits. Use the
calibration button in the test kit. Use only the button
packaged with the kit you are using. Failure to use the
correct calibration button with the test kit could cause
inaccurate results.
• Do NOT use items from more than one test kit at a time.
• Always make sure that the lot numbers on the sensor
container and calibration button match the SENSOR LOT
number on the analyzer display.

®
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Turning the Analyzer On and Off
The LeadCare® II Blood Lead Analyzer power switch is located at the back of
the device as shown in Figure 2-1.

Power Switch

Off

On

Figure 2-1

Power Switch

If the analyzer is not in use for 15 minutes (battery operation) or 60 minutes
(AC operation), it will go into “sleep” mode. Inserting a sensor or moving the
power switch to the ON position will restart the analyzer.
Turn On the Analyzer
To turn on the analyzer for the first time:
1.

Make sure the analyzer is plugged in using the AC adapter, or that batteries
are installed if you are using the analyzer in a remote location.

2.

Move the switch on the back of the analyzer to the ON (|) position.

Figure 2-2

®
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Analyzer Self-Tests
When you first turn on the analyzer, you will hear a beep and see the startup and
self-test messages.
The analyzer performs a series of self-tests. The LeadCare II self-test is a set of
internal electrical and software checks that ensure the proper operation of the
system's electronic components. The purpose of the tests is to ensure that each
critical hardware component of the system is operating at the correct level. If any
one component of the system fails this initial self-test, the user is warned that the
unit requires service and the user is prevented from running any patient samples.
The first time you turn on the analyzer, the screen reads:
PLEASE CALIBRATE
ANALYZER WITH BUTTON

Once the analyzer has been calibrated, the following message appears.
CALIBRATION
SUCCESSFUL

IF NEW LOT
TEST CONTROLS

PREPARE SAMPLE
USE SENSOR LOT XXXX
OR RECALIBRATE
THEN INSERT SENSOR

You can also turn on the analyzer by inserting a sensor.
If you insert a sensor to turn on the analyzer, the following message appears:
ADD SAMPLE
TO X ON SENSOR
SENSOR LOT XXXX

®
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About Calibration
Why Calibration is Important
The analyzer must be calibrated to the lot of sensors to ensure accurate results.
You must calibrate the analyzer:
The first time you use the analyzer.
Each time you start a new lot of test kits.
Any time the analyzer displays a recalibration message.

•
•
•

The Calibration Button
Each LeadCare II Test Kit comes with 48 sensors and a calibration button. The
button transfers calibration and expiration information to the analyzer. When you
touch the calibration button to the button reader, you will hear an audible beep.
The lot number appears on the screen to verify that the button was read properly.
The CALIBRATION SUCCESSFUL message flashes for 2 seconds.

Calibrating the Analyzer
CAUTION:
• Calibration is required for each new lot of test kits. Use only the
calibration button packaged with the test kit you are using.
Failure to use the correct calibration button could cause
inaccurate results.
• Do NOT use items from more than one test kit at a time.
• Each test kit comes with a calibration button marked with the
sensor lot calibration code. Always make sure that the lot
numbers on the sensor container and calibration button match
the SENSOR LOT number on the analyzer display.
See calibration instructions below.
1. Turn on the analyzer. The
analyzer is ready when the
“Prepare Sample” message
appears.
NOTE: The first time you turn on
the analyzer, you will see the
“PLEASE CALIBRATE” message.
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PREPARE SAMPLE
USE SENSOR LOT XXXX
OR RECALIBRATE
THEN INSERT SENSOR

2-4

2. Locate the calibration button in the test kit. Remove the
calibration button from the test kit package.
3. Match the lot number on the sensor container with the
calibration code on the button.
4. Hold the calibration button to the button reader until you
hear the beep. The button must touch both the center
contact and metal side of the button reader.
There is no need to apply pressure.
5. Calibration takes a few seconds.
When calibration is complete, the
screen briefly reads
“CALIBRATION SUCCESSFUL”.
Then the screen reads “IF NEW
LOT TEST CONTROLS”, followed
by the “PREPARE SAMPLE...”
message.

CALIBRATION
SUCCESSFUL

6. Make sure the number of the button matches the display.
The LeadCare II Blood Lead Analyzer is now ready for
testing.
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Chapter 3 Quality Control Procedure
Magellan Diagnostics provides the LeadCare® II Controls in the test kit for quality
control. The Level 1 and Level 2 controls are used to verify system performance
and accuracy. This chapter covers the following information:
•
•
•
•
•

What is a LeadCare II Lead Control
Storage and Handling
How Often Should You Test Controls
Testing Controls
Interpreting the Control Test Results

What is a LeadCare II Lead Control
A control is a standard against which test results can be evaluated. The
LeadCare II controls are room temperature stable solutions designed to mimic
blood, and spiked with lead to specific target values. The product is supplied in a
two level format. Each is assigned a target lead value with an associated
acceptable range.
The testing of controls will ensure your LeadCare II Blood Lead Analyzer is
reporting accurate results.

Storage and Handling
The control material is supplied in liquid form and ready to use. It should be
stored at room temperature and should not be used beyond its expiration date.
CAUTION: Controls should only be used with sensors of the
same lot number. Discard remaining control solutions when the
sensors are gone. Failure to do so may result in inaccurate
patient results.
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How Often Should You Test Controls
According to CLIA guidelines for Waived Laboratories, controls should be run
according to the manufacturer's instructions, which are: 1
• Each new lot.
• Each new shipment of materials, even if it’s the same lot previously received.
• Each new operator (i.e., operator who has not performed the test recently).
• Monthly, as a check on continued storage conditions.
• When problems (storage, operator, instrument, or other) are suspected or
identified.
• If otherwise required by your laboratory's standard QC procedures.
NOTE for
Some certification programs may have additional quality
Non-Waived
control requirements. Follow your federal, state and local
Laboratories: guidelines to ensure compliance.

Testing Controls
Test the LeadCare II Lead Control material as you would any whole blood
sample. You must run both the Level 1 and Level 2 controls to verify the
performance of the system.
CAUTION: When testing controls, make sure that the
value falls within the acceptable range for each control. Do
NOT proceed to patient samples if the control results are
outside acceptable limits. Refer to the Troubleshooting
section of the User's Guide, or call Product Support at
1-800-275-0102 to help you resolve any problem.
Testing controls consists of the following steps:
A) Prepare the Sample
1. Label a treatment reagent tube, "Level 1".
2. Gently swirl the control vial. Remove the cap from the Level 1 control and
place it top down on a clean surface.
3. Fill one capillary tube with the control material. To accomplish this tilt the
control vial, insert the capillary tube into the liquid while holding the green
end of the capillary tube almost horizontally. Capillary action will fill the
tube to the black line.
4. Use a clean wipe to remove excess control material from the outside of
the capillary tube.
Benson, Carol 2008, 'Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA)
Waiver Applications for manufacturers of in Vitro Diagnostic Devices', Guidance for Industry and FDA Staff:,
p.34, viewed 26 January 2009.

1
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B) Mix with Treatment Reagent
1. Remove the cap from the treatment reagent tube and place it top down on
a clean surface.
2. Place the full capillary tube into the treatment reagent. Insert a plunger
into the top of the capillary tube and push down, ensuring the entire
volume of control is dispensed into the treatment reagent.
3. Remove the empty capillary tube and recap the treatment reagent.
4. Invert the treatment reagent tube 8 – 10 times to thoroughly mix the two.
The resulting mixture will be red.
C) Test
1. Insert a fresh sensor into the LeadCare II Analyzer.
2. Ensure the lot number on the display matches the sensor lot you are
using. It must also match the lot number on the control vial.
3. Invert your sample to ensure the sample is well mixed, then remove the
cap.
4. Using a dropper, transfer the sample to the X on the sensor.
5. When the three minute countdown is complete, record your lead result in
micrograms per deciliter (µg/dL).
6. Repeat this process for the Level 2 control.

Testing Controls:

®
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1.

Label a fresh treatment reagent tube "Level 1 control".

2.

Swirl the control vial gently. Remove the cap from the
control and place it top down on a clean laboratory
wipe. Ensure the lot number on the control vial
matches the sensor lot number you will be testing.

3.

Holding the capillary tube almost horizontally with the
green band on top, fill it to the 50 µL black line.
Replace the cap on the control vial.

3-3

4.

Use a downward motion to remove excess control from
the outside of the tube with a clean wipe or gauze pad.
Use caution not to absorb the control from the end of
the capillary tube.

5.

Inspect the capillary tube for proper filling. Make sure
there are no gaps or bubbles, or any excess control on
the outside of the capillary tube.

6.

Remove the cap from a vial of treatment reagent and
place it top down on a clean surface. Do NOT allow the
inside of the cap to touch anything. This could cause
inaccurate test results.

7.

Place the capillary tube into the treatment reagent tube.
Insert a plunger into the top of the capillary tube and
push down ensuring the entire volume of control is
dispensed into the treatment reagent.

8.

Replace the tube cap. Invert the tube 8 to 10 times to
mix the sample completely. The mixture will remain red.

9.

Repeat this process (steps 1 thru 8) for the Level 2
control.

10. Analyze control samples according to the instructions
provided in Chapter 4.
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Interpreting the Control Test Results
The target values are printed on the control vials. The blood lead level that
appears on the LeadCare II Analyzer should be within the acceptable range
provided for that control. If the reported value is within the acceptable limits for
both the Level 1 and Level 2 controls, your LeadCare II System is operating
properly. You may now test patient samples.
If the reported value for the Level 1 and/or Level 2 control is outside the
acceptable range, refer to the troubleshooting section of the LeadCare II User’s
Guide. If, after following the instructions, the control value is still out of range
please contact LeadCare Product Support at 1-800-275-0102.
CAUTION: Do NOT proceed to patient samples unless both
the Level 1 and Level 2 control results are within the
acceptable ranges.
How Magellan Diagnostics Assigns Lead Level Ranges
Acceptable ranges for each lot and lead level are established by Magellan
Diagnostics using LeadCare II Blood Lead Testing Systems. Magellan
Diagnostics establishes these ranges using extensive replicate analyses and
rigid quality control.
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Chapter 4 Blood Lead Testing
Read all instructions carefully before you perform a
blood lead test.

This chapter describes how to test a patient’s blood for lead. It contains the
following topics:
Overview of the Testing Procedure
The LeadCare® II Message Display
Required Materials
Precautions
Testing Procedure
Interpreting Patient Test Results
Follow-up Testing
Printing Test Results
References

•
•
•
•
•
•
•
•
•

Overview of the Testing Procedure
Testing for lead in blood with the LeadCare II Blood Lead Analyzer is fast and
easy. Practice lead testing with the control samples or other samples before you
perform a blood lead test.
The testing procedure consists of the following steps:
1. Verify you have the required materials.
2. Perform quality control testing on both levels of quality control and verify the
results are within the acceptable ranges.
3. Collect capillary blood sample. Check the capillary tube for correct filling.
4. Add blood to the treatment reagent tube.
5. Insert a sensor and match the sensor lot number with the display.
6. Using a dropper, obtain sample from the treatment reagent tube, touch the
dropper tip to the X on the sensor and squeeze the walls to dispense the
sample.
7. Read and record the test result.
8. Remove used sensor.
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The LeadCare II Message Display
The message display screen is designed to guide you through the testing
process. Remember to read the display messages.
PLEASE RECALIBRATE

Figure 4-1

Message Display

Required Materials
CAUTION: Make sure the analyzer, test kit, and samples are
at room temperature before testing.
Protective Powder-free Gloves
Alcohol Wipes, Gauze Pads, Lead Free Wipes (optional)
Lancets
Absorbent Liner and Biohazard Waste Container
LeadCare II Analyzer and Power Cord or Batteries
LeadCare II Quick Reference Guide
LeadCare II User’s Guide
LeadCare Test Kit Items:
o Heparinized Capillary Tubes/Plungers
o Treatment Reagent Tubes
o Blood Lead Sensors
o Calibration Button
o LeadCare II Lead Controls, Level 1 & 2
o Droppers

•
•
•
•
•
•
•
•

Precautions
Observe the precautions listed throughout this section. Failure to follow these
precautions could result in inaccurate test results.
Important precautions for testing are also listed in Chapter 1, Important
Precautions.
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WARNING:
• Blood can transmit infectious diseases. Use universal
precautions while collecting and handling blood samples.
Follow the procedures set up by your institution for
meeting federal, state, and local regulations.
• Dispose of sensors, capillary tubes, plungers, and
droppers in biohazard container.
• Use caution when handling the LeadCare II Treatment
Reagent. This reagent contains dilute hydrochloric acid.
Refer to the LeadCare Treatment Reagent Safety Data
Sheet that appears in Appendix E of this manual for safe
handling instructions.
CAUTION:
• Do NOT use sensors that have been dropped, previously
handled, broken, scratched or damaged in any way. This
could cause inaccurate test results.
• Make sure the sensor is inserted under the sensor guides
and sits flush on the sensor deck. Inserting the sensor
above the guides could cause inaccurate test results.
• Do NOT use any test kit or its components past the
expiration date. This could cause inaccurate test results.
• Do NOT leave the treatment reagent vial uncapped other
than to add the sample or remove the sample/reagent
solution. The tube and its contents could be
contaminated causing inaccurate test results.
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Testing Procedure
CAUTION: Do Not proceed to patient testing if the control
results are outside acceptable limits. Refer to the
Troubleshooting section of the User's Guide, or call
Product Support at 1-800-275-0102 to help you resolve
any problem.
Gather Testing Materials
NOTE:

Be sure the following items are part of the same test kit. Do
NOT mix components from different test kits.

Place the following items in front of you in a clean work space:
Container with heparinized capillary tubes/plungers
Treatment reagent tube
Sensor container
Dropper for depositing sample on the sensor
LeadCare II Blood Lead Analyzer

•
•
•
•
•

WARNING: Use universal precautions while collecting and
handling blood samples. Blood can transmit infectious
diseases. Follow the procedures set up by your institution to
meet local, state and federal regulations.
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Step 1:

Collect Blood
CAUTION: Only use the heparinized capillary tubes provided
with the LeadCare II Test Kit. The capillary tube must be filled to
the fill line (50 µl) for accurate results. Check to make sure that
the tube is free of gaps and bubbles. After collection, wipe the
capillary tube with a gauze pad (wipe downward). The accuracy
of the test depends on a precisely measured sample.

1. Label a treatment reagent tube with the patient ID using
the label provided.

2. Holding the heparinized capillary tube almost horizontally
with the green band on top, fill to the 50 µL black line.
Filling stops when the sample reaches the black line.
Do NOT use plasma or serum. Do NOT use
venous blood samples.

3. Remove excess blood from the outside of the tube with a
clean wipe or gauze pad. Use a downward motion to wipe
excess blood from the capillary tube.
Use caution not to absorb the blood from the end of
the capillary tube.

4. Inspect the capillary tube for proper filling. Make sure
there are no gaps, air bubbles, or any excess blood on
the outside of the capillary tube.
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Step 2:

Prepare Sample
CAUTION:
• The system is intended to test fresh capillary whole blood
(collected in either EDTA or Heparin). Add the blood to the
treatment reagent within 24 hours of collection. Blood older
than 24 hours may produce false negative results.
• Use only fresh, unrefrigerated, whole blood with the LeadCare
Treatment Reagent. Blood must be stored at 10° - 32°C
(50° - 90°F) prior to mixing with treatment reagent.
• Make sure the whole blood sample is free of clots, which can
cause inaccurate results.
1. Remove the treatment reagent cap from the tube and place it
top down on a clean surface. Do NOT allow the inside of the
cap to touch anything. This could contaminate the sample.

2. Place the full capillary tube in the treatment reagent. Insert a
plunger into the top of the capillary tube and push down,
ensuring to dispense the entire volume into the treatment
reagent.

3. Replace the tube cap. Invert the tube 8 to 10 times to mix the
sample completely.
4. The test sample is ready when the mixture turns brown. Repeat
sample collection and preparation for each sample to be tested.
CAUTION: Any visual impairment, such as color
blindness may affect the operator's ability to detect the
sample color change. Operators with vision deficiencies
should invert the tube 8 to 10 times to ensure that the sample
is properly mixed.
Storing Samples
You do not need to test the prepared sample immediately. The
mixture of blood and treatment reagent is stable for up to 48
hours at room temperature and up to 7 days refrigerated. If
refrigerated, bring to room temperature prior to analysis.
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Step 3:

Analyze the Sample
1. Remove one sensor from the sensor container. Close the
container immediately. Grasp the sensor at the end
without the black bars.
CAUTION: Keep the sensors in their container until
you are ready to use them. Minimize handling to prevent
contamination which could cause an inaccurate test
result.
2. Insert a sensor (with the black
bars facing up) completely into
the analyzer. Make sure the
ADD SAMPLE
sensor is inserted under the
TO X ON SENSOR
sensor guides and sits flush on
the analyzer deck. When the
SENSOR LOT 0018A
sensor is inserted properly the
analyzer beeps and displays the
message to the right.
3. Make sure the sensor lot number matches the lot number
on the display. If the number does not match, recalibrate
the analyzer and test controls (refer to Chapter 3).
CAUTION: The control lot number must match the
sensor lot number and the calibration button code.

4. Make sure that the sample mixture is at room temperature
and uniformly mixed before testing.

5. Remove the cap from the treatment reagent. Remove a
transfer dropper from its container. Squeeze the walls of
the dropper and insert the tip into the sample. Release the
pressure to draw the sample into the dropper. There
should be approximately ½” of sample in the dropper.
CAUTION: Make sure the
message to the right is
displayed on the screen before
adding the sample.
6. Touch the dropper tip to the X
on the sensor and squeeze the
walls to dispense the sample.
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ADD SAMPLE
TO X ON SENSOR
SENSOR LOT 0018A
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7. The analyzer will beep when it
has enough sample. It will display
the message to the right. After 3
minutes (180 seconds) the
analyzer will beep again to
indicate that the test is done.

8. Record the test results.

TESTING
XXX SECONDS TO GO
SENSOR LOT 0018A

RECORD TEST RESULT
7.5 µg/dL Pb
THEN REMOVE SENSOR
SENSOR LOT 0018A

9. Remove the used sensor immediately after recording the
result.

10. Discard the used materials in an appropriate biohazard
container.

11. If you do not remove the sensor after recording your last
result, within one minute the analyzer will sound two
short warning beeps every 15 seconds until the sensor
is removed or until the unit powers down.
Once the warning beep begins
the message on the screen
changes to “RECORD TEST
RESULT XXXX µg/dL Pb
PLEASE REMOVE SENSOR
IMMEDIATELY”. The beep
stops when the sensor is
removed.
12. The analyzer is ready for the
next sample when the “LAST
TEST RESULT” message
appears on the screen.
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RECORD TEST RESULT
XXXX µg/dL Pb
PLEASE REMOVE SENSOR
IMMEDIATELY

LAST TEST RESULT
7.5 µg/dL Pb
INSERT SENSOR
SENSOR LOT 0018A
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NOTE: The analyzer displays “Low” when it detects a
blood lead level below 3.3 µg/dL. “Low” results should
be recorded as “<3.3 µg/dL”. It is not uncommon to
obtain patient results that read “Low”.

If you do not run another test within 60 minutes (15 minutes when using
batteries), the analyzer will automatically go into “sleep” mode. If you have not
recorded your test result, it will be lost. You will have to repeat the analysis.

Interpreting Patient Test Results
The analyzer’s display window shows the blood lead result. The result is in
micrograms (µg) of lead per deciliter (dL) of whole blood. No calculation is
needed. Results are displayed to one decimal place. The reportable range of the
LeadCare II system is 3.3 to 65 µg/dL.
“Low” in the display window indicates a blood lead test result less than
3.3 µg/dL. When this occurs, report the blood lead result as less than (<)
3.3 µg/dL.
“High” in the display window indicates a blood lead test result greater than
65 µg/dL. When this occurs, report the blood lead result as greater than (>)
65 µg/dL. “High” results on LeadCare II should be followed up immediately
as an emergency laboratory test.

Follow-up Testing
Blood Lead test results should be shared with the patient’s physician for
interpretation and to determine when retesting and follow-up care are necessary.
A capillary blood sample that generates an elevated lead level should be
confirmed with a venous sample. The venous sample should be run at a
reference laboratory using a high complexity testing method.
In cases where the capillary specimen demonstrates an elevated lead level but
the confirmation venous sample does not, it is important to recognize that the
child may live in a lead-contaminated environment that resulted in contamination
of the fingertip. Efforts should be made to identify and eliminate the source of
lead in these cases.
Report all blood lead test results to the appropriate local, state or federal
agency.

Printing Test Results
®
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You can print the results by connecting the analyzer to a compatible label printer.
Refer to Appendix A: Connecting a Printer.

References
Additional information about lead poisoning is available through the Centers for
Disease Control and Prevention at www.cdc.gov/nceh/lead/
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Chapter 5 Troubleshooting and
Maintenance
Several factors contribute to inaccurate blood lead testing and control testing.
This chapter provides steps you can take if your patient blood lead tests or
control tests are out of range. This chapter contains the following topics:
Calling LeadCare Product Support
Troubleshooting Results Below the Target or Expected Value
Troubleshooting Results Above the Target or Expected Value
Control Test Results Below the Target Range: Possible Causes
Control Test Results Above the Target Range: Possible Causes
Screen Display Messages
Maintaining the Analyzer

•
•
•
•
•
•
•

Calling LeadCare Product Support
If you cannot determine why your system is giving you a problem, call LeadCare
Product Support at 1-800-275-0102 or email LeadCareSupport@magellandx.com.
Please collect this information and have it ready before you call:
•

Serial No. of LeadCare II (on bottom of analyzer)

•

Test kit lot number (on end of box)

•

Calibration code on calibration button *

•

When did you last test with controls?

Date:

•

Control results last recorded:

Level 1 ____ Level 2

•

Control lot number *

•

Control expiration date

•

Sensor lot number *
*NOTE:

®

Calibration code, control lot number and sensor lot number
should all be the same.
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Troubleshooting Results Below the Target or Expected Value
Possible causes include:
Less than 50 µL of blood was transferred to the treatment reagent tube.
Analyzer is not calibrated properly.
The sample is cold.
The sensor is not inserted properly.

•
•
•
•

See detailed precautions below:
Blood Sampling
• Less than 50 µL in the capillary tube will lower blood lead level results.
• Make sure that there are no clots or bubbles in the tube.
• Use only fresh, capillary whole blood from patients collected in heparin or EDTA.
Do NOT use venous samples. Do NOT use plasma or serum.
Blood Sample Preparation
• Every sample must be mixed in treatment reagent. You cannot test untreated
whole blood.
Equipment Setup, Calibration and Testing Materials
• Check the expiration date on the test kit box. Do NOT use a test kit that is beyond
the expiration date. When calibrated properly, the analyzer will not initiate a test
with expired sensors.
Make sure the analyzer is calibrated properly. Use the calibration button supplied
with the test kit you are using. When processing the sample verify the code on the
analyzer screen matches the code of the of the sensor lot in use.

•

Testing Conditions
• Operate the analyzer only within the specified humidity range: (12 to 80% Relative
Humidity).
•

Avoid operating the LeadCare II System in drafts or in locations with low humidity.

•

Make sure that the analyzer and the test kit are maintained at a constant
temperature. If you move any part of the system from one place to another (for
example, from outside into a laboratory) wait for the analyzer and kit components
to reach a stable temperature.

User Technique
• Make sure the sample/treatment reagent mixture is room temperature before
placing it onto a sensor. This is only relevant when testing samples that were
previously mixed with treatment reagent and stored refrigerated.
•

Make sure the blood and treatment reagent is thoroughly mixed before placing it
onto the sensor. The mixture should appear brown, confirming that the red blood
cells have been lysed.

•

Make sure the sensor is inserted under the sensor guides and sits flush on the
sensor deck.

•

Do NOT touch the sensor while the analyzer is running a test.

®
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Troubleshooting Results Above the Target or Expected Value
Possible causes include:
Contamination of blood sample.
Excess blood on the capillary tube.
Sample not mixed properly.
The analyzer is not calibrated properly.

•
•
•
•

See detailed precautions below:
Blood Sampling
• Lead is widespread in the environment. It is easy to contaminate a blood sample.
Thoroughly clean the collection site with soap and water followed by a clean
alcohol wipe prior to puncture. Use clean powder-free gloves during testing and
keep your gloved hands clean.
•

Make sure you are using lead-free collection devices.

•

Make sure the capillary tube is filled properly. Be sure to wipe excess blood from
the capillary tube with a downward motion. The accuracy of the test depends on
filling the capillary tube with 50 µL. Excess blood on the outside of the capillary
tube will tend to produce higher blood lead results.

Blood Sample Preparation
• Do NOT use clotted blood. If there are clots in the blood, obtain a new sample.
Make sure to transfer 50 µL of blood into the treatment reagent. Wipe the end of
the capillary tube with a gauze pad, using a downward motion before adding the
blood to the treatment reagent.

•

Equipment Setup, Calibration and Testing Materials
• Check the expiration date on the test kit. Do NOT use test kit materials that are
beyond the expiration date. When calibrated properly the analyzer will not initiate a
test with expired sensors.
•

Make sure the analyzer is calibrated properly. Use the calibration button supplied
with the test kit in use. When processing the sample, check to make sure the code
on the analyzer screen matches the code of the calibration button for the test kit.

•

Make sure you are using lead-free collection devices.

Testing Conditions
• Operate the analyzer only within the specified humidity range: (12 to 80% Relative
Humidity).
Make sure that the analyzer and the test kit are maintained at a constant
temperature. If you move any part of the system from one place to another, (for
example, from outside into a laboratory) wait for the analyzer and components to
reach a stable temperature.

•
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User Technique
• Do NOT touch the black bars on the sensor. This could damage the sensor.
•

Do NOT touch the ends of the capillary tubes or the plungers. This could cause
contamination.

•

Make sure to thoroughly mix patient blood with the treatment reagent. The mixture
should turn brown.

•

Do NOT leave the treatment reagent tube uncapped other than to add the whole
blood sample or to remove the sample for testing.

•

Do NOT touch the sensor while running a test.

Control Test Results Below the Target Range: Possible Causes
Possible causes of low control test results include:
•

Control lot number does not match the sensor lot and calibration code.

•

Less than 50 µL of control material was transferred to treatment reagent

•

The test sample is colder than detected by the analyzer.

•

The analyzer is not calibrated properly.

•

The sensor is not inserted properly.

See detailed precautions below:
Control Sample Preparation
• Use the capillary tubes and plungers provided with the test kit to transfer 50 µL of
control into the treatment reagent tube.
Always mix the control material with treatment reagent. Control material delivered
directly to the sensor will not yield an accurate result.

•

Equipment Setup, Calibration and Testing Materials
• Make sure the controls were properly stored: Room temperature storage is
considered 15 - 27ºC (59 - 80ºF).
•

Check the expiration date on the control vial to verify the controls have not expired.

•

Check the expiration on the test kit box to make sure the test kit materials have not
expired.

NOTE:

The controls are only intended for use with the test kit in which
they come. When the other reagents included in the test kit are
used up, discard the controls.

Make sure the analyzer is calibrated properly. Use the calibration button supplied
with the test kit in use. When processing the sample, check to make sure the code
on the analyzer screen matches the code of the calibration button for the test kit.

•
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Testing Conditions
• Do NOT operate the LeadCare II System in drafty locations.
Make sure that the analyzer and the test kit are maintained at a constant
temperature. If you move any part of the system from one place to another, (for
example, from outside into a laboratory) wait for the analyzer and components to
reach a stable temperature.

•

User Technique
• Do NOT touch the black bars on the sensor.
•

Make sure the sensor is inserted under the sensor guides and sits flush on the
sensor deck.

•

Do NOT touch the sensor while the analyzer is running a test.

•

Make sure the control and treatment reagent is thoroughly mixed before placing
onto the sensor. The mixture will appear red.

Control Test Results Above the Target Range: Possible Causes
Possible causes of high control test results include:
Control lot number does not match the sensor lot and calibration code.
More than 50 µL of control material was transferred to treatment reagent.
The test sample is warmer than detected by the analyzer.
The analyzer is not properly calibrated.

•
•
•
•

See detailed precautions below:
Control Sample Preparation
• Use the capillary tube and plunger to transfer 50 µL of blood into the treatment
reagent vial.
Wipe excess sample off the outside of the capillary tube with a clean gauze pad or
laboratory wipe before adding the control to treatment reagent.

•

Equipment Setup, Calibration and Testing Materials
• Make sure the controls were properly stored: Room temperature storage is
considered 15 - 27ºC (59 - 80ºF).
•

Check the expiration date on the control vial to verify the controls have not expired.

•

Make sure that the lot number of the control matches the lot number on the sensor
container and the lot number on the display screen.

NOTE:

®

The controls are only intended for use with the test kit in which
they come. When the other reagents included in the test kit are
used up, discard the controls.
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Make sure the analyzer is calibrated properly. Use the calibration button supplied
with the test kit. When processing the sample, check to make sure the code on the
analyzer screen matches the code of the calibration button for the test kit.

•

Testing Conditions
• Do NOT operate the LeadCare II System in drafty locations.
Make sure that the analyzer and the test kit are maintained at a constant
temperature. If you move any part of the system from one place to another (for
example, from outside into a laboratory) wait for the analyzer and components to
reach a stable temperature.

•

User Technique
• Do NOT leave the treatment reagent tube uncapped other than to add the control
sample or to remove the sample for testing.
•

Do NOT touch the black bars on the sensor.

•

Do NOT touch the sensor while the analyzer is running a test.

•

Make sure the control and treatment reagent is thoroughly mixed before placing
onto the sensor. The mixture will appear red.

Screen Display Messages
There are a number of standard screen display messages that appear during the
routine testing procedure. However, other messages may appear if the analyzer
detects a condition that prevents normal operation. The following table shows
some of the display messages.
NOTE:

®

Occasionally, error messages not noted in this guide may
appear on the display. Please note what error message was
displayed and call Product Support for additional instructions.
New users may want to check that the sensor was completely
inserted into the analyzer first. Product Support can be
reached at 1-800-275-0102.
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Screen Display Messages
Message

Definition

What to Do

The analyzer must be calibrated the first
time you use it and for each new sensor
lot.

Calibrate the analyzer. Refer to the
calibration instructions in Chapter 2.

The internal quality control check failed.

Record the error number & call
Product Support at 1-800-275-0102.

The temperature is too hot for testing.

Wait until the screen display the
PREPARE SAMPLE message.

The temperature is too cold for testing.

Wait until the screen display the
PREPARE SAMPLE message.

The temperature is too unstable for
testing.

Wait until the screen display the
PREPARE SAMPLE message.

The sensor in the analyzer is wet or
previously used.

Remove the used sensor and insert a
new sensor COMPLETELY into the
analyzer to retest.

PLEASE REMOVE SENSOR

A sensor was left in the analyzer.

Remove the sensor.

SENSOR OUT OF VIAL
TOO LONG
PLEASE REMOVE SENSOR

The sensor in the analyzer has been out
of the tube too long and cannot be used.

Remove the sensor and insert a new
sensor.

TEST FAILED
PLEASE REMOVE SENSOR

There is not enough sample on the
sensor or the sensor failed.

SENSOR REMOVED
TOO SOON

The sensor was removed from the
analyzer before the end of the test.

PLEASE CALIBRATE ANALYZER
WITH BUTTON
ELECTRONIC
QC CHECK FAILED
CALL TECH SERVICE
ERROR X
TEMP IS TOO HOT
PLEASE WAIT UNTIL
ANALYZER IS IN
TEMP RANGE
TEMP IS TOO COLD
PLEASE WAIT UNTIL
ANALYZER IS IN
TEMP RANGE
WARNING
TEMP IS UNSTABLE
TEST MAY FAIL
THIS IS A
USED SENSOR
PLEASE REMOVE SENSOR

TEMP IS UNSTABLE
RESULT DISCARDED
PLEASE REMOVE SENSOR

The temperature in the room is too
unstable to yield accurate test results.

PLEASE RECALIBRATE

There was a problem transferring the
calibration data from the calibration
button to the analyzer.

SENSOR LOT TOO OLD
PLEASE RECALIBRATE

The sensor is from a lot that has
expired.

SYSTEM FAILURE
CALL TECH SERVICE
CHANGE BATTERIES SOON

(Message flashes before or after
a test)
PLEASE CHANGE BATTERIES
LOW POWER
CHECK POWER CORD
LOW POWER
CHECK POWER CORD
OR CALL TECH SERVICE

Remove the sensor, discard it, and insert
a new sensor. When adding the sample
to the sensor, make sure the sample
completely covers the X area.
Remove the sensor. Insert a new sensor
and add another drop of sample. Wait
180 seconds (3 minutes) for the test to
finish.
Move the analyzer to an area where there
are fewer temperature changes (away
from sources of cold or heat). The
temperature is stable enough when the
PREPARE SAMPLE message indicates
that the analyzer is ready.
Repeat the calibration procedure. Refer
to Chapter 2, Calibrating the analyzer.

One of the main system components
failed.

Discard the sensor and the expired lot.
Use a sensor from a new lot and
recalibrate the analyzer.
Power analyzer off & on. If error persists,
call Product Support at 1-800-275-0102.

Voltage too low for the analyzer to run a
test.

Change the batteries. Use four 1.5 V AA
alkaline or lithium batteries.

The battery voltage is too low.

Change the batteries. Analyzer uses four
1.5 V AA alkaline or lithium batteries.

This message flashes for 2 seconds if
the voltage from the AC adapter is low.
The voltage from the AC adapter is too
low. The lead test is NOT allowed.

You can run a test.
Call Product Support at
1-800-275-0102.

*If an error message is encountered repeatedly, contact Product Support at 1-800-275-0102.
®
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Maintaining the Analyzer
Cleaning the Analyzer
Remove used sensors from the analyzer as soon as a result is recorded.
Clean the analyzer with a damp cloth and warm, soapy water. Do NOT
immerse in water.
Disinfect with dilute (10%) bleach solution.
Do NOT leave any soap film on the analyzer.
Do NOT allow liquid of any kind into the sensor connector.
Do NOT get the metal pins in the sensor connector wet.
Do NOT wash the inside of the calibration button reader.

•
•
•
•
•
•
•

®
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Chapter 6 LeadCare II Blood Lead Testing
System Limited Warranty
Magellan Diagnostics, Inc. (Magellan) warrants that each product manufactured and sold by it will be free from
defects in material and workmanship in normal use and service from the date of delivery to you as the original
purchaser for the following periods: Magellan Instruments - one year; Sensors and Electrodes - 90 days. This
warranty does not cover, and no warranty is provided for, consumables and parts that by their nature are normally
required to be replaced periodically consistent with normal maintenance. If any product covered by this warranty is
returned to the original shipping point, transportation charges prepaid, within the applicable warranty period set
forth above and upon examination Magellan determines to its satisfaction that such product was defective in
material or workmanship Magellan will, at its option, repair or replace the product or defective part thereof or refund
the original purchase price of the product to you. The foregoing notwithstanding, Magellan will not be responsible
for damage to any product resulting from misuse, negligence or accident or resulting from repairs, alterations or
installation made by any person or firm not duly authorized by Magellan in writing.
If, at any time during the period ending ninety (90) days after delivery of any product to you, you report and document
any error in any software provided with the product and developed by Magellan or any failure of any such software
substantially to conform to Magellan’s software documentation that limits or prevents use of the software by you,
Magellan, at its option, will use reasonable efforts to correct any such error or failure, will replace such software, or will
terminate your license to use the software and refund the price of the related product. In connection with any such
termination and refund, you will return the related product to Magellan forthwith upon request. This warranty shall
apply only to those portions of the software that were developed by Magellan and that incorporate all program
corrections and modifications, if any, delivered to you. It shall not apply to any error or failure due to machine error or
to the misuse by or negligence of any person or entity other than Magellan or to any software which is modified by any
person or entity other than Magellan.
With respect to products sold to you but not manufactured by Magellan, MAGELLAN MAKES NO WARRANTY OF
ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, but will make available to you, to the extent
permitted, the warranties of the manufacturer of the relevant products .
THIS LIMITED WARRANTY IS THE ONLY WARRANTY GIVEN BY MAGELLAN WITH RESPECT TO THE
PRODUCTS AND SOFTWARE AND IS GIVEN IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE. YOUR EXCLUSIVE REMEDIES AND MAGELLAN'S SOLE LIABILITY FOR ANY NONCONFORMITY OR DEFECT IN THE PRODUCTS AND SOFTWARE WILL BE THOSE EXPRESSED HEREIN.
UNDER NO CIRCUMSTANCES WILL MAGELLAN'S LIABILITY ARISING FROM THE PERFORMANCE OR
FAILURE TO PERFORM OF ANY PRODUCT OR SOFTWARE IN CONTRACT, IN TORT (INCLUDING
NEGLIGENCE), OR OTHERWISE, EXCEED THE PURCHASE PRICE OF THE PRODUCT. IN NO EVENT WILL
MAGELLAN BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR ANALOGOUS DAMAGES,
INCLUDING, WITHOUT LIMITATION, DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, LOSS
OF BUSINESS OR LOSS OF GOODWILL, EVEN IF MAGELLAN HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES.
This warranty shall be governed by and construed and enforced in accordance with, the substantive laws of the
Commonwealth of Massachusetts, excluding its conflict of law principles. This warranty shall be non-transferable
and shall run to the benefit of the original purchaser only.
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Appendix A Connecting a
Compatible Serial Printer
CAUTION: The LeadCare® II Analyzer must run on AC
power in order to generate a label. Battery power is
insufficient to generate a label.
The LeadCare II Analyzer has printing capabilities. After a result is generated the
information is transmitted via a serial connection to a label printer. The USB
connection cannot be utilized for printing purposes.

Connections

DB9 End
RJ11 End

Figure A-1

®

LeadCare II User's Guide

Serial Cable

A-1

Serial Port

Figure A-2

Rear Panel of the LeadCare II

1. Using the serial cable supplied with the printer, connect the DB9 end to
the LeadCare II’s serial port.
2. Connect the RJ11 end of the cable to the printer’s serial (telephone jack)
connection port.
3. Plug the printer’s AC adapter into a power outlet. Label the adapter so it
only gets plugged into the SLP printer.
4. Ensure the LeadCare II is plugged into a power outlet with its appropriate
adapter. Note: Battery operation is insufficient to generate a label.
NOTE:

The USB port cannot be used for printing LeadCare II
results.

Power On Cycle

1. Turn on the printer. A steady green light indicates ready mode.
2. Turn on the LeadCare II Analyzer.
3. Analyze a sample. The result will generate a label with the following
information: :

Figure A-3
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Power Off Cycle

1. Turn off the LeadCare II.
2. Turn off the printer.

Note on Labels: The SmartLabels have a mark on the backing of each label
that the SLP 650SE and future models use for top of label alignment. Check to
be sure the labels have this mark before loading them into the printer.

Loading Labels

1. Power on the printer. The green status light will flash until labels are
loaded.
2. Lift the left side of the roll cover to open. Remove the spindle and place a
roll of labels on the spindle. (The LeadCare II utilizes shipping labels:
2 1/8” W X 4” L label stock.) Adjust the guides to fit the labels (see below).

Figure A-4

Label Placement

3. Feed the labels into the entrance slot, label side down. The labels will
automatically feed and align the end in the exit slot.
4. Close the roll cover.

Troubleshooting Information
•
•
•
•
•

Steady green light indicates the printer is on-line.
Blinking green light indicates the printer is awaiting labels.
Blinking yellow indicates a label jam.
Blinking red indicates a voltage error or print head error.
Steady yellow light indicates the printer is off-line.

Call LeadCare Product Support for additional assistance: 1-800-275-0102.
®
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Appendix B Specifications, Operating
Requirements, and
Performance Characteristics
Specifications
Table B-1

Physical Dimensions

Dimensions (Approximate, Analyzer Only)
Weight (Approximate, Analyzer with
Batteries)

Table B-2

DC Input Power (External Mode)
DC Input Power (Battery Mode)
Battery Life
Automatic Shutoff

Switching power supply (AC input 100-240 V, 0.25
A, 50-60 Hz, DC output +3.3 V-1.2 A)
or 1.5 V AA alkaline or lithium batteries (4 each)
The correct power adapter is included in the
analyzer kit.
Less than 600 mA
Less than 400 mA
Up to 80 tests (7 hours)
15 minutes after last use with batteries
60 minutes after last use with AC adapter

Other Specifications

CPT Code
CLIA Complexity
Reportable Range
Sample Volume
Test Time
Calibration

®

1.13 kg (2.5 lb)

Electrical Specifications

Power Requirements

Table B-3

Height 9 cm (3.5 in.)
Width 17 cm (6.5 in. )
Depth 23 cm (9 in.)

LeadCare II User's Guide

83655 (Quantitative Blood Lead Analysis)
Waived
3.3 - 65.0 µg/dL
Note: Displays "Low" below 3.3 µg/dL
Displays "High" above 65.0 µg/dL
50 µL
3 minutes (180 seconds)
Electronic calibration; calibration button included
with each test kit

B-1

Operating Requirements
Table B-4

Storage and System Operating Ranges

Storage Ranges
15°C to 30°C (59°F to 86°F)
Analyzer
Up to 80% Relative humidity
Test Kit
15°C to 27°C (59°F to 80°F)
Store at room temperature (RT) prior to mixing with
Capillary Whole Blood Sample (human)
Treatment Reagent.
EDTA or Heparin are the anticoagulants of
choice
RT is 10°C to 32°C (50°F to 90°F )

Temperature
Relative Humidity
Altitude

®
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System Operating Ranges
15°C to 27°C (59°F to 80°F )
12%-80%, non-condensing
Operating up to 2,440 meters (8,000 feet ) above
sea level does not affect results.

B-2

Interference Substances
Tests were conducted by adding the potential interferences at the concentrations
listed below to bovine blood with elevated lead levels. Lead results for samples with
each potential interference did not differ statistically from lead results obtained on
unadultered samples.
The following substances at the following concentrations do NOT affect the results of
the LeadCare® II System:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

5,5-Diphenylhydantoin (phenytoin), 100 µg/mL
Acetominophen, 500 µg/mL
Amoxicillin, 100 µg/mL
Amphotericin, 50 µg/mL
Arsenic III, 0.01 µg/mL
Arsenic V, 0.005 µg/mL
Carboplatin, 0.25 µg/mL
Cephalexin (Keflex), 60 µg/mL
Ciprofloxacin, 100 µg/mL
Clondine, 100 µg/mL
Cyclophosphamide, 500 µg/mL
d-Amphetamine Sulfate, 100 µg/mL
Diphenylhydramine Hydrochloride, 100 µg/mL
Doxorubicin, 100 µg/mL
Doxycycline, 100 µg/mL
Erythromycin, 100 µg/mL
Ferric chloride, 100 µg/mL
Ferrous sulfate, 100 µg/mL
Fexofenadine HCl (Allegra), 50 µg/mL
Fluconazole (Diflucan), 100 µg/mL
Gabapentin (Neurontin), 100 µg/mL
Ganciclovir (AZT), 100 µg/mL
Glyburide, 100 µg/mL
Guanfacine, 100 µg/mL
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•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Hydroxyurea, 250 µg/mL
Ibuprofen, 500 µg/mL
Indinavir Hydrate, 100 µg/mL
Isoniazid, 100 µg/mL
Loratadine, 100 µg/mL
Methyl Phenidate (Ritalin) HCl, 100 µg/mL
Methotrexate, 60 µg/mL
Metronidazole, 100 µg/mL
Niacin, 100 µg/mL
Nicotine , 10 µg/mL
Nystatin, 100 µg/mL
Penicillamine, 25 µg/mL
Phenylephrine, 100 µg/mL
Piperazine, 100 µg/mL
Pseudoephedrine (guiafenesin), 100 µg/mL
Pyridoxine, 100 µg/mL
Riboflavin, 0.5 µg/mL
Rifampicin, 100 µg/mL
Sitagliptin, 100 µg/mL
Thiamine, 50 µg/mL
Trimethoprim, 100 µg/mL
Valproic Acid, Na salt, 500 µg/mL
Vitamin D3, 100 µg/mL
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Appendix C Steps for Collecting
Fingerstick Blood Samples in
Micro-Vials for Lead Testing
The following references provide additional information about blood sample collection,
blood lead testing, and Magellan Diagnostics LeadCare II products.

Blood Sample Collection
Information about sample collection is available from the Clinical Laboratory Standards
Institute (CLSI) or the Centers for Disease Control (CDC).
•

CLSI (Clinical and Laboratory Standards Institute) GP44-A4: Procedures for the Handling
and Processing of Blood Specimens; Approved Guideline – 4th ed. (ISBN 1-56238-724-3).
www.clsi.org

•

CDC Guidelines for Collecting and Handling Blood Lead Samples – 2004 - Video
presentation describes how to collect and handle samples that will be used for blood lead
testing. www.cdc.gov/nceh/lead/training/blood_lead_samples.htm
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Appendix D Safety Data Sheets (SDS)
This chapter contains the following LeadCare® II Safety Data Sheets:
•

LeadCare II Controls

•

LeadCare II Treatment Reagent
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Attachment D2: Venipuncture Collection Process

Venipuncture Specimens for Blood Lead Collection and Transport
Lead confirmatory testing will be offered when results from the blood lead analyzer LeadCare® II
capillary test are ≥ 5 µg/dL.
The Venipuncture Collection Kit includes:
•
•
•
•
•

One (1) sterile alcohol prep
One (1) needle and holder or one (1) needle and syringe
One (1) transport zip lock bag
One (1) dry sterile gauze pad
One (1) Vacutainer EDTA tube (purple top)

Personal Protective Equipment:
•
•
•

Powder free gloves
Eye protection
Face mask

Preparation of the Puncture Site:
1. Thoroughly wash hands and don powder free gloves.
2. Expose the selected antecubital fossa and apply tourniquet to mid-biceps. Scrub the puncture
site briskly with the alcohol pad to remove any environmental contamination and to increase
blood flow.
3. Allow the site to air dry or use the sterile gauze to dry the area.
Collection of the Sample:
1. Prepare needle assembly, either needle and vacutainer holder, or needle and syringe.
2. Perform venipuncture per standard operating procedures. Make sure the vacutainer tube is
completely filled before stopping collection. If using a needle and syringe, obtain a minimum of
2 mL of whole blood.
3. Remove tourniquet first, then needle from arm.
4. Apply pressure to the puncture site with a gauze pad to stop the patient’s bleeding.
parent/guardian or child may continue holding direct pressure on the puncture site.
5. If drawn directly into vacutainer tube, immediately mix the specimen manually by inverting a
minimum of 10 times.
6. If drawn with a needle into the syringe, immediately inject the blood from the syringe into the
vacutainer tube, gently mixing while filling. Continue to mix the specimen by inverting 10
times.
7. Dispose of used needle and syringe equipment into puncture proof sharps container.
8. Identify each skin puncture specimen with the patient’s name, at a minimum, and collection
date.
Submitting Specimens to the State Laboratory for Testing:
1. Specimens should be clearly labeled with two patient identifiers (name, DOB) and collection
date.
2. Complete a Public Health Laboratory Request Form to include the patient’s name, date of
birth, gender, collection date, and submitter information.

3. Place the well mixed, un-clotted blood specimen in an individual biohazard zip lock bag
containing absorbent material and seal bag tightly. Fold the requisition form and place in
sleeve of the bag.
4. Store specimen(s) in the refrigerator until brought to St. James Community Hospital Laboratory
the same day to coincide with the courier schedule. Specimens are stable for 7 days at
refrigeration temperatures.
Results:
1. After test results are received from the state lab, the patient will be contacted to discuss the
results and any next steps if applicable.
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MONTANA PUBLIC HEALTH LABORATORY
LABORATORY SERVICES MANUAL
Updated April 2020

MONTANA LABORATORY SERVICES BUREAU Contact Information
1400 BROADWAY
W. F. COGSWELL BUILDING
1400 E. Broadway, P.O. BOX 4369
HELENA, MONTANA 59604-4369
CLIA ID. # 27D0652531
PHONE: 406-444-3444
800-821-7284 (24 hour)
MAIN FAX: 406-444-1802
******************************************************************************************

LABORATORY SERVICES BUREAU LEADERSHIP
Laboratory Services Bureau Chief,
Ron Paul, 444-5559 or rpaul@mt.gov
Laboratory Systems Improvement Section Supervisor and Deputy Laboratory Director
Deborah Gibson 444-5970 or debgibson@mt.gov
LABORATORY SERVICES BUREAU SUPERVISORS
Laboratory Business Operations Manager,
Danielle Lindeman, 444-5246 or
DLindeman@mt.gov

Serology & Newborn Screening Laboratory
Manager, Angela Dusko,
444-3040 or adusko@mt.gov

Micro & Molecular Laboratory Manager,
Carrie Biskupiak, 444-5526 or cbiskupiak@mt.gov

Environmental Laboratory Supervisor,
Russ Leu, 444-5259 or rleu2@mt.gov

******************************************************************************************

For most up-to-date contact information and testing information, see our website:

http://dphhs.mt.gov/publichealth/LaboratoryServices

The Eleven Core Functions of Public Health Laboratories (courtesy of APHL)
1. Disease Prevention, Control and Surveillance—Provide accurate and precise analytical data in a timely
manner
2. Integrated Data Management—Serve as the conduit for scientific data and information in support of public
health programs
3. Reference and Specialized Testing—Serve as centers of excellence using their expertise, reference and
resources in the areas of biological, chemical and radiologic issues of public health importance
4. Environmental Health and Protection—Collaborate with partners to coordinate and ensure scientific
analysis of environmental and human samples to identify, quantify and monitor potential threats to health
5. Food Safety—Collaborate in the detection, monitoring and response to food safety issues
6. Laboratory Improvement and Regulation—Provide leadership for laboratory improvement in areas of
public health importance
7. Policy Development—Play a role in the development of state and federal health policy
8. Public Health Preparedness and Response—Fulfill a key partnership role in local, state and national disaster
preparedness and response
9. Public Health Related Research—Engage in research to improve and expand the scientific and policy bases
of public health laboratory practice and assure their optimal application in support of the public health
system
10. Training and Education—Facilitate access to training and education
11. Partnerships and Communication—Support their respective state public health laboratory systems

The Montana Laboratory Services Bureau and its sentinel laboratories are part of the
CDC’s Laboratory Response Network (LRN)
LRN Mission: The LRN and its partners will maintain an integrated national and international network of laboratories
that are fully equipped to respond quickly to acts of chemical or biological threats, emerging infectious diseases, and
other public health threats and emergencies.
Sentinel laboratories play a key role in the early detection of biological agents. Sentinel laboratories provide routine
diagnostic services, rule-out, and referral steps in the identification process. While these laboratories may not be
equipped to perform the same tests as LRN reference laboratories, they can test samples.
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Montana Sentinel Laboratories
“In the broadest sense, all laboratories capable of analyzing or referring specimens or samples that may contain
microbial agents, biological toxins, chemical agents, chemical agent metabolites, or radiological agents function as
sentinels in the public health laboratory system. This includes environmental, food, veterinary, agriculture, military,
public health and clinical laboratories. Because of their routine activities, all these laboratories have the potential to
encounter samples that may contain agents that threaten the public’s health. While all these laboratories are sentinel
laboratories, they may have different roles within the public health laboratory system.

Role of Sentinel Clinical Laboratories in the Public Health Laboratory System
Clinical laboratories testing human and animal samples are often the first interface with patients and the public health
system. These laboratories perform a variety of critical tests, providing timely results to impact patient care. Optimally,
these laboratories also work with local and state health departments to provide information on nationally notifiable
diseases and other threats. While reporting of nationally notifiable diseases to the Centers for Disease Control and
Prevention (CDC) is not federally mandated, it is currently required by legislation or regulation at the state or local levels.
As such, the list of reportable diseases varies slightly by jurisdiction. Ongoing communications and trainings from public
health staff, including laboratorians and epidemiologists, help to assure that clinical laboratories are integrated into the
public health laboratory system. This coordination is vital to the surveillance and responses for endemic and emerging
pathogens, including identification of novel threats such as pandemic influenza and the development of appropriate
countermeasures such as vaccines.

Role of Sentinel Clinical Laboratories in the LRN for Biological Threat Preparedness
In addition to their broad role in the public health laboratory system, clinical laboratories work closely with local and
state public health and federal laboratories to recognize potential biological threat agents and other emerging threats to
public health. Such laboratories are part of the nation’s Laboratory Response Network (LRN) founded by the CDC, the
Federal Bureau of Investigation (FBI) and the Association of Public Health Laboratories (APHL). The strength of the LRN
lies in its standardized approach and its tiered capability construct—with sentinel clinical laboratories serving at the
foundation to quickly recognize, rule-out or refer potential biothreat agents to the LRN Reference Laboratories.”
(excerpt taken from “Definition of LRN Sentinel Laboratories” on the ASM website)

We would like to recognize Montana’s 18 sentinel laboratories for serving in this role:
Benefis East Health Services, Great Falls
Big Horn County Memorial Hospital, Hardin
Billings Clinic, Billings
Bozeman Health, Bozeman
Clark Fork Valley Hospital, Plains
Community Medical Center, Missoula
Frances Mahon Deaconess Hospital, Glasgow
Glendive Medical Center, Glendive
Holy Rosary Hospital, Miles City

IHS Fort Belknap Hospital, Harlem
Kalispell Regional Hospital, Kalispell
Livingston Memorial Hospital, Livingston
Madison Valley Hospital, Ennis
Sidney Health Center, Sidney
St. Patrick’s Hospital, Missoula
St. Peter’s Hospital, Helena
St. Vincent’s Hospital, Billings
VA Medical Center, Ft. Harrison, Helena

For more information on sentinel laboratories and rule-out testing, see the American Society for
Microbiology website, https://www.asm.org/Articles/Policy/Laboratory-Response-Network-LRN-SentinelLevel-C
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Laboratory Outreach
The Montana Laboratory Services Bureau offers not only testing, but also consultation and outreach in several
different areas.
One of our most recent outreach programs is biosafety. The Ebola crisis of 2014 revealed that, on a national
level, there are gaps in laboratory biosafety programs. Measures that can be put in place to protect ourselves
and the public from laboratory acquired infections include risk assessments, standardized training, and nonpunitive systems for reporting incidents and near misses, to name a few. The Association of Public Health
Laboratories, with funding by the CDC, has developed tools and provided training and other programs to
enhance biosafety in each state. Public Health laboratories have been tasked with passing these resources on
to clinical partners in their jurisdictions. Part of our outreach is to provide copies of our newly updated
Laboratory Services Manual.
Please contact our program managers and subject matter experts for any assistance you may need. If you
need assistance with a topic not listed below, please give one of us a call, and we can find someone to help.
For assistance with biosafety, packaging and shipping, biopreparedness training, jurisdictional transport plans
(county level), Copia accounts, and Portacount requests or technical assistance, contact: Biosafety Officer and
Laboratory Training Specialist, Crystal Fortune, 444-0930 or cfortune@mt.gov
For assistance with biopreparedness, jurisdictional sample transport plans (county level), CAP LPX facility
feedback, and sentinel laboratory outreach, contact: Bioterrorism Specialist, Lana Moyer, 444-0944 or
lmoyer@mt.gov
For assistance with chemical terrorism preparedness, including rapid toxic screening questions or training,
contact: Chemical Terrorism Specialist, Joel Felix, 444-9653 or jfelix@mt.gov
For assistance with Copia, contact: Data Coordinator, Kim Varvel, 444-4115 or kvarvel@mt.gov
For assistance with laboratory safety/biosafety; quality assurance, including rapid HIV/HCV; and Portacount
requests, contact: Quality Assurance and Safety Specialist, Donna Jo Hosmer, 444-5941 or dhosmer@mt.gov
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Clinical Testing List of Services
For most up-to-date manual, refer to our website. For tests not listed, please contact the laboratory (800-8217284) for availability.

******************************************************
Summary of Changes:
Some serology reference testing removed
Additional testing such as HCV and HIV quantitation added
Changes made to Syphilis screening, HIV screening per CDC algorithm
QuantiFERON updated to four-tube method
Added instructions for Blood Parasite Screen Thick EDTA Blood Smear Preparation
Microbiology testing updated to include MALDI-TOF technology, where applicable
Updates to specimen requirements and shipment temperatures

******************************************************
Note: To avoid rejection, all patient specimens should be clearly marked with two identifiers (name, DOB,
medical record number, etc.) and collection date. Additionally, specimens should be submitted, with
absorbent material, inside a biohazard transport bag and the corresponding requisition in the outer pouch of
the transport bag. Please do not submit more than one patient or more than one specimen type (example,
culture and blood) per transport bag or allow requisitions to be in contact with specimens.
Call the laboratory (800) 821-7284 with any questions regarding safe transport.

******************************************************
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Tests in Alphabetical Order
A
Acid Fast Bacilli (AFB) (see Mycobacterium spp. Culture/Identification)
Actinomyces spp. Culture Isolation/ Identification (see Bacterial Culture, Anaerobic)
Adenovirus Direct Detection by Real Time PCR
Specimen Requirements: Respiratory specimen in Universal Viral Transport Media. See Molecular (Nucleic Acid
Amplification) Testing Collection and Transport instructions.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 3 working days. Results are telephoned to the submitter.
CPT Code:
87798
Price: $107.00

Amebiasis Detection (see Ova and Parasite Exam)
Anthrax (see Bacillus anthracis Culture Isolation/ Identification/Rapid Test Methods)
Antimicrobial Resistant Bacteria Confirmation
Confirmation testing for an isolate that demonstrates a resistance pattern with high epidemiologic significance such as
potential Vancomycin Intermediate or Resistant Staphylococcus aureus, Methicillin Resistant Staphylococcus aureus,
Vancomycin Resistant Enterococci, ESBL producing Enterobacteriaceae, or resistant Streptococcus pneumoniae.
Specimen Requirements: Pure culture isolate submitted in Cary-Blair transport or on solid media.
Transport Temperature: Ambient
Turn-around Time: 2 to 4 working days. May be referred to the Centers for Disease Control in Atlanta, Georgia.
CPT Code:
87081 (ESBL, MRSA, VRE, VISA/VRSA)
Price: $38.00
CPT Code:
None (Streptococcus pneumoniae)
Price: Fee Waived

Arbovirus Serology by ELISA
Specimen Requirements: 1 mL serum or CSF; Paired acute and convalescent serum recommended. Date of onset must
be included on requisition form.
Transport Temperature: 4-30°C (Refrigeration preferable)
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Referred to the Centers for Disease Control, Fort Collins, CO.
Turn-around Time: 4 weeks
CPT Codes:
86654 (Western Equine Encephalitis)
86651 (California Group)
Total Price: $30.00

Aspergillus spp. Culture Isolation/ Identification (see Fungal Culture)
Autoclave Monitoring
Specimen Requirements: EZ Test vials containing Geobacillus stearothermophilus are obtained by contacting the
laboratory. Place the EZ Test vial in center of the load to be sterilized, then autoclave using normal procedures.
Transport Temperature: Ambient
Turn-around Time: 2 working days from receipt of specimen
CPT Code:
No code
Price: $23.00

B
Babesia Detection (see Blood Parasite Screen)
Babesiosis Serology by IFA
Specimen Requirements: 1.5 mL serum
Transport Temperature: 4-30°C (Refrigeration preferable)
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 18 days
CPT Code:
86256
Price: $38.00

Bacillus anthracis Culture Isolation/ Identification/Rapid Test Methods
Specimen Requirements: Lesion swab, clinical specimen or pure culture isolate on solid media or in Cary-Blair transport.
Note: A suspected B. anthracis culture requires Category A Infectious Disease packaging (Class 6.2) and trackable
shipping. Please notify the laboratory by telephone at time of shipment.
Please contact the laboratory prior to submission regarding environmental samples, rapid test methods, and transport
instructions.
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Transport Temperature: Ambient
Turn-around Time: Rapid test methods are performed in Molecular Diagnostics and are available within 6 - 8 hours of
specimen receipt. A positive or negative PCR result is a CONFIRMATORY result. Results are telephoned to the submitter
as soon as testing is complete.
CPT Codes:
87081 (Culture screen)
Price: Fee Waived
87798 (PCR)
Price: Fee Waived

Bacterial Culture Identification, Aerobic
Specimen Requirements: Send non-fastidious Gram negative or Gram-positive isolates on solid media or on swab in
Cary-Blair, Stuart’s, or Amies transport medium. Fastidious or slow growing organisms require careful transport on an
enriched agar medium.
Transport Temperature: Ambient
Turn-around Time: Normally 3 to 14 working days, depending on the purity and the growth rate of the isolate.
CPT Codes:
87070 (culture, presumptive ID)
Price: $25.00
87077 (Each add’l ID)
Price: $25.00

Bacterial Culture Identification, Anaerobic
Specimen Requirements: Send pure culture isolate in an anaerobic transport system.
Transport Temperature: Ambient
Turn-around Time: Normally 3 to 14 working days, depending on the growth rate of the isolate.
CPT Codes:
87075 (culture, presumptive ID)
Price: $25.00
87076 (Each add’l ID)
Price: 25.00

Bartonella spp. (formerly Rochalimaea spp.) Serology by IFA
Specimen Requirements: 2 mL serum, plus completed cat scratch fever disease history form. The laboratory will fax you
a form upon request.
Referred to the Centers for Disease Control, Atlanta, Georgia
Transport Temperature: 2-8°C
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Turn-around Time: 2 weeks
CPT Code:
86256
Price: $30.00

Blastomyces, Histoplasma, Coccidoides Identification by Nucleic Acid Probe
Specimen Requirements: Isolates sent on Sabouraud’s slants or as reflex testing on positive primary specimens
submitted for culture.
Transport Temperature: Ambient
Turn-around Time: 1 to 3 working days for submitted isolates, others dependent on growth rate.
CPT Code:
87149 (each)
Price: $35.00 each

Blastomyces spp. Culture Isolation/ Identification (see Fungal Culture)
Blastomyces Serology (see Fungal Serology)
Blood Borne Pathogen Exposure - Exposed Worker (HBsAb, HIV, HCV) by EIA
Specimen Requirements: 1 mL serum
Transport Temperature: 2-8°C
Turn-around Time: Routinely batch tested once per week. Positive results are telephoned to the submitter. These tests
may be ordered as a panel but are billed individually.
CPT Codes:
86706 (HBsAb)
Price: $30.00
87389 (HIV)
Price: $31.00
86803 (HCV)
Price: $40.00
Total Price: $101.00

Blood Borne Pathogen Exposure - Source Patient (HBsAg, HIV, HCV) by EIA
Specimen Requirements: 2 mL serum
Transport Temperature: 2-8°C
Turn-around Time: Routinely batch tested once per week. Positive results are telephoned to the submitter. These tests
may be ordered as a panel but are billed individually.
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CPT Codes:
87340 (HBsAg)
Price: $25.00
87389 (HIV)
Price: $31.00
86803 (HCV)
Price: $40.00
Total Price: $96.00

Blood Lead by Anodic Stripping Voltometry
Specimen Requirements: 1 mL venous or 0.3 mL capillary whole blood, EDTA (purple top). Adult and child specimen
collection kits are available through the laboratory. See Blood Lead Collection and Transport instructions on the
collection and transport of capillary and venous specimens.
Transport Temperature: 2-30°C (Refrigeration preferable)
Note: Venous specimens are referred to South Dakota Public Health Laboratory for testing.
Turn-around Time: 1-2 days for capillary specimens; 1 week for venous specimens.
CPT Code:
83655
Price: $23.00

Blood Parasite Screen
Analysis includes Plasmodium spp. (Malaria), Babesia spp., Trypanosoma spp., and Filarial nematodes (Brugia malayi,
Loa loa, Mansonella spp., Onchocera volvulus, and Wuchereria bancrofti).
Specimen Requirements: Two sets of thick and thin EDTA Blood smears; one set of thick and thin smears stained with
Giemsa or Wright’s Stain, and 1-5 ml whole blood in EDTA tube (for possible PCR testing). See Blood Parasite Screen
Thick EDTA Blood Smear Preparation Instructions for correct preparation and RBC lysing of thick blood smears.
Please contact the laboratory prior to submission of specimen. Patient travel history is required.
Transport Temperature: Ambient
Turn-around Time: 1 to 2 working days. Positive samples for confirmation and specimens for PCR testing are referred to
the Centers for Disease Control, Atlanta, Georgia.
CPT Code:
87207
Price: $38.00

Bordetella pertussis/B. parapertussis/B. holmesii Direct Detection by Real Time PCR
Specimen Requirements: Nasopharyngeal (NP) swab in a sterile container without transport media. Do not submit a
throat or nares specimen or a specimen submitted in Regan Lowe Media. See Molecular (Nucleic Acid Amplification)
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Testing Collection and Transport instructions.
Turn-around Time: 1 to 2 working days. Positive results are telephoned to the submitter.
NOTE: PCR testing should be performed only on symptomatic patients; a positive PCR in an asymptomatic patient does
not meet the standard CDC case definition and cannot be considered a case of pertussis. PCR testing may be able to
detect B. pertussis 3 to 4 weeks post onset.
CPT Code:
87801
Price: $107.00
Transport Temperature: Ambient or 2-8°C

Borrelia burgdorferi Culture
Specimen Requirements: Skin punch biopsy, synovial fluid, CSF, 0.5 ml EDTA whole blood, or blood smears (unstained or
stained with Wright’s or Giemsa). Contact the laboratory prior to collection for special instructions and transport media
requirements.
Referred to the Centers for Disease Control, Fort Collins, Colorado
Transport Temperature: Ambient
Turn-around Time: 8 weeks
CPT Code:
87081
Price: $30.00

Borrelia burgdorferi Serology Total Antibody by EIA with reflex Western Blot confirmation
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch-tested once per week. Specimens that test positive or equivocal are referred to
South Dakota Public Health Laboratory in Pierre, SD, for Lyme IgG and IgM Western Blot confirmation.
CPT Code:
86618 (Screen)
Price: $40.00
86617 (Western Blot)
Price: $100.00

Borrelia hermsii Serology (Tick Borne Relapsing Fever) by IgM/IgG ELISA
Specimen Requirements: 2 mL serum; Paired acute and convalescent serum recommended. Date of onset, signs,
symptoms, and antibiotic treatment information must be included on requisition form.
Referred to the Centers for Disease Control, Fort Collins, Colorado
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Transport Temperature: 2-30°C or frozen (Refrigeration preferable)
Turn-around Time: 3 weeks
CPT Code:
86619
Price: $30.00

Brucella spp. Culture Isolation/ Identification/Rapid Test Methods
Specimen Requirements: EDTA whole blood (PCR) or pure culture isolate on solid medium.
Note: A suspected Brucella spp. culture requires Category A Infectious Disease packaging (Class 6.2) and trackable
shipping. Please notify the laboratory by telephone at time of shipment.
Please contact the laboratory prior to submission regarding environmental samples, rapid test methods, and transport
instructions.
Transport Temperature: Ambient
Turn-around Time: Cultures will be held for five (5) working days before reporting as negative. Results are telephoned as
soon as possible to the submitter.
Rapid test methods (PCR) are performed in Molecular Diagnostics and are available within 6 - 8 hours of specimen
receipt. Culture is considered CONFIRMATORY for specimens that are PCR PRESUMPTIVE Positive. Further confirmatory
testing at the CDC may be needed.
CPT Codes:
87081 (Culture screen)
Price: Fee Waived
87798 (PCR)
Price: Fee Waived

Brucella Serology by Bacterial Agglutination
Specimen Requirements: 2 ml. Serum; Paired acute and convalescent serum recommended.
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week.
NOTE: Tularemia serology will be automatically performed on all requests for Brucella serology due to antigen cross
reactivity.
CPT Codes:
86622 (Brucella)

86668 (Tularemia)

Price: $25.00 (each)
Total Price: $50.00
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Burkholderia mallei, B. pseudomallei Culture Isolation / ID / Rapid Test Methods
Specimen Requirements: EDTA whole blood (PCR) or pure culture isolate submitted in Cary-Blair transport or on solid
medium.
Note: A suspected Burkholderia mallei or B. pseudomallei culture requires Category A Infectious Disease packaging (Class
6.2) and trackable shipping. Please notify the laboratory by telephone at time of shipment.
Please contact the laboratory prior to submission regarding environmental samples, rapid test methods, and transport
instructions.
Transport Temperature: Ambient
Turn-around Time: Cultures will be held for five (5) working days before reporting as negative. Results are telephoned as
soon as possible to the submitter.
Rapid test methods (PCR) are performed in Molecular Diagnostics and are available within 6 - 8 hours of specimen
receipt. CONFIRMATION requires a combination of culture, biochemical, and PCR results. Presumptive Positives may
need additional testing at the CDC.
CPT Codes:
87081 (Culture screen)
Price: Fee Waived
87798 (PCR)
Price: Fee Waived

C
Campylobacter spp. Culture Isolation/Identification
Specimen Requirements: Stool in submitted in Cary-Blair transport or pure culture isolate on solid media sent in a
Campylobacter transport system.
Transport Temperature: 2-8°C for stool specimens, ambient for isolates
Turn-around Time: 3 to 5 working days. Positive results from a primary culture are telephoned to the submitter.
CPT Codes:
87046 (Culture ID)
Price: $18.00
87077 (Each add’l ID)
Price: $25.00

Candida albicans Culture Isolation/Identification (see Fungal Culture)
Candida auris Identification/Antifungal Susceptibility Testing
Specimen requirements: Send a pure culture isolate on solid medium - Sabouraud’s Dextrose, blood, or chocolate agar
slants.
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Please contact the laboratory prior to submitting the isolate.
Transport Temperature: Ambient
Referred to the regional ARLN Laboratory
Turn-around Time: 2-4 days
CPT Code:
None
Price: Fee waived

Carbapenem-Resistant Organisms Direct Detection by Real-Time PCR (including Carbapenem-Resistant
Enterobacteriaceae (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA)
Detects and differentiates KPC, NDM, VIM, OXA-48, and IMP gene sequences associated with Carbapenem nonsusceptibility in gram-negative bacteria.
Specimen requirements: Pure culture isolate on solid media or in Cary-Blair transport or direct rectal swab collection.
Rectal swabs specific to this test are provided by MTPHL. Store the collection swabs at room temperature. For collection
of a paired rectal swab, See Molecular (Nucleic Acid Amplification) Testing Collection and Transport instructions.
Please contact the laboratory prior to submission regarding surveillance (fee waived) criteria. Isolates that do not meet
the surveillance criteria can be tested for a fee.
Transport Temperature: Ambient
Turn-around Time: Routinely tested each working day. Positive results are telephoned to the submitter.
CPT Code:
None (Surveillance)
Price: Fee Waived
CPT Code:
87184 (mCIM)
Price: $38.00
CPT Code:
87801 (Carba-R)
Price: $107.00

Cat Scratch Fever (see Bartonella spp. Serology)
Chagas Disease (see Trypanosomiasis Detection)
Chikungunya Virus by PCR (see Zika Trioplex PCR)
Chlamydia trachomatis Direct Detection by Nucleic Acid Amplification
Specimen Requirements: Endocervical or male urethral swab in APTIMA Uni-Sex Swab Specimen Collection Tube; throat,
rectal, or vaginal swab in APTIMA Multitest Specimen Collection Tube; or urine in APTIMA Urine Specimen Collection
Tube. See Chlamydia/Gonorrhea Amplified Testing Collection and Transport instructions.
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Transport Temperature: 2-30°C
Turn-around Time: Routinely tested daily (Monday through Friday). Positive results are telephoned to the submitter.
NOTE: Can be run in tandem with Neisseria gonorrhoeae Direct Detection by APTIMA Amplification (see Combination
Amplification Test below)
CPT Code:
87491
Price: $44.00

Chlamydia trachomatis/Neisseria gonorrhoeae Direct Detection by NAAT (Combo Test)
Specimen Requirements: Endocervical or male urethral swab in APTIMA Uni-Sex Swab Specimen Collection Tube; throat,
rectal or vaginal swab in APTIMA Multitest Specimen Collection Tube; or urine in APTIMA Urine Specimen Collection
Tube. See Chlamydia/Gonorrhea Amplified Testing Collection and Transport instructions.
Transport Temperature: 2-30°C
Turn-around Time: Routinely tested daily (Monday through Friday). Positive results are telephoned to the submitter.
These tests can be ordered as a panel but will be billed individually.
CPT Codes:
87491 (Chlamydia)

87591 (GC)

Price: $44.00 (each)
Total Price: $88.00

Cholera (see Vibrio spp. Culture Isolation/ Identification)
Clostridium botulinum (Botulism) Bacterial ID, Toxin, and Serology Testing
Call the Montana Public Health Laboratory at (800)821-7284 for consultation on sending specimens; an epidemiologic
consultation is also required for preapproval of testing, and for making arrangements to receive antitoxin.
Specimen Requirements: 10 mL serum, and 25 gm stool. Special requirements for infants are a stool sample only, serum
will not be accepted.
Food testing is not performed at MTPHL. Human testing referred to the Utah State Public Health Laboratory in Salt Lake
City, UT
Transport Temperature: 2-8°C
Turn-around Time: Preliminary results in 2 to 4 working days.
CPT Code:
None
Price: Fee Waived*

Clostridium difficile PCR, including NAP1
Specimen Requirements: Liquid or unformed stool in a sterile container
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Transport Temperature: 2-8°C (Stable for up to 5 days when stored at 2-8°C)
Turn-around Time: 1 to 2 working days. Positive results are telephoned to the submitter.
CPT Code:
87493
Price: $107.00

Clostridium spp. (except C. botulinum) Culture Isolation/ ID (see Bacterial Culture, Anaerobic)
Coccidioides spp. Culture Isolation/ Identification (see Fungal Culture)
Coccidioides Serology (see Fungal Serology)
Colorado Tick Fever Virus (CTFV) Serology, IgG by Indirect Immunofluorescence
Specimen Requirements: 1 mL serum; Paired acute and convalescent serum recommended.
Transport Temperature: 2-30°C (Refrigeration preferable)
Referred to the Centers for Disease Control, Fort Collins, Colorado
Turn-around Time: 6 weeks
NOTE: Rocky Mountain Spotted Fever testing will automatically be performed on all requests for Colorado Tick Fever.
CPT Codes:
86790 (CTFV)
Price: $30.00
86757 (RMSF)
Price: $25.00 (each)
Total Price: $55.00

Corynebacterium diphtheriae Culture Isolation/ Identification
Specimen Requirements: Throat, nasal, and wound swabs, pseudo-membrane, and sputum. Swabs may be placed in
Amies or Stuart transport medial. Pseudo-membrane should be sent in leak proof container with saline (not formalin).
Please contact the State Epidemiology Department (406)-444-0273) for consultation prior to submission of specimens.
Transport Temperature: 2-8°C
Referred to the Centers for Disease Control, Atlanta, Georgia.
Turn-around Time: One week. Positive results are telephoned to the submitter.
CPT Code:
87081
Price: $30.00
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Corynebacterium spp. (not C. diphtheriae) Culture Isolation/ Identification (see Bacterial Culture, Aerobic)
Coxiella burnetii by Real-Time PCR
Specimen Requirements: EDTA whole blood or environmental samples
Please contact the Montana Public Health Laboratory prior to submission regarding sample collection and transport
instructions.
Transport Temperature: Ambient
Turn-around Time: Rapid test methods are performed in Molecular Diagnostics and are available within 6 - 8 hours of
specimen receipt. Results are telephoned as soon as possible to the submitter.
NOTE: This is a presumptive assay. Confirmation for Coxiella burnetii is performed at the Centers for Disease Control and
Prevention (CDC).
CPT Code:
87798
Price: Fee Waived

Coxiella burnetii Serology (see Q fever Serology)
Cryptococcus spp. Culture Isolation/ Identification (see Fungal Culture)
Cryptosporidium / Cyclospora / Cystoisospora Detection by Fluorescent Stain
Specimen Requirements: Stool in Total-Fix preservative or 10% Formalin
Transport Temperature: Ambient
Turn-around Time: Performed each working day. Positive results are telephoned to the submitter.
CPT Code:
87207
Price: $35.00

Culture for Storage
Specimen Requirements: Pure culture isolate submitted in Cary-Blair transport or on solid media.
Submit organisms that are of epidemiologic interest and need to be stored for molecular comparison to other strains.
Laboratories are encouraged to submit organisms which may be part of an outbreak or which demonstrate a significant
antibiotic resistance, i.e. E. coli O157, Toxigenic E. coli, Salmonella spp., Shigella spp., Legionella spp., Listeria
monocytogenes, Vibrio spp., Yersinia enterocolitica, N. gonorrhoeae, N. meningitidis from a sterile site, H. influenzae
from a sterile site, resistant Streptococcus pneumoniae, CRE, CRPA, KPC, and potential VISA or VRSA.
Transport Temperature: Ambient
CPT Code:
None
Price: Fee Waived
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Cyclospora Detection (see Cryptosporidium / Cyclospora / Cystoisospora Detection by Fluorescent Stain)
Cystoisospora Detection (see Cryptosporidium / Cyclospora / Cystoisospora Detection by Fluorescent Stain)

D
Dengue Fever Serology by ELISA IgM and IgG
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C or frozen (refrigeration or frozen specimens preferred)
Referred to the Centers for Disease Control, San Juan, Puerto Rico. An additional form must be filled out.
Turn-around Time: 7 days
CPT Code:
86790
Price: $30.00

Dengue Fever Virus by PCR (see Zika Trioplex PCR)
Dermatophytes Culture Isolation/ Identification (see Fungal Culture)
Diphtheria (see Corynebacterium diphtheriae Culture Isolation)

E
Ebola Virus
Specimen Requirements: Whole blood, serum, or plasma. Urine may be submitted, but only when accompanied by a
blood specimen.
NOTE: Contact your local health department or the State Epidemiology Department (406-444-0273) to ensure the patient
meets criteria for testing.
A specimen SUSPECTED of containing Ebola Virus requires Category A Infectious Disease packaging (Class 6.2) and
trackable shipping. Please contact the Montana Public Health Laboratory prior to submission regarding sample collection
and transport instructions.
Transport Temperature: Whole blood: 2-8°C
Serum, plasma, or urine: 2-8°C or frozen
Turn-around Time: Rapid test methods are performed in Molecular Diagnostics and are available within 6 - 8 hours of
specimen receipt. Samples that yield positive, equivocal, or inconclusive results will be forwarded to CDC for additional
evaluation.
Note: Negative EBOV rRT-PCR results do not preclude Ebola virus infection and should not be used as the sole basis for
patient management decisions. The level of Ebola virus that would be present in whole blood, serum or plasma
specimens from individuals with early systemic infection is variable but generally positive at the time of symptom
onset. In asymptomatic individuals or individuals within 72 hours of symptom onset, a negative result does not
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exclude the possibility of Ebola virus infection and does not demonstrate that an individual is not infectious. If
negative results are obtained for an individual with 72 hours of symptom onset, testing should be repeated at or after
the 72-hour time point.
CPT Code:
87798
Price: Fee Waived

Echinococcosis Serology by Western Blot or Immunoblot
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 18 days
CPT Code:
84182
Price: $30.00

EHEC, Enterohemorrhagic E. coli (see Escherichia coli Shiga-Like Toxin Assay or Enteric Panel)
Ehrlichia spp. Serology by Indirect Immunofluorescence
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 6 weeks
CPT Code:
86682
Price: $30.00

Entamoeba histolytica Serology by EIA
Specimen Requirements: 2 mL serum Include documentation of negative stool examinations for E. histolytica.
Referred to the Centers for Disease Control, Atlanta, Georgia
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: 3 to 6 weeks
CPT Code:
86753
Price: $30.00

Enteric Isolate Surveillance
Specimen Requirements: All isolates of Campylobacter spp., Shiga-toxin producing Escherichia coli (STEC including
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serotype O157:H7), Salmonella spp., Shigella spp., Vibrio, Yersinia spp., and Listeria should be referred for surveillance
purposes. All stools that are positive by Culture-Independent Testing (e.g. PCR, EIA) for the listed organisms should be
sent for surveillance purposes.
Confirmation of isolates is performed are reported to submitter. In addition, Whole Genome Sequencing will be
performed to determine strain-relatedness on certain organisms of interest; results are compared to other strain
patterns in Montana and across the nation using the CDC PulseNet database. Results are communicated to the DPHHS
Epidemiology staff for follow up.
Transport Temperature: 2-8°C for stool, ambient for isolates
Turn-around Time: Routinely tested each week.
CPT Code:
none
Price: Fee Waived

Enteric Panel Culture Isolation/ Identification
Includes screens for Salmonella, Shigella, Campylobacter, E. coli O157, EHEC, Aeromonas, and Plesiomonas
Specimen Requirements: Stool in Cary-Blair transport, or other commercial enteric transport media. Collect stool
directly from patient into a clean specimen container. Do not collect from toilet bowl or use stool contaminated with
urine. Use a sterile swab to collect a portion of the stool (collect from bloody or mucous-containing areas if present) and
insert swab to the lower part of a Cary-Blair transport tube and break or cut the swab stick. A rectal swab is also
acceptable if there is evidence of fecal staining on the swab. Cary-Blair transport tubes are supplied upon request.
Escherichia coli Shiga-Like Toxin Assay will be performed on all specimens. Stools with positive toxin tests will be further
cultured to isolate and identify the toxin-producing organism.
Transport Temperature: 2-8°C
Turn-around Time: 2 to 4 working days. Positive test results are telephoned to the submitter.
CPT Codes:
87045 (Salmonella and Shigella culture)
87046 (E. coli culture)
87046 (Campy culture)

87046 (Aeromonas culture)
87046 (Plesiomonas culture)

87449 (EHEC)
Price: $30.00
Total Price: $84.00
87077 (Each add’l ID)
Price: $25.00

Enterovirus (D68) Detection by Real-Time PCR
Specimen Requirements: CSF in a sterile transport container without transport media, respiratory specimens (NP swab)
in Universal Viral Transport Media. See Molecular (Nucleic Acid Amplification) Testing Collection and Transport
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instructions.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 3 working days. Positive results are telephoned to the submitter.
CPT Code:
87498
Price: $107.00

Enterovirus (Pan-Enterovirus) Detection by Real-Time PCR
Specimen Requirements: CSF in a sterile transport container without transport media, respiratory specimens (NP swab)
in Universal Viral Transport Media. See Molecular (Nucleic Acid Amplification) Testing Collection and Transport
instructions.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 3 working days. Positive results are telephoned to the submitter.
CPT Code:
87498
Price: $107.00

ESBL (see Antimicrobial Resistant Bacteria Confirmation)
Escherichia coli O157 Culture Isolation/Identification
Specimen Requirements: Stool specimen in Cary-Blair transport, or other commercial enteric transport media, or pure
culture isolate submitted in Cary Blair transport or on solid media.
Note: A suspected E. coli O157 culture requires Infectious Disease packaging (Class 6.2) and trackable shipping. Please
notify the laboratory by telephone at time of shipment.
For public health surveillance, please submit all isolates of E. coli O157 to the laboratory. See Enteric Isolate Surveillance.
Transport Temperature: 2-8°C for stool, ambient for isolates
Turn-around Time: 2 to 4 working days. Positive results are telephoned to the submitter.
CPT Codes:
87046 (Culture ID)
Price: $18.00
87077 (Each add’l ID)
Price: $25.00

Escherichia coli Shiga-Like Toxin Assay (Enterohemorrhagic E. coli, EHEC or STEC) by EIA
Specimen Requirements: Stool specimen in Cary-Blair transport, or other commercial enteric transport media, or pure
culture Escherichia coli isolate submitted in Cary Blair transport or on solid media.
EHEC is also performed on all routine enteric panels.
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Transport Temperature: 2-8°C
Turn-around Time: 2 to 4 working days. Positive results are telephoned to the submitter. Stools with positive toxin tests
will be further cultured to isolate and identify the toxin-producing organism.
CPT Code:
87449
Price: $30.00

F
Francisella tularensis Culture Isolation/ Identification/Rapid Test Methods
Specimen Requirements: Clinical specimen in sterile container or pure culture isolate on solid medium.
Note: A suspected F. tularensis culture requires Category A Infectious Disease packaging (Class 6.2) and trackable
shipping. Please notify the laboratory by telephone at time of shipment.
Please contact the laboratory prior to submission regarding environmental samples, rapid test methods, and transport
instructions.
Transport Temperature: Ambient
Turn-around Time: Cultures will be held for five (5) working days before reporting as negative. Results are telephoned as
soon as possible to the submitter.
PCR testing methods are performed in Molecular Diagnostics and are available within 6 - 8 hours of specimen receipt.
Culture is considered confirmatory for specimens that are PCR-positive.
CPT Codes:
87081 (Culture screen)
Price: Fee Waived
87798 (PCR)
Price: Fee Waived

Francisella tularensis Serology by Bacterial Agglutination
Specimen Requirements: 2 mL serum; Paired acute and convalescent specimens recommended.
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week.
NOTE: Brucella serology testing will be automatically performed on all requests for Tularemia serology due to antigen
cross reactivity.
CPT Codes:
86668 (Tularemia)

86622 (Brucella)

Price: $25.00 (each)
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Total Price: $50.00

Fungal Culture Isolation/ Identification
Specimen Requirements: Send original specimens in a sterile container. Send cutaneous specimens dry. Send pure
fungal isolates (molds or yeasts) on an agar slant. See Mycology (Fungal) Culture Collection and Transport instructions.
Transport Temperature: Ambient
Turn-around Time: Primary specimen cultures are monitored for 4 weeks prior to a negative report.
CPT Codes:
87101 (culture, skin)
87102 (culture, other)

87103 (culture, blood)

Price: $42.00 Each
87106 (ID, yeast)
Price: $22.00 Each

87107 (ID, mold)
Price: $22.00 Each

Fungal Serology (Histo, Cocci, Blasto) by Complement Fixation & Immunodiffusion
Specimen Requirements: 1.5 mL serum or CSF. Serum cannot be hemolyzed and plasma is not accepted.
Transport Temperature: 2-8°C
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 4 weeks
CPT Codes:
86698 (Histoplasma)
86612 (Blastomyces)

86635 (Coccidioides)

Price: $30.00

G
Gardnerella vaginalis Culture Isolation/ Identification (see Bacterial Culture, Aerobic)
Giardia Detection (see Ova and Parasite Exam)
Gonococcal Infections (see Neisseria gonorrhoeae Culture Isolation)

H
Haemophilus influenzae Culture Isolation/ Identification
Specimen Requirements: Primary specimen or pure culture isolate on chocolate media.
Transport Temperature: Ambient
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Turn-around Time: 2 to 4 working days. Positive H. influenzae results from sterile sites are telephoned to the submitter.
NOTE: Serogrouping is routinely performed on H. influenzae isolates from sterile body sites such as blood or cerebral
spinal fluid. Please submit all H. influenzae isolates from sterile body sites to the laboratory for serogrouping and storage
for future epidemiologic purposes.
CPT Codes:
87081 (culture)
Price: $38.00
87185 (beta lactamase)
Price: $9.00

Haemophilus spp. Culture Isolation/ Identification (see Bacterial Culture, Aerobic)
Hantavirus IgM Serology by EIA, capture EIA
Specimen Requirements: 3 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week. STAT testing is available each working day, or on weekends
and holidays as needed. Call ahead to notify the laboratory and to make arrangements.
Positive and STAT results are telephoned to the submitter. Specimens that yield a positive result are referred to the
Centers for Disease Control, Atlanta, Georgia for IgG and IgM testing. Confirmation testing turn-around time is 10 days.
To qualify for STAT testing, all the following criteria must be met:
1. The patient is hospitalized with an acute respiratory illness, typical of Hantavirus Pulmonary Syndrome (HPS).
2. The patient is critically ill.
3. The patient does not have any relevant underlying medical condition that could account for the symptoms
(COPD, malignancy, immunosuppression, diabetes)
4. The onset of illness (date when prodromal symptoms such as low-grade fever and myalgia were noted) is
three (3) or more days prior to serum sample collection. IgM antibody to SNV is usually not detectable until the
patient develops shortness of breath.
CPT Codes:
86790 (IgM)
Price: $ 100.00

Hepatitis A IgM Antibody (HAV IgM) by EIA
Specimen Requirements: 1 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Testing is routinely batch tested once per week but may be available each working day as needed.
Call ahead to notify the laboratory and to make arrangements if immediate testing is needed.
CPT Code:
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86709
Price: $35.00

Hepatitis, Acute Panel by EIA (HAV IgM Ab, HBsAg, HBc IgM Ab, HCV)
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Testing is routinely batch tested once per week but may be available each working day as needed.
Call ahead to notify the laboratory and to make arrangements if immediate testing is needed.
CPT Codes:
80074 (entire panel)
Total Price: $135.00

Hepatitis B Core IgM (HBc IgM) Antibody by EIA
Specimen Requirements: 1 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Testing is routinely batch tested once per week but may be available each working day as needed.
Call ahead to notify the laboratory and to make arrangements if immediate testing is needed. Positive and STAT results
are telephoned to the submitter.
CPT Code:
86705
Price: $35.00

Hepatitis B Core Total Antibody (HBc Total) by EIA
Specimen Requirements: 1 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Testing is routinely batch tested once per week. Positive results are telephoned to the submitter.
CPT Code:
86704
Price: $40.00

Hepatitis B Post-Vaccination Panel with Reflex Confirmation (Infants Only)
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Testing is routinely batch tested once per week.
NOTE: This test is only for post-vaccination serologic testing for infants born to Hepatitis B-infected women.
Confirmatory Neutralization testing will be automatically performed on all repeat reactive HBsAg.
CPT Code:
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86706 (HBsAb)
Price: $30.00
87340 (HBsAg)
Price: $25.00
Total Price: $55.00
87341 (HBsAg Neutralization)
Price: $31:00

Hepatitis B Surface Antibody (HBsAb) by EIA (Quantitation)
Specimen Requirements: 1 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Testing is routinely batch tested once per week.
CPT Code:
86706
Price: $30.00

Hepatitis B Surface Antigen (HBsAg) by EIA with Reflex Confirmation
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week. Call ahead to notify the laboratory and to make arrangements
if immediate testing is needed. Positive and STAT results are telephoned to the submitter.
NOTE: Confirmatory Neutralization testing will be automatically performed on all repeat reactive screens.
CPT Code:
87340 (HBsAg)
Price: $25.00
87341 (HBsAg Neutralization)
Price: $31.00

Hepatitis C (HCV) Antibody Screen by EIA
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: EIA screens routinely batch tested twice per week. Positive results are telephoned to the submitter.
NOTE: Repeat positive samples will automatically reflex to HCV RNA for confirmation and quantitation.
CPT Code:
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86803 (Screen)
Price: $40.00

Hepatitis C (HCV) RNA Quantitation
This CONFIRMATORY testing is a reflex test for repeat positive HCV specimens.
Specimen Requirements: 2 mL serum or plasma (EDTA, anticoagulant citrate dextrose solution or plasma preparation
tubes). Whole blood can be stored at 2-30°C and must be centrifuged within 6 hours of specimen collection. Separate
the plasma or serum from the pelleted red blood cells following the manufacturer’s instruction for the tube used.
Transport Temperature: 2-8°C. Ship specimen within 5 days of collection.
Turn-around Time: 3-5 days. Positive results are telephoned to the submitter.
CPT Code:
87522
Price: $107.00

Herpes Simplex Virus (HSV), Type 1 and 2, Direct Detection by NAAT
Specimen Requirements: Cervical Swab or Lesion swab in Aptima Multitest Specimen collection tube. See
Chlamydia/Gonorrhea Amplified Testing Collection and Transport instructions.
Note: CSF in a sterile container without transport media is sent to North Dakota Public Health Laboratory for testing.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 3 working days. Positive results are telephoned to the submitter.
CPT Code:
87529
Price: $107.00
Herpes Simplex Virus (HSV), Type 1 and 2, IgG Serology by type specific EIA
Specimen Requirements: 1 mL serum; Screen or paired acute and convalescent specimens
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week.
CPT Codes:
86695 (HSV 1)

86696 (HSV 2)

Price: $25.00 (each)
Total Price: $50.00
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Herpes Zoster Virus IgG Serology by EIA (see Varicella Zoster Virus Serology)
Histoplasma Culture Isolation/ Identification (see Fungal Culture)
Histoplasma Serology (see Fungal Serology)
HIV 1/2 Ab/p24 Ag by EIA, with Reflex Confirmation
Specimen Requirements: 1 mL K2 EDTA or serum (note that plasma is required for HIV RNA quantitation).
Transport Temperature: 2-8°C or frozen
Turn-around Time: EIA screens routinely tested at least two (2) days each week. Specimens sent for confirmation will be
tested the day they are received.
NOTE: Reflex supplemental testing is performed on all repeat reactive EIA screens using the CDC HIV testing algorithm.
HIV-1/HIV-2 Geenius testing will be performed to confirm the presence of HIV antibody and to differentiate HIV-1 and
HIV-2.
HIV NAT testing will be performed to confirm the presence of HIV p24 antigen (acute infection) when the HIV Ab/Ag
Combo test is repeat reactive and the HIV-1/HIV-2 Geenius test is negative. It will also be performed for any newly
detected cases.
CPT Codes:
87389
Price: $31.00

HIV-1/HIV-2 Geenius
This test is used to differentiate HIV-1 and HIV-2 and is used in an algorithm when the HIV Combo Ag/Ab EIA is repeatreactive. Repeat reactive EIA screens with inconclusive or conflicting Geenius results are reflexed to HIV RNA
Quantitation testing.
Specimen Requirements: 1 mL K2 EDTA or serum (note that plasma is required for HIV RNA quantitation).
Transport Temperature: 2-8°C or frozen
Turn-around Time: Within 1 to 2 working days of repeat reactive HIV Combo Ag/Ab EIA
CPT Code:
86703
Price: $55.00

HIV RNA Quantitation
Per CDC recommendations for HIV testing: Specimens that are positive by the HIV EIA method and negative by the HIV
supplemental test will be reflex tested for HIV RNA Quantitation.
Specimen Requirements: 2 mL plasma obtained by K2 EDTA or Acid Citrate Dextrose (ACD) anticoagulants or Plasma
Preparation tubes (PPTs). Whole blood can be stored at 2-30°C and must be centrifuged within 24 hours of specimen
collection. Separate the plasma from the pelleted red blood cells following the manufacturer’s instructions for the tube
used. Ship the separated plasma.
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Transport Temperature: 2-8°C. Ship specimen within 3 days of collection.
Turn-around Time: 3-5 days
CPT Code:
87536
Price: $107.00

I
Influenza A and B Direct Detection by Real Time PCR
Specimen Requirements: Respiratory specimen in Universal Viral Transport Media. See Molecular (Nucleic Acid
Amplification) Testing Collection and Transport instructions.
This test detects Influenza B and all subtypes of Influenza A. All specimens positive for Influenza A will be reflexed to
real-time PCR subtyping. Specimens positive for Influenza B will be reflexed to real-time PCR genotyping.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 3 working days. Positive results are telephoned to the submitter.
CPT Code:
87502
Price: $55.00

Influenza A Sub-typing by Real Time PCR
Detects Influenza A subtypes H3N2, H1N1 2009 pdm, H5, H7, or variant subtypes.
Note: if H5 or H7 is suspected, call the laboratory for a consultation prior to submission. The individual case must meet
Epidemiological testing criteria.
Specimen Requirements: Nucleic acid derived from a PCR specimen screened positive for Influenza A. Reflex testing is
performed on all Influenza A positive specimens.
Transport Temperature: 2-8°C
Turn-around Time: Sub-typing is performed each working day. Results are telephoned to the submitter.
CPT Code:
87503
Price: $33.00

Influenza B Genotyping by Real Time PCR
Detects Yamagata and Victoria lineage genotypes
Specimen Requirements: Nucleic acid derived from a PCR specimen screened positive for Influenza B. Reflex testing is
performed on all Influenza B positive specimens.
Transport Temperature: 2-8°C
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Turn-around Time: Sub-typing is performed each working day. Results are telephoned to the submitter.
CPT Code:
87503
Price: $33.00

Influenza Isolate Susceptibility Testing and Characterization
Specimen Requirements: Influenza A isolate in Universal Transport Media. The laboratory routinely selects significant
isolates for susceptibility testing and characterization.
*Testing is performed at no cost for epidemiological purposes.
Transport Temperature: 2-8°C
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 6 to 8 weeks
Price: Fee Waived

J
K
KPC (K. pneumoniae Carbapenemase) (see Carbapenem-Resistant Organisms Direct Detection by Real-Time
PCR)

L
Lead Testing (see Blood Lead)
Legionella pneumophila Groups 1-6 Direct Detection by Immunofluorescence
Specimen Requirements: Submit fresh or frozen lung tissue, pleural fluid, bronchial washings, trans-tracheal aspirates,
chest drainage, BAL, or sputum. Put a minimum of 1 mL specimen in a sterile, leak-proof container, and transport on ice
in an insulated container.
Transport Temperature: 2-8°C
Turn-around Time: Performed each working day. Positive results are telephoned to the submitter.
CPT Code:
87278
Price: $29.00

Legionella spp. Culture Isolation/ Identification
Specimen Requirements: Submit fresh or frozen lung tissue, pleural fluid, bronchial washings, trans-tracheal aspirates,
chest drainage, BAL, or sputum. Put a minimum of 1 mL specimen in a sterile, leak-proof container, and transport on ice
in an insulated container. A suspect pure culture isolate submitted on BCYE medium may be submitted.
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Transport Temperature: 2-8°C for specimen, ambient for isolate
Turn-around Time: DFA test performed each working day. Positive test results are telephoned to the submitter. Cultures
are monitored for 14 working days before reporting as negative.
NOTE: Both a DFA test and culture is performed on each primary specimen received.
CPT Codes:
87081 (Culture screen)
Price: $38.00
87278 (DFA)
Price: $29.00

Leishmania Detection
Specimen Requirements: Tissue, 1-5 ml of whole EDTA blood, or bone marrow.
Please contact the laboratory prior to submission regarding proper CDC-provided transport medium for tissue specimens.
Transport Temperature: 2-8°C for whole blood and bone marrow, ambient for inoculated culture medium
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 3 to 6 weeks
CPT Code:
87207
Price: $30.00

Leishmaniasis Serology by IFA
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 3 weeks
CPT Code:
86717
Price: $30.00

Leptospira Serology by INDX Dip-S-Ticks or IgM EIA
Specimen Requirements: 2 mL serum; Paired acute and convalescent serum specimens are recommended.
Transport Temperature: 4°C; ambient specimens not accepted
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 18 days
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CPT Code:
86720
Price: $30.00

Listeria Culture Isolation/ Identification (see Bacterial Culture, Aerobic)
Lyme Disease Culture (see Borrelia burgdorferi culture)
Lyme Disease Serology (see Borrelia burgdorferi serology)

M
Malaria Detection/ Identification (see Blood Parasite Screen)
Malaria Serology (see Plasmodium Serology)
Measles PCR (see Rubeola (Measles) Direct Detection by Real Time PCR)
Measles Serology (see Rubeola Serology)
Meningococcal Infection (see Neisseria spp. including N. meningitidis Culture)
MERS Co-V
Detects Middle Eastern Respiratory Syndrome Virus from individuals meeting MERS-CoV clinical and/or Epidemiological
criteria. History of travel to a geographic location where MERS-CoV cases have been detected, contact with a probable
or confirmed MERS-CoV case, or other epidemiologic links for which MERS-CoV testing may be indicated as part of a
public health investigation.
Note: Call the laboratory for a consultation prior to submission. The individual case must meet Epidemiological testing
criteria.
Specimen Requirements: Respiratory specimens; Nasopharyngeal or oropharyngeal swabs, lower respiratory
aspirates/washes.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 3 working days. Results are telephoned to the submitter.
CPT Code:
87798
Price: Fee Waived

Methicillin Resistant Staphylococcus aureus (MRSA) (see Antimicrobial Resistant Bacteria Confirmation)
Modified Acid-Fast Stain
Specimen Requirements: Send specimens in sterile container. Add 1.0 ml sterile saline or broth to tissues or other nonliquid specimens. Send isolates on LJ medium.
Transport Temperature: Ambient
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Turn-around Time: 1 to 2 working days. Positive results will be called to the submitter.
CPT Code:
87206 (smear)
Price: $18.00

Mold Culture Isolation/ Identification (see Fungal Culture)
Mumps Direct Detection by Real Time PCR
Specimen Requirements: Oral/buccal or oropharyngeal Dacron swabs in viral transport media and/or 50 ml minimum of
urine.
Urine should be centrifuged at 2500xg for 15 min at 4° C. Resuspend sediment in 2 ml viral transport media. Swabs are
the preferred specimen.
Note: Urine may not be positive until 4 days after symptom onset.
CSF may be submitted in meningitis/encephalitis-suspect cases with prior consult.
Transport Temperature: 2-8° C within 24 hours or freeze at -70° C and transport on dry ice.
Turn-around Time: 1 to 2 working days. Positive results are telephoned to the submitter.
CPT Code:
87798
Price: $107.00

Mumps IgG Serology by EIA
Specimen Requirements: 1 mL serum; Screen or paired acute and convalescent specimens
Transport temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week.
CPT Code:
86735
Price: $25.00

Mumps IgM Serology by IFA
Specimen Requirements: 1 mL serum; collect acute phase serum only and include an immunization history.
Transport Temperature: Frozen
Turn-around Time: Testing performed at North Dakota Public Health Laboratory as needed. Results are available within
2-3 days. Results are telephoned to the submitter.
CPT Code:
86735
Price: $22.00
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Mycobacterium spp. Culture Isolation/ Identification
Specimen Requirements: Send specimens in sterile container. Add 1.0 ml sterile saline or broth to tissues or other nonliquid specimens. Send isolates on LJ medium or in liquid media vials. See Mycobacterium spp. (AFB or TB) Testing
Collection and Transport instructions.
Note: The specimen must be received within 5 days of collection.
Transport Temperature: Ambient for Heparinized blood or bone marrow; 2-8°C for all other specimens
Turn-around Time: Smear reports are faxed to submitter by 5 p.m. the same day that the specimen is processed. Positive
results are telephoned to the submitter; cultures are monitored for 6 weeks prior to issuing a negative report. Cultures
positive for Mycobacterium tuberculosis complex will be reflexed for Mycobacterium tuberculosis complex Antimicrobial
Susceptibility Testing.
NOTE: After a patient has tested positive for M. tuberculosis, no more than three specimens per week from the same
body site will be processed to determine response to therapy and infectious status, without prior consultation. To
determine response to therapy, specimens should be obtained no sooner than 7 days post initiation of therapy.
CPT Codes:
87206 (smear)
Price: $18.00
87015 (concentration)
Price: $20.00
87116 (culture)
Price: $38.00
87176 (tissue digestion)
Price: $12.00

Mycobacterium spp. Identification by Nucleic Acid Probe/MALDI-TOF MS Identification
Specimen Requirements: Isolates sent on LJ slants or in liquid media vials, or as reflex testing on positive primary
specimens submitted for culture.
Transport Temperature: Ambient
Turn-around Time: 1 to 3 working days for submitted isolates, others dependent on growth rate.
NOTE: On initial isolation of an AFB from a new patient, both M. tuberculosis complex and M. avium complex probes will
be run on the isolate. After M. tuberculosis complex has been confirmed in the patient, subsequent cultures received
during the next six weeks will only be probed for M. tuberculosis complex.
CPT Codes:
87555 (M. tuberculosis probe)
87560 (M. avium probe)

87550 (M. gordonae probe)

Price: $35.00 each probe
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83789 (MALDI-TOF MS Identification)
Price: 38.00 MALDI-TOF MS ID

Mycobacterium tuberculosis complex Antimicrobial Susceptibility Testing
Specimen Requirements: Isolates sent on LJ slants or in liquid media vials, or primary specimens submitted for culture.
Reflex testing is performed on Mycobacterium tuberculosis complex isolates identified in this laboratory.
Agents tested include Isoniazid, Rifampin, Ethambutol and PZA.
Transport Temperature: Ambient for isolates or liquid media vials; 2-8°C for primary specimens
Turn-around Time: 14 to 21 working days from date susceptibility testing is begun.
NOTE: Susceptibility testing for M. tuberculosis will be performed only on the first isolate from the patient and will be
repeated as requested by the MT TB Program director. Other susceptibility testing including molecular drug
susceptibility testing or second line drug testing is available upon consultation.
CPT Code:
None
Price: Fee Waived

Mycobacterium tuberculosis Nucleic Acid Amplification Testing (NAAT) with Rifampin resistance marker
Specimen Requirements: Processed concentrated respiratory specimen or primary respiratory specimen. See
Mycobacterium spp. (AFB or TB) Testing Collection and Transport instructions.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 2 working days. Call ahead to make testing arrangements. Results are telephoned to the
submitter.
NOTE: Nucleic acid amplification testing (NAAT) is recommended on specimens of patients highly suspected or known to
have TB.
If NAAT is not ordered and an AFB smear is positive, the laboratory will contact the submitter to offer NAAT testing for
M. tuberculosis complex.
CPT Code:
87556
Price: $107.00

Mycology Culture (see Fungal Culture)

N
Neisseria gonorrhoeae Culture Isolation/ Identification
Specimen Requirements: Primary culture or pure culture isolate on MTM or chocolate media; identification performed
by MALDI-TOF.
Transport Temperature: Ambient
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Turn-around Time: 2 to 3 working days. Positive results are telephoned to the submitter.
NOTE: For public health surveillance, please submit all N. gonorrhoeae isolates to the laboratory. This is at no cost to the
submitter (See Culture for Storage).
CPT Codes:
87081 (Culture screen)
Price: $38.00
87590 (ID)
Price: $38.00
87185 (Beta-lactamase)
Price: $9.00

Neisseria gonorrhoeae Direct Detection by Nucleic Acid Amplification
Specimen Requirements: Endocervical or male urethral swab in APTIMA Uni-Sex Swab Specimen Collection Tube; throat,
rectal, or vaginal swab in APTIMA Multitest Specimen Collection Tube; or urine in APTIMA Urine Specimen Collection
Tube. See Chlamydia/Gonorrhea Amplified Testing Collection and Transport instructions.
Transport Temperature: 2-30°C
Turn-around Time: Routinely tested daily (Monday through Friday). Positive results are telephoned to the submitter.
NOTE: Can be run in tandem with Chlamydia trachomatis Direct Detection by Amplification (see Combination
Amplification Test).
CPT Code:
87591
Price: $44.00

Neisseria spp. (including N. meningitidis) Culture Isolation /Identification/Typing
Specimen Requirements: Primary specimen or pure culture isolate on chocolate media
Transport Temperature: Ambient
Turn-around Time: 2 to 4 working days. Positive N. meningitidis results are telephoned to the submitter.
NOTE: Serogrouping is routinely performed on N. meningitidis isolates from sterile body sites such as blood or cerebral
spinal fluid. Please submit all N. meningitidis isolates from sterile body sites to the laboratory for serogrouping and
storage for future epidemiologic purposes.
CPT Codes:
87081 (Culture screen)
Price: $38.00
87185 (Beta-lactamase)
Price: $9.00
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Newborn Screening Panel
Specimen Requirements: Dried Blood Spots. See Newborn Screening Collection and Transport instructions.
Transport Temperature: Ambient
Turn-around Time: 3 to 5 working days. Abnormal results are telephoned to the submitter. Contact the laboratory for
further information.
Total Price: $134.00

Screening Tests
Acylcarnitine Disorders by Tandem Mass Spectrometry (MS/MS) *
Fatty Acid Oxidation Disorders
Carnitine Uptake Defect
Long Chain L-3-Hydroxyacyl CoA Dehydrogenase Deficiency (LCHAD)
Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)
Trifunctional Protein Deficiency (TFP)
Very Long Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD)
Organic Acidemia Disorders
3-OH 3-CH3 Glutaric Aciduria
3-Methylcrotonyl-CoA Carboxylase Deficiency
β-ketothiolase Deficiency
Glutaric Acidemia Type I
Isovaleric Acidemia
Methylmalonic Acidemia (Cbl A and B)
Methylmalonic Acidemia (mutase deficiency)
Multiple CoA Carboxylase Deficiency (MCD)
Proprionic Acidemia
Amino Acid Disorders by Tandem Mass Spectrometry (MS/MS) *
Argininosuccinic acidemia
Citrullinemia
Homocystinuria (due to CBS deficiency)
Maple syrup urine disease
Tyrosinemia type I
Biotinidase*
Classic Galactosemia
Congenital Adrenal Hyperplasia (CAH)*
21 hydroxylase deficiency
Congenital Hypothyroidism (CH)
Thyroxine (T4) testing, TSH reflex testing
Cystic Fibrosis (IRT)
Confirmatory DNA Mutational Analysis* as warranted
Phenylketonuria (PKU)
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CPT Code

Price

82017

$11.75

82136

$4.65

82261
82775
83498

$6.00
$28.90
$11.50

84437 (T4)
84443 (TSH)
83516

$20.41
$23.05
$15.97

84030

$19.06
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Hemoglobinopathies by Isoelectric Focusing
Hb S/B-thalassemia
Hb SC disease
Hb SS disease (Sickle cell anemia)
HPLC reflex testing*
Severe Combined Immunodeficiency (SCID Immunodeficiency: TREC) *
* Tests referred to the Wisconsin State Newborn Screening Laboratory

83020

$17.66

87143 (HGB
Confirmation)

$12.00

TBD

$6.00

The cost of reflex confirmatory testing (TSH, Hemoglobinopathies by HPLC and Cystic Fibrosis DNA Mutational Analysis)
has been incorporated into the cost of the Newborn Screening panel, and no additional charges will be assessed.

Norovirus Direct Detection by Nucleic Acid Amplification
Specimen Requirements: 2 mL stool in a sterile container. See Molecular (Nucleic Acid Amplification) Testing Collection
and Transport instructions.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 3 working days. Positive results are telephoned to the submitter.
CPT Code:
87798
Price: $107.00

O
Orthopoxvirus, including Variola (Smallpox), Direct Detection by Real Time PCR
Specimen Requirements: Lesion swab in Universal Viral Transport Media plus an additional lesion swab transported dry
in a sterile container.
NOTE: Contact your local health department or the State Epidemiology Department (406-444-0273) to ensure the patient
meets criteria for testing. Please contact the Montana Public Health Laboratory prior to submission regarding sample
collection and transport instructions.
A suspect Orthopoxvirus requires Category A Infectious Disease packaging (Class 6.2) and trackable shipping. Please
notify the laboratory by telephone at time of shipment.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 3 working days. Results are telephoned to the submitter.
CPT Code:
87798
Price: Fee Waived

Orthopoxvirus, Other Than Variola, Direct Detection by Real Time PCR
Specimen Requirements: Lesion swab in Universal Viral Transport Media plus an additional lesion swab transported dry
in a sterile container. See Molecular (Nucleic Acid Amplification) Testing Collection and Transport instructions.
Transport Temperature: 2-8°C
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Turn-around Time: 1 to 3 working days. Results are telephoned to the submitter.
CPT Code:
87798
Price: Fee Waived

Ova and Parasite Exam
Specimen Requirements: Stool transported in a vial of Total-Fix preservative. Collect stool into a clean specimen
container. Using the spoon inside the transport vial, immediately transfer stool to the vial until the liquid level reaches
the red fill line. Stool should be emulsified into the transport media with the spoon. Recap the vial tightly and shake the
vial until the contents are well mixed. Total-Fix transport kits are available from the laboratory upon request.
For optimal recovery, a series of three (3) specimens should be submitted.
Transport Temperature: Ambient
Turn-around Time: 1 to 2 working days. Positive results are telephoned to the submitter.
CPT Codes:
87177 (concentration/ID)

87209 (Trichrome stain)

Price: $27.00 (each)
Total Price: $54.00

P
Parasite Detection (see Ova and Parasite Exam)
Paratyphoid Fever (see Salmonella spp.)
Pasteurella spp. Culture Isolation/ Identification (see Bacterial Culture, Aerobic)
Pertussis (see Bordetella pertussis)
Phenylalanine (PKU) Monitor by Fluorescent Immunoassay
Used to monitor levels in patients diagnosed with phenylketonuria (PKU) only.
Specimen Requirements: Dried Blood Spots. See Newborn Screening Collection and Transport instructions.
Transport Temperature: Ambient
Turn-around Time: 1 to 2 working days.
CPT Code:
84030
Price: Fee Waived. Phone the laboratory for more information 1-406-444-2930.

Pinworm Examination (Enterobius vermicularis)
Specimen Requirements: Microscopic identification of eggs collected in the perianal area is the method of choice for
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diagnosing enterobiasis. In the morning, before defecation and washing, press transparent adhesive tape (“Scotch test”)
on the perianal skin and then place the tape sticky side down on a slide. Alternatively, the tape can be attached to the
glass slide in a loop, and then folded over the glass surface after application to the perianal skin.
Transport Temperature: Ambient
Turn-around Time: 1 to 2 working days. Positive results are telephoned to the submitter.
CPT Code:
87172 (concentration/ID)
Price: $27.00

Plague (see Yersinia pestis Culture Isolation)
Plasmodium Detection (see Blood Parasite Screen)
Pneumococcal Infection (see Streptococcus pneumoniae)
Pseudomonas spp. Culture Isolation/ Identification (see Bacterial Culture, Aerobic)

Q
Q-Fever (Coxiella burnetii) Phase 1 and 2 IgG Serology by Indirect Immunofluorescence
Specimen Requirements: 1 mL serum; Paired acute and convalescent serum specimens are recommended.
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week.
CPT Code:
86638
Price: $25.00

QuantiFERON – Gold (QFT – Gold) In-Tube Testing
Specimen Requirements: Stimulated plasma, obtained from vacutainer tubes specifically coated with antigens. Requires
access to a 37°C incubator. See QuantiFERON®-TB Gold In-Tube Testing Collection and Transport instructions.
Transport Temperature: Ambient
Turn-around Time: Routinely batch tested twice a week.
CPT Code:
86480 (Single Test)
Price: $90.00

R
Rabies Detection for Diagnostic Purposes (Animal Testing)
Animal testing is not performed by our laboratory.
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Refer specimens to the Veterinary Diagnostic Laboratory in Bozeman, (406) 994-4885

Rabies Detection for Diagnostic Purposes (Human Testing)
Human Testing for Diagnostic Purposes: Consult with the Epidemiology Section (406) 444-0273 for pre-approval prior to
testing. Consult the laboratory for specific sampling requirements and proper handling and transport.
Human Diagnostic Testing is referred to the Centers for Disease Control, Atlanta, Georgia.
Transport Temperature: Call for instructions
Turn-around Time: Preliminary results (PCR) are available as soon as possible, usually the same day as receipt.
CPT Code:
None
Price: Fee Waived

Rabies Serology for Immune Status Antibody Testing by RFFIT
Testing not available through this laboratory
Testing available from
Atlanta Health Associates, Alpharetta, Georgia (770) 667-8023
http://www.atlantahealth.net
Kansas State University, Manhattan, KS (785) 532-4483
http://www.ksvdl.org/rabies-laboratory/rffit-test/

Rapid Toxic Screen, (for Chemical Exposure)
Consult with the Epidemiology Section (406) 444-0273 for pre-approval prior to testing. Arrangements must be made
with the laboratory regarding proper collection, packaging, and transport of blood and urine specimens.
Transport Temperature: 2-8°C for whole blood, -70°C for urine (call for instructions)
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 36 hours
CPT Code:
None
Price: Fee Waived

Retail Meat Testing (E. coli)
Specimen Requirements: 325g minimum of ground beef or beef trim, and 400ml poultry rinse samples. Must be
received within 24 hours of collection.
Transport Temperature: 2-8°C within 24 hours
Turn-around Time: 2 to 3 working days for negative samples; up to 5 days for a positive sample. Positive results are
telephoned to the submitter.
CPT Code:
None
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Price: $70.00

Retail Meat Testing (Listeria)
Specimen Requirements: 25g minimum of ground beef, poultry, or ready-to-eat meat samples, and environmental
swabs or sponges. Must be received within 24 hours of collection. Ready-to-eat samples should be submitted by
Wednesday; samples submitted on Thursday or Friday will not be processed until the following Monday.
Transport Temperature: 2-8°C within 24 hours
Turn-around Time: 2 to 3 working days for negative samples; up to 5 days for a positive sample. Positive results are
telephoned to the submitter.
CPT Code:
None
Price: $75.00

Retail Meat Testing (Salmonella)
Specimen Requirements: 25g minimum of ground beef or beef trim, 325g minimum of ready-to-eat meats, 50 ml wholebird poultry rinse, carcass sponges and environmental swabs. Must be received within 24 hours of collection.
Transport Temperature: 2-8°C within 24 hours
Turn-around Time: 2 to 3 working days for negative samples; up to 5 days for a positive sample. Positive results are
telephoned to the submitter.
CPT Code:
None
Price: $70.00

Ricin Rapid Tests
Specimen Requirements: Environmental samples only
NOTE: Contact your local health department or the State Epidemiology Department (406-444-0273) to ensure the sample
meets criteria for testing. Please contact the Montana Public Health Laboratory prior to submission regarding sample
collection and transport instructions.
Transport Temperature: Ambient
Turn-around Time: 1 to 3 working days. Results are telephoned to the submitter.
CPT Code:
None
Price: Fee Waived
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Rickettsial Serology (see Rocky Mountain Spotted Fever, Typhus Fever Serology)
Rochalimea spp. Serology (see Bartonella Serology)
Rocky Mountain Spotted Fever (RMSF)
Specimen Requirements: 1 mL serum; Paired acute and convalescent serum recommended.
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week. Positive results are telephoned to the submitter.
NOTE: Colorado Tick Fever testing will be automatically performed on all requests for Rocky Mountain Spotted Fever.
CPT Codes:
86757 (RMSF)
Price $25.00
86790 (CTFV)
Price: $30.00
Total Price: $55.00

Rubella IgG Serology by EIA
Specimen Requirements: 1 mL serum; Screen or paired acute and convalescent specimens
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week.
CPT Code:
86762
Price: $25.00

Rubella IgM Serology by EIA
Specimen Requirements: 1 mL serum; Collect acute phase serum only and include an immunization history.
Collect specimen at least two (2) days after onset of rash and include date of onset.
Transport Temperature: Frozen
Turn-around Time: Testing performed at North Dakota Public Health Laboratory as needed. Results are available within
2-3 days.
CPT Code:
86762
Price: $39.00

Rubeola (Measles) Direct Detection by Real Time PCR
Specimen Requirements: Throat, nasopharyngeal or nasal Dacron swabs in viral transport media and/or 50 ml minimum
of urine.
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Urine should be centrifuged 2500xg for 15 min at 4° C. Resuspend sediment in 2 ml viral transport media. Swabs are the
preferred specimen.
CSF may be submitted in meningitis/encephalitis-suspect cases with prior consult
Note: Collect specimens as soon after the rash as possible. Detection is optimum with a collection the day one (1)
through 3 (three) of rash onset.
Transport Temperature: 2-8° C within 24 hours or freeze at -70° C and transport on dry ice.
Turn-around Time: 1 to 2 working days. Positive results are telephoned to the submitter.
CPT Code:
87798
Price: $107.00

Rubeola (Measles) IgG Serology by EIA
Specimen Requirements: 1 mL serum; Screen or paired acute and convalescent specimens.
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week. Significant results are telephoned to the submitter.
CPT Code:
86765
Price: $25.00

Rubeola (Measles) IgM Serology
Specimen Requirements: 1 mL serum; Collect specimen at least two (2) days after onset of rash and include date of
onset.
Transport Temperature: Frozen
Turn-around Time: Testing performed at North Dakota Public Health Laboratory as needed. Results are available within
2-3 days. Results are telephoned to the submitter.
CPT Code:
86765
Price: $30.00

S
Salmonella spp. (including S. typhi) Culture Isolation/Identification
Specimen Requirements: Stool in Cary-Blair transport or other commercial enteric transport media, or pure culture
isolate in Cary Blair transport or on solid media. See Enteric Panel for specific instructions.
Biochemically confirmed Salmonella spp. will be serotyped for epidemiologic purposes at no additional cost.
For public health surveillance, please submit all isolates of Salmonella spp. to the laboratory. See Enteric Isolate
Surveillance.
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Transport Temperature: 2-8°C for stool, ambient for isolates
Turn-around Time: 2 to 4 working days. Positive identification results of primary cultures or test of cure cultures are
telephoned to the submitter.
CPT Codes:
87045 (Culture ID)
Price: $18.00
87077 (Each add’l ID)
Price: $25.00

Shigella spp. Culture Isolation/ Identification
Specimen Requirements: Stool in Cary-Blair Transport or other commercial enteric transport media, or pure culture
isolate in Cary Blair transport or on solid media. See Enteric Panel for specific instructions.
For public health surveillance, please submit all isolates of Shigella spp. to the laboratory. See Enteric Isolate
Surveillance.
Transport Temperature: 2-8°C for stool, ambient for isolates
Turn-around Time: 2 to 4 working days. Positive results of primary cultures or test of cure cultures are telephoned to the
submitter.
CPT Codes:
87045 (Culture ID)
Price: $18.00
87077 (Each add’l ID)
Price: $25.00

Sporothrix Culture Isolation/ Identification (see Fungal Culture)
Staphylococcus spp. Culture Isolation/ Identification (see Bacterial Culture, Aerobic)
STEC (see Escherichia coli Shiga-Like Toxin Assay or Enteric Panel)
Stool Culture (see Enteric Panel)
Streptococcus pneumoniae Culture Isolation/ ID (see Bacterial Culture, Aerobic)
Streptococcus spp. Culture Isolation/ Identification (see Bacterial Culture, Aerobic)
Strongyloides Detection (see Ova and Parasite Exam)
Strongyloides Serology
Specimen Requirements: 2 mL serum or plasma
Transport Temperature: 4-8°C
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Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 18 days
CPT Code:
86317
Price: $30.00

Syphilis IgG Antibody Screen - Serum
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C
Turn-around Time: Routinely batch tested twice per week. Positive results are reflexed to a quantitative Syphilis VDRL
Titer Monitor. A positive IgG Antibody screen with a negative Syphilis VDRL Titer Monitor result is reflexed to a
Treponema pallidum Particle Agglutination Assay.
CPT Code:
86592
Price: $16.00

Syphilis VDRL Titer Monitor - Serum
This test is for testing known positive Syphilis patients who are currently or recently have received treatment.
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C
Turn-around Time: Routinely batch tested twice per week.
CPT Code:
86593
Price: $16.00

Syphilis Serology Screen - CSF (Qualitative) by VDRL
Specimen Requirements: 1 mL CSF
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested twice per week. Positive results are reflexed to quantitative VDRL.
CPT Code:
86592
Price: $15.50

Syphilis Serology Screen - CSF (Quantitative) by VDRL
Specimen Requirements: 1 mL CSF
Transport Temperature: 2-30°C (Refrigeration preferable)
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Turn-around Time: Routinely batch tested twice per week. Significant results are telephoned to the submitter.
NOTE: Reflex confirmatory TP-PA testing is performed on all positive serum VDRL specimens.
CPT Code:
86593
Price $16.00

T
Tick-borne Disease IgG Serology Panel by IFA, Bacterial Agglutination
Includes RMSF, CTFV, Q-Fever, Tularemia and Brucella antibodies. The panel can be ordered with or without Lyme
Disease antibodies.
Specimen Requirements: 3 mL serum; Paired acute and convalescent serum recommended.
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week. Positive results are telephoned to the submitter. These tests
may be ordered as a panel but will be billed individually.
Note: Although not a tick-borne disease, Brucella testing is performed on all requests for Tularemia due to antigen cross
reactivity.
CPT Codes:
86622 (Brucella)
86757 (RMSF)
86790 (CTFV)

86638 (Q-Fever)
86668 (Tularemia)

Total Price: $125.00
86618 Lyme Screen
Total Price w/Lyme: $165.00

Tick-borne Relapsing Fever (see Borrelia hermsii Serology)
Treponema pallidum Particle Agglutination Assay
This test is not available as a stand-alone test to be ordered. Please refer to the Syphilis IgG Antibody Screen – Serum for
the testing algorithm.
Specimen Requirements: 2 mL serum
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week. Positive results are telephoned to the submitter.
CPT Code:
86780
Price: $38.00
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Trypanosomiasis Detection (including Trypanosoma cruzi / Chagas Disease) (see Blood Parasite Screen)
Tuberculosis (See Mycobacterium spp.)
Tularemia Culture (See Francisella tularensis culture)
Tularemia Serology (See Francisella tularensis serology)
Typhoid Fever (see Enteric Panel or Salmonella spp.)
Typhus Fever IgG Serology by Indirect Immunofluorescence
Specimen Requirements: 2 mL serum; Paired acute and convalescent serum specimens are recommended.
Transport Temperature: 2-30°C (Refrigeration preferable)
Referred to the Centers for Disease Control, Atlanta, Georgia
Turn-around Time: 3 to 6 weeks
CPT Code:
86256
Price: $30.00

U
V
Vancomycin Resistant Enterococci (VRE) (see Antimicrobial Resistant Bacteria Confirmation)
Vancomycin Intermediate/ Resistant Staphylococcus aureus (see Antimicrobial Resistant Bacteria
Confirmation)
Varicella Zoster Virus (VZV) (Herpes Zoster Virus) Direct Detection by Real Time PCR
Specimen Requirements: Vesicular lesion swab in Universal Viral Transport Media. See Molecular (Nucleic Acid
Amplification) Testing Collection and Transport instructions.
Transport Temperature: 2-8°C
Turn-around Time: 1 to 3 working days. Positive results are telephoned to the submitter.
CPT Code:
87798
Price: $107.00

Varicella Zoster Virus (VZV) (Herpes Zoster Virus) IgG Serology by EIA
Specimen Requirements: 1 mL serum; Screen or paired acute and convalescent specimens.
Transport Temperature: 2-30°C (Refrigeration preferable)
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Turn-around Time: Routinely batch tested once per week; available each working day, as needed. Significant and STAT
results are telephoned to the submitter.
CPT Code:
86787
Price: $25.00

VDRL Serology (see Syphilis VDRL Titer Monitor or Syphilis Serology Screen-CSF)
Vibrio spp. Culture Isolation/ Identification
Specimen Requirements: Stool in Cary-Blair transport or other commercial enteric transport media, or pure culture
isolate submitted in Cary-Blair transport or on solid media. Specify species on request form.
Transport Temperature: 2-8°C for stool, ambient for isolates
Turn-around Time: 2 to 4 working days. Positive results are telephoned to the submitter.
CPT Codes:
87046 (Culture ID)
Price: $18.00
87077 (Each add’l ID)
Price: $25.00

W
West Nile Virus (WNV) IgG Serology by EIA
Specimen Requirements: 1 mL serum. Paired acute and convalescent specimens recommended.
Date of onset is required, and the city or county of patient’s residence is requested.
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week; during seasonal outbreaks, testing may be performed each
working day, depending on workload. Positive results are telephoned to the submitter.
CPT Code:
86789
Price: $25.00

West Nile Virus (WNV) IgM Serology by EIA
NOTE: Serology is the recommended method of testing for WNV in both serum and cerebral spinal fluid (CSF), because
viremia (as detected by PCR) is very transient.
Specimen Requirements: 1 mL serum and/or 1 mL CSF
Date of onset is required, and the city or county of patient’s residence is requested.
NOTE: Negative results on specimens drawn less than 9 days from date of onset should have a convalescent serum
tested if active disease is suspected.
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Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: Routinely batch tested once per week; during seasonal outbreaks, testing may be performed each
working day, depending on workload. Positive results are telephoned to the submitter. Certain specimens may be
referred to the Centers for Disease Control in Fort Collins, Colorado for confirmation using more specific Plaque
Reduction Neutralization tests, and equivocal (borderline) results may be reflexed to St. Louis Encephalitis IgM Serology.
CPT Code:
86788
Price: $25.00

X
Y
Yeast Culture (see Fungal Culture)
Yersinia enterocolitica Culture Isolation/Identification
Specimen Requirements: Stool in Cary-Blair transport or other commercial enteric transport media, or pure culture
isolate submitted in Cary-Blair transport or on solid media.
Transport Temperature: 2-8°C for stool, ambient for isolates
Turn-around Time: 2 to 4 working days. Positive results are telephoned to the submitter.
CPT Codes:
87046 (Culture ID)
Price: $18.00
87077 (Each add’l ID)
Price: $25.00

Yersinia pestis Culture Isolation/ Identification/Rapid Test Methods
Specimen Requirements: Pure culture isolate submitted on solid medium or clinical respiratory specimens transported
cold in sterile saline.
Note: A suspected Y. pestis culture requires Category A Infectious Disease packaging (Class 6.2) and trackable shipping.
Please notify the laboratory by telephone at time of shipment.
Please contact the laboratory prior to submission regarding environmental samples, rapid test methods, and transport
instructions.
Transport Temperature: 2-8°C for tissue, ambient for isolates
Turn-around Time: Cultures will be held for five (5) working days before reporting as negative. Results are telephoned as
soon as possible to the submitter. Rapid test methods are performed in Molecular Diagnostics and are available within 6
- 8 hours of specimen receipt.
CPT Codes:
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87081 (Culture screen)
Price: Fee Waived
87798 (PCR)
Price: Fee Waived

Yersinia pestis Serology by Passive Hemagglutination
Specimen Requirements: 2 mL serum
Referred to the Centers for Disease Control, Fort Collins, Colorado
Transport Temperature: 2-30°C (Refrigeration preferable)
Turn-around Time: 4 to 6 weeks
CPT Code:
86793
Price: $30.00

Z
Zika Virus Testing by CDC Trioplex Real-Time PCR Assay
This PCR assay detects Zika, Chikungunya, and Dengue Virus
Specimen Requirements: Serum only or serum and urine. Urine must be submitted with serum.
*Serum should be collected within <= 14 days of symptom onset in a separator (gold or tiger top tube) or decanted into
a sterile screw-capped vial (labeled “serum”) and secured with parafilm
*1 ml aliquot of urine poured off into a sterile screw-capped vial (labeled “urine”) and secured with parafilm. Do not
submit urine in its original collection container (i.e. urine cup)
Additional specimen types that are accepted with a consult include CSF and amniotic fluid.
Transport Temperature: Store at 4°C and ship in a biohazard bag with cold packs within 48 hours of collection.
Turn-around Time: Specimens are tested on the day of arrival and reported within 24 hours
CPT Code:
Urine and Serum:
Price: $175.00
Serum only:
Price: $107.00
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Collection and Transport of Specimens
Chlamydia/Gonorrhea Amplified Testing Collection and Transport
The Unisex Swab Specimen Collection Kit, Multitest Swab Specimen Collection Kit, and Urine Specimen
Collection Kit are stored at room temperature.
Eye Swab Collection
1.
2.
3.
4.
5.
6.

Use the Unisex Swab Specimen Collection Kit (white label) or Viral Transport Medium.
Gently rotate the blue-shafted collection swab clockwise across the surface of the eye to ensure adequate sampling.
Remove the cap from the swab specimen transport tube and immediately place the specimen collection swab into the
transport tube.
Carefully break the blue swab shaft at the score line; use care to avoid splashing of contents.
Re-cap the swab specimen transport tube tightly.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and the
collection date.

Endocervical Swab Collection
1.
2.
3.
4.
5.
6.
7.
8.
9.

Use the Unisex Swab Specimen Collection Kit (white label).
Remove excess mucus from the cervical os and surrounding mucosa using the white shafted cleansing swab. Discard the
white shafted swab.
Insert the blue-shafted specimen collection swab into the endocervical canal.
Gently rotate the swab clockwise for 10 to 30 seconds in the endocervical canal to ensure adequate sampling.
Withdraw the swab carefully; avoid any contact with the vaginal mucosa.
Remove the cap from the swab specimen transport tube and immediately place the specimen collection swab into the
transport tube.
Carefully break the blue swab shaft at the score line; use care to avoid splashing of contents.
Re-cap the swab specimen transport tube tightly.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and the
collection date.

Vaginal Swab Collection
1.
2.
3.
4.
5.
6.
7.
8.
9.

Use the Multitest Swab Specimen Collection Kit (orange label).
Patient can collect own specimen in a health care facility. Vaginal swab collection is preferred over urine collection in
women when a pelvic examination is not performed.
Insert the specimen collection swab into the vagina about two inches inside the opening of the vagina.
Gently rotate the swab clockwise for 10 to 30 seconds touching the walls of the vaginal to ensure adequate sampling.
Withdraw the swab carefully; avoid any contact with skin.
Remove the cap from the swab specimen transport tube and immediately place the specimen collection swab into the
transport tube.
Carefully break the swab shaft at the score line; use care to avoid splashing of contents.
Re-cap the swab specimen transport tube tightly.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and the
collection date.

Male Urethral Swab Collection
1.
2.
3.
4.

Use the Unisex Swab Specimen Collection Kit (white label).
The patient should not have urinated for at least one hour prior to sample collection.
Insert the blue-shafted specimen collection swab 2 – 4 cm into the urethra.
Gently rotate the swab clockwise for 2 to 3 seconds in the urethra to ensure adequate sampling.
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5.
6.
7.
8.
9.

Withdraw the swab carefully.
Remove the cap from the swab specimen transport tube and immediately place the specimen collection swab into the
transport tube.
Carefully break the blue swab shaft at the score line; use care to avoid splashing of contents.
Re-cap the swab specimen transport tube tightly.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and the
collection date.

Penile Meatal Swab Collection
1.
2.
3.
4.
5.
6.
7.
8.
9.

Use the Multitest Swab Specimen Collection Kit (orange label).
Use the small blue-shafted collection swab, not the larger white shafted cleansing swab.
For uncircumcised males roll the foreskin down before staring collection.
Roll the swab on the tip of the penis, outside the opening of the urethra, ensuring to roll the swab all the way around the
opening to obtain the best sample.
Withdraw the swab carefully without touching any other area of the skin.
Remove the cap from the swab specimen transport tube and immediately place the specimen collection swab into the
transport tube.
Carefully break the blue swab shaft at the score line; use care to avoid splashing of contents.
Re-cap the swab specimen transport tube tightly.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and the
collection date.

Rectal Swab Collection
1.
2.
3.
4.
5.
6.
7.
8.
9.

Use the Multitest Swab Specimen Collection Kit (orange label).
Use the small blue-shafted collection swab, not the larger white shafted cleansing swab.
Insert the small blue-shafted collection swab approximately 3 – 5 cm into the rectum and rotate against the rectal wall
several times (at least 3 times).
Swabs that are grossly contaminated with feces should be discarded and the collection repeated.
Withdraw the swab carefully without touching the skin.
Remove the cap from the swab specimen transport tube and immediately place the specimen collection swab into the
transport tube.
Carefully break the blue swab shaft at the score line; use care to avoid splashing of contents.
Re-cap the swab specimen transport tube tightly.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and the
collection date.

Throat Swab Collection
1.
2.
3.
4.
5.
6.
7.
8.
9.

Use the Multitest Swab Specimen Collection Kit (orange label).
Use the small blue-shafted collection swab, not the larger white shafted cleansing swab.
Using a tongue depressor, insert the small blue shafted collection swab and vigorously rub the tonsils and the posterior
pharynx.
Carefully remove the swab, not touching any area of the mouth.
Remove the cap from the swab specimen transport tube and immediately place the specimen collection swab into the
transport tube.
Carefully break the blue swab shaft at the score line; use care to avoid splashing of contents.
Re-cap the swab specimen transport tube tightly.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and the
collection date.
Complete the requisition form; be sure to record the specimen source.
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Urine Collection
1.
2.
3.

4.

5.
6.

Use the Urine Specimen Collection Kit (yellow label).
The patient should not have urinated for at least one hour prior to sampling.
Direct patient to provide a first-catch urine (approximately 20 to 30 mL of the initial urine stream) into a urine collection
cup. Collection of larger volumes of urine may reduce test sensitivity. Female patients should not cleanse the labial area
prior to providing the specimen. This is NOT a clean-catch urine – we want the initial urine stream, which contains sloughed
cells.
Remove the cap and transfer 2 mL of urine into the urine specimen transport tube using the disposable pipette provided.
The correct volume of urine has been added when the fluid level is between the black lines on the urine specimen transport
tube label.
Re-cap the urine specimen transport tube tightly. This is now known as the processed urine specimen.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and the
collection date.

Swab and Urine Specimen Transport
After collection, ensure that specimens are properly labeled.
Fill out the Public Health Laboratory Request Form.
Place the corresponding transport tube in an individual zip lock bag containing absorbent material and seal the bag tightly. Place the
form in the sleeve of the zip lock bag; DO NOT put the request form inside the zip lock bag.
Store swab specimen transport tubes and processed urine specimens (those in urine specimen transport tubes) at 2°C to 30°C. Place
transport tubes in white mailing canisters and send to the laboratory by mail or courier.
NOTE: Although swab specimens in the specimen transport tube must be tested within 60 days of collection and urine specimens in
the specimen transport tube must be tested within 30 days of collection, we advise you to submit specimens in a timely manner so
that test results can be obtained as soon as possible.
Utilize the MTPHL courier service if available, or ship specimens to the following address:
Montana Public Health Laboratory
(Street Address)
1400 Broadway
Helena, MT 59601
Or
PO Box 4369
Helena, MT 59604-4369

Result Reporting
Positive results are telephoned to the provider; additionally, positive GC results are notified electronically to the DPHHS STD
Program.

Specimen Rejection
Specimens with unresolved labeling issues, leaking containers, expired containers, or with insufficient volume may be rejected. The
provider will be notified and asked to resubmit.

Requests for Additional Information or Specimen Collection Questions:
For additional information or questions, or to order collection kits, contact the laboratory at 800-821-7284 or 406-444-3444.
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Molecular (Nucleic Acid Amplification) Testing Collection and Transport
For technical assistance in determining proper specimen selection for specific agents, call the laboratory at 800-821-7284.
Universal Viral Transport Media for Viral Agents is supplied by the laboratory. Store the kits at room temperature.

Specimen Type

Instructions

Bronchial Alveolar Lavage (BAL)
/Bronchial Washings

For Viral Agents, mix an equal portion of the BAL with Universal Viral Transport
Media. Store in cold conditions and ship on cold packs.

Cerebral Spinal Fluid (CSF)
Lesion swab (HSV)

Nasopharyngeal Aspirate

Nasopharyngeal Wash

Nasopharyngeal Swab

For Bacterial Agents, collect in sterile container. Store in cold conditions and ship on
cold packs.
Place 1 – 2 mL in sterile container without viral transport media. Store in cold
conditions and ship on cold packs.
Use the Aptima Multitest Swab Specimen Collection Kit (orange label).
If needed, expose the base of the lesion to access fluid. Vigorously swab the base of
the lesion to absorb fluid, being careful not to draw blood. Withdraw the swab
without touching any other site outside the lesion. Remove the cap from the swab
specimen transport tube and immediately place the specimen collection swab into
the transport tube. Carefully break the swab shaft at the score line; use care to
avoid splashing of contents. Re-cap the swab specimen transport tube tightly.
Store and transport at ambient temperature.
Introduce 1-2 mL of sterile saline into the nasopharyngeal cavity, aspirate into
sterile vial. Store in cold conditions and ship on cold packs. *Note: If the specimen is
also being submitted for viral agents, please submit in Universal Viral Transport
Media. Store in cold conditions and ship on cold packs.
Use only sterile saline to collect the NP wash. Instruct the patient to sit with head
slightly tilted backwards, and to hold the sterile collection cup. Instruct the patient
on how to constrict the muscles at the back of the throat by saying the “K” sound
rapidly and repetitively. Inform the patient that this process may prevent the saline
from draining down the throat. Fill a 5-cc syringe with warm sterile saline. Gently
push the tip of the patient’s nose back with your thumb, and quickly inject 1 – 2 mL
of sterile saline into each nostril. Instruct the patient to contain the saline in the
nostrils for approximately 10 seconds while repetitively saying the “K” sound. After
10 seconds, ask the patient to tilt their head forward and collect the saline in the
sterile cup. Cap the washings tightly. Refrigerate the nasopharyngeal washings until
transport and ship on cold packs. Store in cold conditions and ship on cold packs.
Use a flexible wire Dacron or polyester swab. Do not use Calcium Alginate swabs or
swabs with wooden shafts. Instruct the patient to sit with head slightly tilted
backwards. Bend the flexible wire in a small arc and insert the swab into the nostril
back to the nasopharyngeal cavity. The patient’s eyes will momentarily tear. Slowly
rotate the swab as it is being withdrawn.
For Viral Agents, place swab into Universal Viral Transport Media, trim swab shaft,
and tightly cap. Store in cold conditions and ship on cold packs.
For Pertussis and other Bacterial Agents, place swab in sterile tube without
transport.
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Rectal swabs (for CRE)

Serum

Collection of paired rectal swab: Carefully insert both swab tips approximately one
(1) cm beyond the anal sphincter and rotate gently. Do not collect highly soiled
swabs.
Place swab pair back in original transport tube. Swabs in the transport tube can be
stored at 15-28oC for up to five days and transported at ambient temperature.
Collect 5-10 mL of whole blood in serum separator tube. Allow blood to clot,
centrifuge and aliquot resulting sera. Store in cold conditions and ship on cold
packs. If serum has already been frozen, ship on dry ice.

Stool

Collect at least 2 mL of stool in a leak-proof, clean, dry container. Do not add
transport media. Store in cold conditions and ship on cold packs.

Throat Swab

Use a plastic-shafted Dacron swab. Do not use Calcium Alginate swabs or swabs
with wooden shafts. Using a tongue depressor, insert the swab and vigorously rub
the tonsils and the posterior pharynx. Carefully remove the swab, not touching any
area of the mouth.
For Viral Agents, place swab into Universal Viral Transport Media, trim swab shaft,
and tightly cap. Store in cold conditions and ship on cold packs.
For Bacterial Agents, place swab in sterile tube without transport.

Tissue Specimens
Autopsy or Biopsy

For Viral Agents, place each specimen in separate sterile containers containing small
amounts of Universal Viral Transport Media. Store and ship on cold packs or dry ice.
Do Not submit formalized tissue.
For Bacterial Agents, place each specimen in separate sterile containers containing
small amounts of sterile saline or PBS. Store and ship on cold packs. Do Not submit
formalized tissue.

Vesicles/Vesicular Fluid/ Scrapings

Aspirate fluid from multiple fresh unbroken vesicles and place into 1-2 mL of
Universal Viral Transport Media. Remove the top of the vesicle and place the skin of
the vesicle top into a sterile tube without transport. Store both samples in cold
conditions and ship on cold packs.

Whole Blood

Collect 5 -10 mL whole blood in EDTA anticoagulant. Store in cold conditions and
ship on cold packs.

Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.), collection
date and specimen source. Place each specimen container in an individual biohazard zip lock bag containing absorbent
material and seal bag tightly.
Fill out the Public Health Laboratory Request Form completely and place in the outer sleeve of the biohazard zip lock
bag. Do not place the request form inside the biohazard zip lock bag.
Ship specimens promptly, maintaining cold temperature from collection until receipt at the laboratory. For those
specimens that must be shipped in a cold condition, use cold packs and Styrofoam containers. Mailers will be returned
for reuse. Transport by UPS, FedEx, mail or courier.
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Mycobacterium spp. (AFB or TB) Testing Collection and Transport
All specimens are potentially infectious; handle carefully.

Specimen Type

Instructions

Sputum or Nebulized Sputum

Collect three early morning specimens on successive days (within 72 hours) and submit
daily in separate containers. Good specimens are material brought up by the lungs
after a productive cough or nebulization. Send a minimum of 5 mL in a sterile
container.
Collect multiple first morning "clean catch" specimens on three successive days. Send a
minimum of 40 mL in a sterile container.

Urine
Gastric

Collect three early morning fasting specimens on successive days. Send a minimum of
10 mL in a sterile container. Add 10 mg of sodium bicarbonate to neutralize the acidity.
Send promptly after collection; these specimens should be processed as soon as
possible.

Bronchial Washings

Submit first sputum specimen following bronchoscopy as well as the bronchial
washings. Send a minimum of 5 mL in a sterile container.

Tissues

Collect aseptically and place in sterile container. Add 1 mL sterile broth or sterile saline
to tissues to prevent dehydration.

CSF or Other Sterile Body Fluids

Submit in a sterile collection tube; at least 2 mL is needed for an adequate test.

Blood or Bone Marrow

Collect in heparinized tube or add sterile heparin (0.2 mg/mL) to prevent clotting. Send
a minimum of 1 mL in a sterile container.

Stool

Submit 1 gram of raw stool in a sterile container. Send on ice.

Swab (Not Optimal)

Specimens submitted on swabs are highly discouraged. Please make every effort to
submit tissue or aspirated fluid, as these are preferred sources. If swabs are submitted,
add 1 ml of sterile saline or sterile broth to the swab to prevent dehydration.

Use only sterile materials in the collection of the specimen. Collect the specimen directly into the sterile bottle provided
or into a sterile container. Screw the lid onto the specimen container tightly so specimen does not leak. Place each
specimen container in an individual biohazard zip lock bag containing absorbent material and seal the bag tightly.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and the
collection date.
Refrigerate the specimen until transported and send as soon as possible. Specimens must be received within 5 days of
obtaining the specimen.
Fill out the Public Health Laboratory Request Form. Place the form in outside sleeve of biohazard zip lock bag and put
into TB mailing container. Respiratory specimens should be packaged and transported cold by mail or courier. All other
specimens may be transported at ambient temperature.
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Mycology (Fungal) Culture Collection and Transport
Specimen Type

Instructions

Tissue

Place tissue in a sterile screw cap container and cover with 1 mL of sterile saline or broth.
Refrigerate until time of mailing.

Blood

Collect blood aseptically an automated blood culture system bottle. If mold or yeast is suspected,
submit blood culture bottle for culture identification.

Bone marrow

Collect approximately 0.3 mL of bone marrow in a heparinized tube. Store specimen at room
temperature or incubate until mailing. Ship in sterile screw cap container.

Bronchial wash, Pleural
fluid, Joint fluid, Sputum

Send in sterile screw cap container. May be sent in TB transport container. Refrigerate specimen
until mailing.

CSF

Send a minimum of 1.0 mL in sterile screw cap container. Store specimen at room temperature or
incubate until mailing.

Hair

Remove about 10 hairs with roots using forceps and send in a sterile container. NOTE: Hairs that
break off at scalp level when using forceps must be removed with a knife. Scraping the scalp rarely
yields infected hairs. Store and transport at room temperature.

Skin

Wipe lesions well with alcohol sponge (cotton will leave too many fibers on skin). Scrape the entire
periphery of the lesion(s) with a sterile scalpel. Send scrapings in a sterile container. Store and
transport at room temperature.

Nails

Clean nail with alcohol sponge. Scrape and discard outer portion of nail. Collect scrapings from
inner nail and send in a sterile screwcap container. Send an entire nail, if it has been removed, in a
sterile screw cap container. Store and transport at room temperature.

Please Note: Both a TB culture and a fungal culture can be processed from a single specimen by request. Make certain
that the test request form is clearly marked for both tests.
Place each specimen container in an individual biohazard zip lock bag containing absorbent material and seal the bag
tightly. Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and
the collection date.
Fill out the Public Health Laboratory Request Form. Place the form in the outside sleeve of biohazard zip lock bag and
put into mailing container. Transport at ambient temperature by mail or courier.

PHL Lab Manual Effective April 2020

65

Blood Parasite Screen Thick EDTA Blood Smear Preparation Instructions
1. Specimen: an EDTA-preserved tube of peripheral blood that has not cooled to room temperature nor had its lid
removed prior to this sampling. Make two thick smears per specimen (one to be stained in-house and the other
to be stained at MTPHL).
2. Wear gloves when performing this procedure.
3. Place a pre-cleaned 1 X 3” glass microscope slide on a horizontal surface.
4. Place a 30-40 µl drop of blood onto one end of the slide about 0.5 inches from the end.
5. Lay an applicator stick across the glass slide and contact the drop of blood. Allow the blood to spread along the
applicator stick until it spreads from one side of the slide to the other.
6. Keeping the applicator in contact with the blood and glass, rotate (DO NOT “ROLL”) the stick in a circular motion
while moving the stick down the glass slide to the opposite end. See figure below.

7. The appearance of the blood smear should be alternate thick and thin areas of blood that cover the entire slide.
8. Immediately place the slide over some small print and be sure that the print is just barely readable through the
blood film.
9. Allow the film to air dry horizontally and protected from dust for at least 30 min. to 1 hour. DO NOT speed the
drying process by applying any type of heat as the heat will fix the RBCs and they subsequently will not lyse in
the staining process.
10. Dip the thick slides twice in acetone and allow them to air dry in a vertical position. This step improves the
durability of the blood film and will prevent the blood from flaking off in transit.
11. Lyse the RBCs on the thick films by either:
a. Dipping each slide in Buffered Methylene Blue solution (0.65%) for 1-2 seconds and allow the slides to air
dry in a vertical position. This is the preferred option as RBCs are hemolyzed, color is introduced into the
cytoplasm of the parasites, and prestaining with methylene blue helps to preserve the organisms on the
smear. The formula for 0.65% Buffered Methylene Blue solution is as follows:
Methylene Blue
0.65 g.
Di-sodium hydrogen phosphate Na2HPO4 2.0 g.
Potassium di-hydrogen phosphate KH2PO4 0.65 g.
Distilled water
1.0 L
Mix and store the solution in a brown stoppered bottle.
b. Alternatively, the slides may be placed in Buffered water (pH 7.0 to 7.2) for 10 min. and allow the slides to
air dry in a vertical position.
12. Stain one thick smear with either Giemsa or Wright’s Stain. Submit both slides to MTPHL.
13. Note on the Public Health Laboratory Request Form as to which method the thick smears were lysed.
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Newborn Screening Collection and Transport
Newborn screening specimen cards for collection of dried blood spot samples are available from the laboratory. See
Supply Request Form. These forms contain the requisition form along with the attached filter paper collection device.
Store specimen cards in a cool dry place on edge; flat stacking compresses the filter paper fibers. Do not handle the filter
paper portion, as skin oils will prevent saturation.
Complete all the information on the requisition form legibly in block capital letters.

Sample Collection
The usual puncture site is illustrated below (shaded areas).

1. Sterilize and dry skin. Puncture heel with sterile lancet.
2. Allow large blood droplet to form.
3. Touch filter paper to blood and allow to soak through completely in each circle. Total saturation of the circles
must be evident when the paper is viewed on both sides. Do not apply blood to both sides.
4. Be certain to properly fill all five (5) circles on the card. These need to all be satisfactory spots.
5. Use of capillary tubes is not recommended because they tend to roughen the filter paper and cause over
absorption.
6. Allow blood spots to air dry thoroughly for 2-3 hours at room temperature. Keep away from direct sunlight and
heat. Do not stack filter papers before thorough drying. Protective cover can be used to hold specimen while
drying.
7. Cover with end flap only after specimen is completely dry.
8. Inspect the dried blood spots for adequacy prior to transport. Do not send unsatisfactory specimens.
9. Transport specimen by UPS or courier at ambient temperature within 24 hours of collection.
Note: Specimens may be UNSATISFACTORY if:
• All circles not completely filled (QNS)
• Blood is layered by application on both sides or by multiple spotting
• Filter paper is scuffed or torn
• Specimen is contaminated or improperly dried
• Information is incomplete
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Capillary (Fingerstick Specimens) for Blood Lead Collection and Transport
Collection supplies are available free of charge by contacting the laboratory. Kits include:
Two (2) Sterile Alcohol Preps
One (1) Lancet

One (1) Capillary collection device
One (1) Dry Sterile Gauze Pad

One (1) Transport zip lock bag
One (1) Instruction sheet

Performing the Skin Puncture:
1.
2.

3.
4.
5.

Thoroughly wash hands and don powder free gloves.
Select the puncture site. Blood can be obtained from:
• fingertip (for adults and children older than 1 year)
• the bottom of the big toe (infants only)
• the heel (infants only)
Clean the puncture site with alcohol pad. If the site is extremely soiled or very cold, wash with warm soapy water and towel dry.
Use the alcohol swab to briskly scrub the puncture site to remove any environmental contamination and to increase blood flow.
Allow the site to air dry or use the sterile gauze to dry the area.
Puncture the skin with the lancet.

Collection of the Sample:
1.

2.
3.
4.

Use the gauze to wipe off the first drop of blood, which contains excess tissue fluid. A rounded drop of blood will form over the
puncture site. When the tip of the collection device touches this drop, blood will flow by capillary action into the tube. Care
should be taken that the tip of the collection device is in contact with the blood only, not skin. Gently apply continuous pressure
to the surrounding tissue; avoid milking the site.

Important: The flow of blood must be adequate to fill the capillary rapidly. Do not stop to shake or tap the
tube until the capillary is filled. Capillary must be held continuously in a horizontal position during the drawing of the blood.
After filling, turn the capillary device immediately to a vertical position to allow the blood to flow into the tube. Remove
capillary with holder at the same time. Close tube with attached cap.
Apply pressure to the puncture site with a gauze pad to stop bleeding, while mixing the specimen by inverting a minimum of five
times.
Identify each skin puncture specimen with the patient’s name and collection date.

Submitting Specimens to the Laboratory for Testing:
1.
2.
3.

4.

Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and collection date.
Complete a Public Health Laboratory Request Form to include the patient’s name, date of birth, gender, collection date,
submitter information, and, if applicable, Medicaid billing information.
Place the well-mixed blood specimen container into the individual biohazard zip lock transport bag and seal bag tightly. Fold the
requisition form and place in sleeve of the bag. Place the zip lock bag(s) into a preaddressed white mailing canister. Store the
specimen(s) in the refrigerator until shipped. Specimens are stable for 7 days at refrigeration temperatures.
Specimens are transported at ambient temperature by mail or courier.

Results:
1. Laboratory test results will be mailed to the submitter upon completion of testing.
2. Should the initial test be elevated, a venous specimen will be requested for verification.
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Venipuncture Specimens for Blood Lead Collection and Transport
Collection supplies are available free of charge by contacting the laboratory.

The Venipuncture Collection Kit includes:
One (1) sterile alcohol preps
One (1) needle and holder or one (1)
needle and syringe

One (1) transport zip lock bag
One (1) dry sterile gauze pad
One (1) Vacutainer EDTA tube

One (1) instruction sheet

Preparation of the Puncture Site:
1.
2.
3.

Thoroughly wash hands and don powder free gloves.
Expose the selected antecubital fossa and apply tourniquet to mid-biceps. Scrub the puncture site briskly with the alcohol pad to
remove any environmental contamination and to increase blood flow.
Allow the site to air dry or use the sterile gauze to dry the area.

Collection of the Sample:
1.
2.
3.
4.
5.
6.
7.
8.

Prepare needle assembly, either needle and vacutainer holder, or needle and syringe.
Perform venipuncture per standard operating procedures. Make sure the vacutainer tube is completely filled before stopping
collection. If using a needle and syringe, obtain a minimum of 2 mL of whole blood.
Remove tourniquet first, then needle from arm.
Apply pressure to the puncture site with a gauze pad to stop the patient’s bleeding. Parent/guardian or child may continue
holding direct pressure on the puncture site.
If drawn directly into vacutainer tube, immediately mix the specimen manually by inverting a minimum of 10 times.
If drawn with a needle into the syringe, immediately inject the blood from the syringe into the vacutainer tube, gently mixing
while filling. Continue to mix the specimen by inverting 10 times.
Dispose of used needle and syringe equipment into puncture proof Sharps container.
Identify each skin puncture specimen with the patient’s name, at a minimum, and collection date.

Submitting Specimens to the Laboratory for Testing:
1.
2.
3.

4.

Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and collection date.
Complete a Public Health Laboratory Request Form to include the patient’s name, date of birth, gender, collection date,
submitter information, and, if applicable, Medicaid billing information.
Place the well mixed, unclotted blood specimen in an individual biohazard zip lock bag containing absorbent material and seal
bag tightly. Fold the requisition form and place in sleeve of the bag. Place the zip lock bag(s) into a preaddressed white mailing
canister.
Store the specimen(s) in the refrigerator until shipped. Specimens are transported at ambient temperature by mail or courier.
Specimens are stable for 7 days at refrigeration temperatures.

Results:
Laboratory test results will be mailed to the submitter upon completion of testing.
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QuantiFERON®-TB Gold In-Tube Testing Collection and Transport
The QuantiFERON-TB Gold assay (QFT®) measures the Interferon-gamma (IFN-γ) response in whole blood stimulated with antigen.
The kit uses specialized QFT blood collection tubes. The following is a guide for blood collection into these tubes.

Please read and follow the complete directions carefully!
Filling QuantiFERON®-TB Gold blood collection tubes
QuantiFERON®-TB Gold IT uses the following collection tubes; the set will be provided for you free of charge by calling 800-8217284, or e-mailing mtphl@mt.gov.
1. Nil Tube (Grey cap with yellow ring). The yellow ring designates a high-altitude tube.
2. TB1 Tube (Green cap with yellow ring).
3. TB2 Tube (Yellow cap with yellow ring).
4. Mitogen Tube (Purple cap with yellow ring).

These procedures should be followed for optimal results:
1.
2.

3.

Tubes should be at 17 - 25°C at the time of blood filling.
Collect 1 mL of blood by venipuncture directly into each QFT blood collection tube in the order Nil, TB1, TB2, and Mitogen. As 1
mL tubes draw blood relatively slowly, keep the tube on the needle for 2-3 seconds once the tube appears to have completed
filling to ensure that the correct volume is drawn.
The black mark on the side of the tubes indicates the 1 mL fill volume. QFT blood collection tubes have been validated for
volumes ranging from 0.8 to 1.2 ml. If the level of blood in any tube is not close to the indicator line, it is recommended to
obtain another blood sample.
•If a “butterfly needle” is used, prime tubing with a “purge” tube before filling the QFT tubes.

Mixing Tubes
1.

2.

Antigens have been dried onto the inner wall of the blood collection tubes. It is essential that the tubes’ contents be thoroughly
mixed with the blood. Thorough mixing will dissolve the heparin, preventing clotting, and allow resolubilization of the
stimulating antigen. Mixing is performed by shaking, not just inverting, the tubes vertically ten (10) times, firmly enough to
ensure that the entire inner surface of the tube is coated with blood. Over-energetic shaking may cause gel disruption and
could lead to aberrant results.
Label tubes appropriately with two patient identifiers. Ensure each tube (Nil, TB1, TB2, Mitogen) is identifiable by its label or
other means once the cap is removed.

Incubation of Tubes
1.

2.
3.
4.
5.

Following filling, shaking and labeling, the tubes must be transferred to a 37°C ± 1°C incubator as soon as possible, and within 16
hours of collection. If the blood is not incubated immediately after collection, re-mixing of the tubes by inverting 10 times must
be performed immediately prior to incubation.
Incubate the tubes UPRIGHT at 37°C ± 1ºC for 16 to 24 consecutive hours. The incubator does not require CO2 or
humidification.
If tubes are not incubated on site, maintain tubes at room temperature (22°C ± 5°C). Do not refrigerate or freeze the blood
samples. Tubes must be received in the Public Health Laboratory within 16 hours of collection for incubation.
Following 37ºC ± 1ºC incubation, blood collection tubes may be transported between 2°C and 27°C. Specimens must be
received in the Public Health Laboratory within 3 days of incubation. If this is not possible, call MTPHL for direction.
Complete a black and white Public Health Laboratory Request Form; include date and TIME of draw, and whether the
specimen(s) have been incubated prior to shipment. Please note this information in the Comments/Pertinent Information
section of the request form.

An illustrated Quick Guide for Blood Collection is available at http://www.cellestis.com/. Click on the links: QuantiFERON Products,
QuantiFERON®-TB Gold In-Tube, Technical Resources, Technical Documents, and Blood Collection Quick Guide.

QUESTIONS? Contact the MTPHL at 800-821-7284 or mtphl@mt.gov
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Serology Specimens Collection and Transport
TESTING POLICY: If a convalescent specimen is received, it will be tested in parallel with the original acute specimen, and only the
convalescent specimen will be billed.

Specimen Type

Instructions

Acute serology specimen

The DATE OF ONSET of symptoms or disease is less than 7 days from the date serum is
obtained, usually the first few days of the illness. IgG antibody titers are not elevated.
Exceptions: Rubeola, Rubella, and Colorado Tick Fever and Rocky Mountain Spotted Fever
may have a significant IgG titer in 7-10 days.

Convalescent serology specimen

The DATE OF ONSET of symptoms or disease is 2 weeks or greater from the date serum is
obtained. IgG antibody levels should be at a significant level. Exception: Legionella sp.
antibody levels may not be significant for 4-6 weeks.

Serology screen only

The patient has a chronic condition, with the DATE OF ONSET of symptoms or disease being a
very long period (months to years, OR patient is being screened for antibodies to a certain
infectious agent (HIV, Hepatitis B, Rubella, VZV, etc.) ALTERNATIVELY, IgM testing is
available.

Post-convalescent serology
specimen

Single specimen test results may be difficult to interpret, and an additional specimen may be
requested if results warrant.

Submit approximately 2 - 4 mL of clear non-hemolyzed serum for testing. Contact the laboratory for exact volumes
needed if serum is difficult to obtain. Serum separator tubes can be used. Spin the SST tubes well to separate the serum
and cells and submit the whole tube. Serum does not have to be poured off. DO NOT submit unspun SST tubes. If serum
is not submitted in the original SST tube, place in a leakproof container.
Cerebral Spinal Fluid (CSF) may also be submitted for serological testing in certain instances. A serum sample should also
be submitted with the CSF for comparison testing.
Specimens should be clearly labeled with two patient identifiers (name, DOB, medical record number, etc.) and
collection date. Completely fill out the Public Health Laboratory Request Form.
Place each specimen container in an individual biohazard zip lock bag containing absorbent material and seal bag tightly.
Place the completed laboratory request form in the outer sleeve of the biohazard zip lock bag. Do not place the
completed laboratory request form inside the zip lock bag.
If specimen is stored prior to shipment, store at 4°C. If storage is longer than 1 week, freeze the specimen. Specimens
may be shipped at room temperature. Labeled pre-addressed mailing canisters are available from the laboratory.
Transport by mail or courier.
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Clinical Laboratory Requisition Forms
Request forms are available by calling the laboratory at 800-821-7284:
The Public Health Laboratory Request Form, preprinted with your account information; all clinical testing can be ordered
with this form.
A Newborn Screening Panel Form; this form contains the dried blood spot collection kit.
Examples of each form are included on the following pages, as well as specific instructions on filling out the Newborn
Screening Form.
General Instructions:
Please fill the forms out completely to include (at a minimum):
Patient Last Name or anonymous identifier (required)
Patient First Name
Patient ID #/ Medical Record #
Date of Birth
Gender
Medicaid # (if applicable)
NPI (or UPIN) # of Physician/Clinician (preferred)
Physician/Clinician Name (if NPI is not provided)
Specimen Collection Date (required)
Date of Onset of Illness (for serology and molecular testing)
Source of Specimen
Test(s) Ordered
There will need to be two forms of patient identification on both the requisition form and the submitted specimen for
the submission to be acceptable.
NOTE: Forms are read using an optical scanning device. Please PRINT information clearly in boxes indicated. Do not use
preprinted labels or stamps.
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Public Health Laboratory Request Form
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Newborn Screening Requisition Form
This form has attached special filter paper for collection of the blood spots.

All information contained on the form must be completed.
Complete the patient information (name, sex, ID#, race, and ethnicity) as well as the mother’s name and baby’s
provider. It is important to specify the provider that will be providing care for the infant once he or she is released from
the hospital. We will not accept hospitalists or obstetricians in this field.
Mark the specimen as to whether this is the first screen performed on the baby or repeat screen. If the baby was
screened at the hospital, and then is followed up with a repeat test at the physician’s office, mark the repeat box.
Accurately complete the birth date and time and the specimen collection date and time. Samples obtained from a child
less than 24 hours old must be repeated.
Complete the birth weight in grams.
Answer the questions on transfusion history. In cases when the baby received a transfusion, please include the date of
transfusion.
If the baby is on TPN (Total Parenteral Nutrition) at the time of collection, please indicate that on the form.
This same form can be used for monitoring Phenylalanine levels on patients with known PKU disease.
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Supply Order Form
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Packaging and Shipping Guidelines
It is the responsibility of the facility to ensure proper packaging and shipping of all potentially infectious and biological
substances. Listed below are some general guidelines and links to websites that will provide more detailed information.
Category A (UN2814 “Infectious Substance Affecting Humans”): “An infectious substance in a form capable of causing
permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals when exposure to it
occurs. An exposure occurs when an infectious substance is released outside of its protective packaging, resulting in
physical contact with humans or animals. Classification must be based on the known medical history or symptoms of the
source patient or animal, endemic local conditions, or professional judgment concerning the individual circumstances of
the source human or animal. Category A poses more risk than Category B.”
Category B (UN 3373 “Biological Substance, Category B”): “An infectious substance NOT in a form generally capable of
causing permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals when exposure
to it occurs. This includes Category B infectious substances transported for diagnostic or investigational purposes.”
Exempt Human Specimens: Exempt Human Specimen label indicates there is no infectious substance in the package.
(Examples include fecal occult blood and dried blood spots.)
For more information, please visit the following sites:
49 CFR PART 172—HAZARDOUS MATERIALS TABLE, SPECIAL PROVISIONS, HAZARDOUS MATERIALS COMMUNICATIONS,
EMERGENCY RESPONSE INFORMATION, TRAINING REQUIREMENTS, AND SECURITY PLANS
http://www.ecfr.gov/cgibin/retrieveECFR?gp=&SID=44acea8f201b183f75c4e90179e00f56&n=49y2.1.1.3.9&r=PART&ty=HTML#se49.2.172_1704
49 CFR PART 173—SHIPPERS—GENERAL REQUIREMENTS FOR SHIPMENTS AND PACKAGINGS
http://www.ecfr.gov/cgi-bin/textidx?SID=b939d5f0b1d7600fa4adf1a00c1f49d6&node=49:2.1.1.3.10&rgn=div5#49:2.1.1.3.10.2.25.8
A Guide for Shippers of Infectious Substances, 2015
http://www.who.int/ihr/infectious_substances/en/
Guidance on regulations for the Transport of Infectious Substances
http://www.who.int/ihr/publications/who_hse_ihr_2015.2/en/
International Air Transport Association (IATA) Dangerous Good Regulations:
https://store.iata.org/IEC_SearchResults?site-search=dangerous+goods+regulations
DOT: Transporting Infectious Substances Safely
https://www.phmsa.dot.gov/sites/phmsa.dot.gov/files/docs/Transporting_Infectious_Substances_brochure.pdf
ASM SENTINEL LEVEL CLINICAL LABORATORY GUIDELINES FOR SUSPECTED AGENTS OF BIOTERRORISM AND EMERGING
INFECTIOUS DISEASES: Packing and Shipping Infectious Substances
https://asm.org/Articles/Policy/Laboratory-Response-Network-LRN-Sentinel-Level-C
CDC Packaging and Shipping Training Course
https://www.cdc.gov/labtraining/training-courses/packing-shipping-division-6.2-materials.html
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Attachment G: Montana Public Health Laboratory Clinical Improvements
Amendments

